

**Funding Opportunities Monthly Edition  
Jan 2022 Due Dates**

## Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in Jan 2022. The opportunities are organized in the following order:

1. [National Institutes of Health \(NIH\)](#)
2. [National Science Foundation \(NSF\)](#)
3. [Other Federal](#)
4. [Non Federal](#)

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
099847	<a href="#">RFA-CA-20-051 -- Social and Behavioral Intervention Research to Address Modifiable Risk Factors for Cancer in Rural Populations (R01 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-20-051	18-Jan-2022	3,500,000 USD
	<p>Contact Name   Kelly D. Blake, ScD</p> <p>Contact Telephone   240-281-5934</p> <p>Contact Email   <a href="mailto:kelly.blake@nih.gov">kelly.blake@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   18-Jan-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to develop, adapt, and test individual-, community- or multilevel interventions to address modifiable risk factors for cancer in rural populations. Applications should focus on primary prevention and assess and address one or more of the social and behavioral risk factors that contribute to cancer disparities in rural populations: tobacco use; diet, physical activity and weight; alcohol use; UV exposure; and HPV vaccination. Applications should also assess and address myriad social determinants of health, cultural factors, and health care and technology access barriers that may contribute to rural cancer disparities. This FOA also encourages implementation science research, to incorporate efficacious cancer control interventions in a coordinated way, into broader, sustainable health programs that are designed to reach rural populations and allow local customization and adaptation.</p>				
105680	<a href="#">Notice of Special Interest (NOSI): National Cancer Institute SBIR/STTR Program Announcement Regarding Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings</a>	National Cancer Institute/NIH/DHHS	NOT-CA-21-062	05-Jan-2022	Not Specified
	<p>Contact Name   Ming Zhao, Ph.D.</p> <p>Contact Telephone   240-276-5225</p> <p>Contact Email   <a href="mailto:zhaoming3@mail.nih.gov">zhaoming3@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jan-2022 , 05-Apr-2022 , 07-Sep-2022 , 05-Jan-2023 , 05-Apr-2023 , 07-Sep-2023 , 05-Jan-2024 , 05-Apr-2024 , 05-Sep-2024</p> <p>Synopsis   The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Cancer Institute (NCI) are issuing this Notice of Special Interest (NOSI) to encourage SBIR/STTR grant applications from small</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>business concerns (SBCs) in response to SBIR/STTR Omnibus Solicitations proposing commercially-directed research for the development of cancer prevention, diagnosis, or treatment technologies to improve cancer outcomes in low- and middle-income countries (LMICs), and low-resource settings in the US. Specifically, the NCI through this NOSI encourages grant applications from SBCs to develop or adapt, apply, and validate existing or emerging technologies into user-friendly products for cancer prevention, diagnosis, or treatment in low-resource settings. These technologies should be practical and affordable in low-resource settings, including remote or underserved populations within or outside the US. The technologies may include but are not limited to tools for vaccine dissemination/delivery, imaging, in vitro diagnosis, or treatment of pre-cancerous (pre-neoplastic) or cancerous lesions that are preventable or treatable within low-resource settings. Strong emphasis is placed on technologies that directly provide or immediately lead to prevention, diagnosis, or treatment options available in the local health system. This funding opportunity is part of a broader NCI-sponsored AffordableCancer Technologies (ACTs) Program. Note: LMIC is defined according to the World Bank Country and Lending Groups and is inclusive of low- and middle-income countries, not including upper-middle income countries, for the purposes of this NOSI.</p>				
106036	<a href="#">Notice of Special Interest (NOSI): Advancing the Development of Tumor Site-Activated Small Molecules</a>	National Cancer Institute/NIH/DHHS	NOT-CA-21-101	26-Jan-2022	Not Specified
	Contact Name	Sharad K. Verma, PhD			
	Contact Telephone	202-657-3694			
	Contact Email	<a href="mailto:sharad.verma@nih.gov">sharad.verma@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	26-Jan-2022 , 05-Feb-2022 , 22-Feb-2022 , 21-Mar-2022 , 07-May-2022 , 26-May-2022 , 05-Jun-2022 , 21-Jun-2022 , 20-Jul-2022 , 07-Sep-2022 , 27-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 26-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 26-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 26-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	This Notice of Special Interest (NOSI) seeks to highlight the interest of NCI's Division of Cancer Treatment and Diagnosis (DCTD) to support investigation of the development of novel therapies for cancer-applied research encompassing chemistry and biology disciplines to support the discovery and testing of novel therapeutics offering improved safety and efficacy profiles for eventual translation to the clinic.			
082789	<a href="#">Research Projects in Cancer Systems Biology (U01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-287	28-Jan-2022	2,000,000 USD
	Contact Name	Dr. Shannon K. Hughes			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   240-276-6224</p> <p>Contact Email   <a href="mailto:shannon.hughes@nih.gov">shannon.hughes@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   28-Jan-2022</p> <p>Synopsis   The National Cancer Institute's (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and cancer researchers who collaborate to advance our understanding of the mechanisms underlying cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must be based upon explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research.</p>				
086964	<a href="#">NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-20-052	20-Oct-2021	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   20-Oct-2021 , 07-Jan-2022 , 24-Feb-2022 , 07-May-2022 , 24-Jun-2022 , 07-Sep-2022 , 20-Oct-2022 , 07-Jan-2023</p> <p>Synopsis   This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</p>				
088519	<a href="#">National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-20-077	07-Jan-2022	Not Specified
	<p>Contact Name   Referral Officer</p> <p>Contact Telephone   240-276-6390</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:ncirefof@dea.nci.nih.gov">ncirefof@dea.nci.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023</p> <p>Synopsis With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.</p>				
106166	<a href="#">Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-278	07-Jan-2022	1,500,000 USD
	<p>Contact Name Sergey Radaev, Ph.D.</p> <p>Contact Telephone 240-276-5630</p> <p>Contact Email <a href="mailto:sradaev@mail.nih.gov">sradaev@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 25-Jan-2022 , 05-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023 , 25-May-2023 , 07-Sep-2023 , 25-Sep-2023 , 07-Jan-2024 , 25-Jan-2024 , 07-May-2024 , 25-May-2024 , 07-Sep-2024</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.</p>				
106210	<a href="#">Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-279	07-Jan-2022	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Sergey Radaev, Ph.D.
Contact Telephone	240-276-5630
Contact Email	<a href="mailto:sradaev@mail.nih.gov">sradaev@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 25-Jan-2022 , 05-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023 , 25-May-2023 , 07-Sep-2023 , 25-Sep-2023 , 07-Jan-2024 , 25-Jan-2024 , 07-May-2024 , 25-May-2024 , 07-Sep-2024
Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.

100806	<a href="#">Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-21-065	07-Jan-2022	300,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Jeannette F. Korczak, Ph.D.
Contact Telephone	240-276-5630
Contact Email	<a href="mailto:korczakj@mail.nih.gov">korczakj@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 25-Jan-2022 , 05-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023 , 25-May-2023 , 07-Sep-2023 , 25-Sep-2023 , 07-Jan-2024
Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.

103805	<a href="#">Notice of Special Interest (NOSI): Expanding Cancer Control Research in Persistent Poverty Areas</a>	National Cancer Institute/NIH/DHHS	NOT-CA-21-071	07-Jan-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Shobha Srinivasan, Ph.D.
Contact Telephone	240-276-6938
Contact Email	<a href="mailto:sriniva2@mail.nih.gov">sriniva2@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023
Synopsis	The purpose of this Notice is to inform potential applicants about the National Cancer Institute (NCI)’s special interest in providing resources to support highly collaborative, multi-disciplinary Program Projects (P01s) that focus on the development and conduct of cancer control research in low-income and/or underserved populations living in persistent poverty (PP) areas. NCI is interested in programs that address the challenges and opportunities related to working in partnership with local clinics and other health or public health-related organizations to enhance the prevention of cancer and delivery of cancer care strategies to reduce the burden of cancer in PP areas. There are several areas where NCI can play a significant role in advancing cancer control research in PP areas and improve efforts to achieving health equity for all. This NOSI is a part of a larger NCI research initiative to inform, test, implement, and strengthen cancer control programs that are sustainable in PP areas across the United States (U.S.).

101162	<a href="#">Notice of Special Interest (NOSI): Tailoring Follow-up Care for Survivors Using Risk-Stratified Pathways</a>	National Cancer Institute/NIH/DHHS	NOT-CA-21-019	07-Jan-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Michelle Mollica, PhD, MPH, RN, OCN
Contact Telephone	240-276-7621



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:michelle.mollica@nih.gov">michelle.mollica@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023</p> <p>Synopsis The purpose of this Notice is to highlight the NCI Division of Cancer Control and Population Sciences' interest in receiving applications focused on identifying important factors for defining risk-stratified survivorship care or developing and testing approaches to improve the clinical management and outcomes for adult cancer survivors using risk-stratified survivorship care pathways. Risk-stratified survivorship care describes a personalized approach to care in which cancer survivors are triaged or stratified to distinct care pathways based on the complexity of their needs and the types of providers their care requires.</p>				
102330	<a href="#">RFA-CA-21-030 -- Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-21-030	07-Jan-2022	2,375,000 USD
	<p>Contact Name Paul C. Pearlman, Ph.D.</p> <p>Contact Telephone 240-276-5354</p> <p>Contact Email <a href="mailto:paul.pearlman@nih.gov">paul.pearlman@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The U01 project includes studies to both adapt this technology as well as demonstrate technical functionality and clinical performance for use of the device or assay in specific LMIC settings by meeting objective performance milestones followed by improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must consider affordability and cost-effectiveness as well as</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		usability at the point-of-need as part of their design criteria. This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.			
102278	<a href="#">Notice of Special Interest (NOSI): Translation of Quantitative Imaging Tools and Methods for the Academic Industrial Partnership</a>	National Cancer Institute/NIH/DHHS		NOT-CA-21-032 07-Jan-2022	Not Specified
	Contact Name	Robert J. Nordstrom, Ph.D.			
	Contact Telephone	240-276-5934			
	Contact Email	<a href="mailto:nordstrr@mail.nih.gov">nordstrr@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022			
	Synopsis	This NOSI highlights the NCI Cancer Imaging Program's interest in receiving investigator-initiated grant applications focused on the translation of mature well-developed and optimized quantitative imaging (QI) tools and methods for prediction and/or measurement of response to cancer therapies, or for planning and translating radiation therapy treatment strategies in clinical trials and workflow.			
106733	<a href="#">Notice of Special Interest (NOSI): Dietary Effects on Nutrient Sensing Pathways in Tumor Etiology and Prevention</a>	National Cancer Institute/NIH/DHHS		NOT-CA-21-121 26-Jan-2022	Not Specified
	Contact Name	Phillip J. Daschner, MSc			
	Contact Telephone	240-276-6227			
	Contact Email	<a href="mailto:pd93u@nih.gov">pd93u@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	26-Jan-2022 , 05-Feb-2022 , 12-Feb-2022 , 22-Feb-2022 , 25-Feb-2022 , 21-Mar-2022 , 26-Apr-2022 , 07-May-2022 , 26-May-2022 , 05-Jun-2022 , 12-Jun-2022 , 21-Jun-2022 , 25-Jun-2022 , 20-Jul-2022 , 26-Aug-2022 , 07-Sep-2022 , 27-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 25-Oct-2022 , 28-Dec-2022 , 07-Jan-2023 , 26-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 25-Feb-2023 , 26-Apr-2023 , 07-May-2023 , 26-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 25-Jun-2023 , 07-Sep-2023 , 26-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 25-Oct-2023 , 28-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 25-Jun-2024 , 07-Sep-2024			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p style="text-align: center;">Synopsis</p> <p>This Notice of Special Interest (NOSI) seeks to support new and ongoing basic research that provides a deeper understanding of the biology and molecular mechanisms that determine the outcome of key diet/nutrient/cell interactions during early tumor development. Specifically, studies that examine the tumor preventive or tumor-promoting effects of dietary modulation of nutrient sensor signaling pathways during early tumor formation (initiation and malignant progression from early lesions) in preclinical cell, organoid, and animal models, with the goal of identifying and testing potential molecular intervention targets.</p>				
106890	<p><a href="#">Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)</a></p>	National Cancer Institute/NIH/DHHS	PAR-21-321	25-Jan-2022	Not Specified
	<p style="text-align: center;">Synopsis</p> <p>This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.</p>	<p>Contact Name</p> <p>Contact Telephone 240-276-5600</p> <p>Contact Email <a href="mailto:ncicenters-r@mail.nih.gov">ncicenters-r@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023 , 25-May-2023 , 25-Sep-2023 , 25-Jan-2024 , 25-May-2024 , 25-Sep-2024 , 25-Jan-2025</p>			
082214	<p><a href="#">Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)</a></p>	National Cancer Institute/NIH/DHHS	PAR-19-274	07-Jan-2022	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Gila Neta, Ph.D.</p> <p>Contact Telephone   240-276-6785</p> <p>Contact Email   <a href="mailto:gila.neta@nih.gov">gila.neta@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 07-May-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.</p>				
077667	<a href="#">Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PA-18-932	07-Jan-2022	Not Specified
	<p>Contact Name   Erica S. Breslau, PhD, MPH</p> <p>Contact Telephone   240-276-6773</p> <p>Contact Email   <a href="mailto:breslaue@mail.nih.gov">breslaue@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 07-May-2022</p> <p>Synopsis   National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that seek to understand strategies to reduce disparities in the uptake of evidence-based screening (e.g. screening recommendations proven to be effective based on rigorous systematic review of scientific evidence by authoritative committees) across the adult lifespan. In this program announcement, screening is defined as a preventive service focused on detection of an undiagnosed disease in asymptomatic populations. Research supported by this initiative should enhance the screening process related to use: (1) in diverse populations, (2) in diverse clinical and community settings, and/or (3) with traditional, non-traditional and/or allied health care providers. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
105645	<a href="#">Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-21-290	05-Nov-2021	499,999 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Shane Woodward</p> <p>Contact Telephone   240-276-6624</p> <p>Contact Email   <a href="mailto:woodwars@mail.nih.gov">woodwars@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Nov-2021 , 07-Jan-2022 , 05-Feb-2022 , 05-Mar-2022 , 07-May-2022 , 05-Jun-2022 , 05-Jul-2022 , 07-Sep-2022 , 05-Oct-2022 , 05-Nov-2022 , 07-Jan-2023 , 05-Feb-2023 , 05-Mar-2023 , 07-May-2023 , 05-Jun-2023 , 05-Jul-2023 , 07-Sep-2023 , 05-Oct-2023 , 05-Nov-2023 , 07-Jan-2024 , 05-Feb-2024 , 05-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 05-Jul-2024 , 07-Sep-2024</p> <p>Synopsis   National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
092626	<a href="#">RFA-CA-20-031 -- Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries (D43 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	RFA-CA-20-031	07-Jan-2022	1,250,000 USD
	<p>Contact Name   Sudha Sivaram, DrPH, MPH</p> <p>Contact Telephone   240-276-5804</p> <p>Contact Email   <a href="mailto:nciglobaltraining@nih.gov">nciglobaltraining@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to establish an institutional program for mentored training in global cancer research. This program will support research training led by the United States (U.S.)-based cancer research-intensive institutions working in collaboration with institutions in low and middle-income countries (LMICs). These training programs will be built upon the US institutions' pre-existing training infrastructure and research collaborations with LMICs and will leverage these resources to expand the global cancer research workforce both in the US and in LMICs. The overarching goal of this initiative is to build capacity to conduct innovative and collaborative global research projects that will contribute to the advancement of basic, clinical, translational, and population-based cancer research in LMICs. This FOA does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	clinical trial led by a mentor or co-mentor.				
100707	<a href="#">National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-21-033	07-Jan-2022	2,499,995 USD
	<p>Contact Name   Lori A. Henderson, Ph.D.</p> <p>Contact Telephone   240-276-5930</p> <p>Contact Email   <a href="mailto:hendersonlori@mail.nih.gov">hendersonlori@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the NCI DCTD website and/or the OHAM website to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not accept phase III clinical trials in any area of cancer research; therefore, applications that propose phase III clinical trials will be deemed non-responsive and will not be reviewed.</p>				
100708	<a href="#">Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)</a>	National Cancer Institute/NIH/DHHS	PAR-21-035	07-Jan-2022	Not Specified
	<p>Contact Name   Brandy Heckman-Stoddard, Ph.D., M.P.H.</p> <p>Contact Telephone   240-276-7048</p> <p>Contact Email   <a href="mailto:heckmanbm@mail.nih.gov">heckmanbm@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA and the application instructions. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.</p>			
083680	<a href="#">Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-309	07-Jan-2022	275,000 USD
	Contact Name	Tanya Agurs-Collins, Ph.D			
	Contact Telephone	240-276-6956			
	Contact Email	<a href="mailto:collinsta@mail.nih.gov">collinsta@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve several stages of the cancer continuum and any phase of the translational spectrum.</p>			
101459	<a href="#">Notice of Special Interest (NOSI): Leveraging Population-based Cancer Registry Data to Study Health Disparities</a>	National Cancer Institute/NIH/DHHS	NOT-CA-21-020	07-Jan-2022	Not Specified
	Contact Name	Kathy Cronin, Ph.D.			
	Contact Telephone	240-276-6836			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:cronink@mail.nih.gov">cronink@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to encourage applications that efficiently use the existing cancer registry infrastructure by augmenting existing data with additional information not routinely collected by registries to study observed health disparities such as those that exist by race, ethnicity, socioeconomic status, income, insurance status, age, education level, or geographic area. The Surveillance, Epidemiology, and End Results (SEER) Program and the National Program of Cancer Registries (NPCR) are uniquely positioned to support research to assess health disparities in the United States (US) population because they contain information on all cases diagnosed within geographically defined areas. The goal of these hypothesis-driven studies should be to understand why disparities in cancer treatment and outcomes persist by identifying factors contributing to disparities and their relative importance.</p>				
104859	<a href="#">Notice of Special Interest (NOSI): New Information Technology-Enabled Care Delivery Models to Improve Depression Care in Cancer</a>	National Cancer Institute/NIH/DHHS	NOT-CA-21-085	08-Nov-2021	Not Specified
	<p>Contact Name Gurvaneet S. Randhawa, M.D., M.P.H.</p> <p>Contact Telephone 240-276-6940</p> <p>Contact Email <a href="mailto:Gurvaneet.Randhawa@nih.gov">Gurvaneet.Randhawa@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-Nov-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-Mar-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 08-Nov-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-Mar-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Nov-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024</p> <p>Synopsis This Notice of Special Interest (NOSI) highlights interest of the National Cancer Institute (NCI)'s Division of Cancer Control and Population Sciences in receiving investigator-initiated applications for conducting research on the design and implementation of new information technology (IT)-enabled care delivery models to improve depression-related care in cancer.</p>				
082215	<a href="#">Dissemination and Implementation Research in Health (R21 Clinical Trial)</a>	National Cancer	PAR-19-	07-Jan-2022	275,000



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Optional)</a>	Institute/NIH/DHHS	275		USD
	Contact Name	Gila Neta, Ph.D.			
	Contact Telephone	240-276-6785			
	Contact Email	<a href="mailto:gila.neta@nih.gov">gila.neta@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed above.			
082216	<a href="#">Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-19-276	07-Jan-2022	50,000 USD
	Contact Name	Gila Neta, Ph.D.			
	Contact Telephone	240-276-6785			
	Contact Email	<a href="mailto:gila.neta@nih.gov">gila.neta@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed above.			
079335	<a href="#">Exploratory/Developmental Bioengineering Research Grants(EBRG) (R21 Clinical Trial Not Allowed)</a>	National Cancer Institute/NIH/DHHS	PAR-19-149	07-Jan-2022	275,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Miguel R. Ossandon, Ph.D.</p> <p>Contact Telephone   240-276-5714</p> <p>Contact Email   <a href="mailto:ossandom@mail.nih.gov">ossandom@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022</p> <p>Synopsis   The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.</p>				
079333	<a href="#">Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)</a>	National Cancer Institute/NIH/DHHS	PAR-19-150	07-Jan-2022	275,000 USD
	<p>Contact Name   Miguel R. Ossandon, Ph.D.</p> <p>Contact Telephone   240-276-5714</p> <p>Contact Email   <a href="mailto:ossandom@mail.nih.gov">ossandom@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022</p> <p>Synopsis   The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of Exploratory/Developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.</p>				
103489	<a href="#">Notice of Special Interest (NOSI): Telehealth in Cancer Care</a>	National Cancer Institute/NIH/DHHS	NOT-CA-21-043	07-Jan-2022	Not Specified
	<p>Contact Name   Gurvaneet Randhawa, M.D., M.P.H.</p> <p>Contact Telephone   240-276-6940</p> <p>Contact Email   <a href="mailto:Gurvaneet.Randhawa@nih.gov">Gurvaneet.Randhawa@nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to highlight the interest of the NCI's Division of Cancer Control and Population Sciences in receiving investigator-initiated applications for conducting research on the use of telehealth in cancer-related care. Studies focused on populations that experience inequities in access to care and have worse cancer outcomes compared to the general population are strongly encouraged. This NOSI for R01 and R21 applications is a companion announcement to the RFA titled "Centers on Telehealth Research and Cancer-Related Care" (RFA-CA-21-029).</p>				
106125	<p><a href="#">Notice of Special Interest (NOSI): National Center for Complementary and Integrative Health (NCCIH) T32 Complementary and Integrative Health Practitioner Supplement Program for Pre- and Postdoctoral Candidates</a></p>	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT-21-014	03-Jan-2022	Not Specified
	<p>Contact Name Lanay Mudd, Ph.D.</p> <p>Contact Telephone 301-594-93466</p> <p>Contact Email <a href="mailto:Lanay.mudd@nih.gov">Lanay.mudd@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 03-Jan-2022 , 01-Jul-2022 , 02-Jan-2023 , 03-Jul-2023 , 02-Jan-2024 , 01-Jul-2024</p> <p>Synopsis NCCIH announces an opportunity to allow existing NCCIH-funded Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (T32) programs to apply for an administrative supplement to support an additional training slot for predoctoral and postdoctoral candidates with professional clinical complementary and integrative health degrees.</p>				
090500	<p><a href="#">Center of Excellence for Research on Complementary and Integrative Health (P01 Clinical Trial Optional)</a></p>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-138	25-Jan-2022	6,250,000 USD
	<p>Contact Name Craig Hopp, Ph.D.D</p> <p>Contact Telephone 301-496-5825</p> <p>Contact Email <a href="mailto:hoppdc@mail.nih.gov">hoppdc@mail.nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023 , 25-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages the submission of applications requiring multi-project, synergistic collaborations blending multiple research approaches from outstanding multidisciplinary research teams. This Center of Excellence for Research on Complementary and Integrative Health (CERCIH) program is designed to support three or more highly meritorious projects that can offer significant scientific advantages and "synergy" that could not be achieved by supporting the same projects as individual research grants. Each CERCIH must be focused on questions of high relevance to the mission of NCCIH and high research priority based on the current Strategic Plan. Applications in response to this FOA may propose to involve human participants in mechanistic studies, but this FOA will not support clinical trials of efficacy or effectiveness.</p>				
101958	<a href="#">Limited Competition for the Continuation or Revision of Multisite Clinical Trial Clinical Coordinating Center (Collaborative UH3 Clinical Trial Optional)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21-117	28-Jan-2022	Not Specified
	<p>Contact Name Wendy Weber, N.D., Ph.D., M.P.H.</p> <p>Contact Telephone 301-402-1272</p> <p>Contact Email <a href="mailto:weberwj@mail.nih.gov">weberwj@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 28-Jan-2022 , 27-May-2022 , 28-Sep-2022 , 27-Jan-2023 , 29-May-2023 , 27-Sep-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) accepts applications for competing renewal of a Clinical Coordinating Center (CCC) for ongoing clinical trials supported by NCCIH or competitive revisions to support ancillary studies to ongoing NCCIH-supported clinical trials. Extension of an ongoing clinical trial will be supported when there is a need for additional time to complete the trial or when an extended period of follow-up is well justified to assess longer term outcomes. Competitive revisions will be supported when there is compelling justification for the addition of an ancillary study to an ongoing clinical trial. The objective of the CCC is to provide the design scientific rationale and a comprehensive scientific and operational plan for the clinical trial. The CCC is expected to be responsible for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Both a Data Coordinating Center (DCC) application and a corresponding CCC application should be submitted simultaneously for consideration by NCCIH if both are needed to complete the ongoing clinical trial. Applicants are strongly encouraged to contact the appropriate</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Scientific/Research contact for the ongoing clinical trial for which they are planning a competing renewal application or competitive revision prior to submitting to this FOA.			
101953	<a href="#">Limited Competition for the Continuation of Multisite Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Optional)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21-116	28-Jan-2022	Not Specified
	<p>Contact Name   Wendy Weber, N.D., Ph.D., M.P.H.</p> <p>Contact Telephone   301-402-1272</p> <p>Contact Email   <a href="mailto:weberwj@mail.nih.gov">weberwj@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   28-Jan-2022 , 27-May-2022 , 28-Sep-2022 , 27-Jan-2023 , 29-May-2023 , 27-Sep-2023</p> <p>Synopsis   This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, accepts applications for competing renewal of Data Coordinating Center (DCC) for ongoing clinical trials supported by NCCIH. Extension of an ongoing clinical trial will be allowed when there is a compelling need for additional time to complete the trial or when an extended period of follow-up is well justified to assess longer term outcomes. The DCC competing renewal application must propose a comprehensive plan for completion of the clinical trial data collection that provides overall project coordination and administrative, data management, and biostatistical support for the ongoing clinical trial. Both a DCC application and a corresponding Clinical Coordinating Center (CCC) application can be submitted simultaneously for consideration by NCCIH if both are needed to complete the ongoing trial. If clinical trial data collection and follow-up can be completed centrally by the DCC and no study visits at clinical sites are needed, a single application for competing renewal for the DCC can be submitted. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the ongoing clinical trial for which they are planning a competing renewal application prior to submitting to this FOA.</p>				
094930	<a href="#">NCCIH Natural Product Mid Phase Clinical Trial Cooperative Agreement (U01 Clinical Trial Required)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-216	07-Jan-2022	1,750,000 USD
	<p>Contact Name   Wendy Weber, N.D., Ph.D., M.P.H.</p> <p>Contact Telephone   301-402-1272</p> <p>Contact Email   <a href="mailto:weberwj@mail.nih.gov">weberwj@mail.nih.gov</a></p> <p>Sponsor Website  </p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for investigator-initiated mid-phase clinical trials of natural products. All applications submitted under this FOA must be supported by sufficient preliminary data of bioavailability and documentation that the natural product produces a replicable and measurable impact on a biological signature (i.e., measure of the mechanism of action). Only in cases when it is not possible/practical to measure a biological signature in the patient population of interest or when there is a fundamental understanding of the product's mechanism of action will this preliminary data requirement be waived. Applications submitted to this FOA should propose a mid-phase clinical trial to do the following: determine the optimal dose or formulation of a given natural product for use in a future multi-site clinical trial; or determine which patient phenotypes will be responders versus non-responders to the natural product to inform inclusion/exclusion criteria of a future efficacy study. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This FOA will not support single-site or multi-site efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.</p>				
094929	<a href="#">Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-215	07-Jan-2022	Not Specified
	<p>Contact Name Wendy Weber, N.D., Ph.D, M.P.H.</p> <p>Contact Telephone 301-402-1272</p> <p>Contact Email <a href="mailto:weberwj@mail.nih.gov">weberwj@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for investigator-initiated, multi-site, clinical trials (Phase III and beyond) to study the effects of natural products in NCCIH designated areas of high research priority. Applicants should describe plans for a Clinical Coordinating Center to develop and implement the proposed multi-site clinical trial. The objective of the Clinical Coordinating Center is to provide the design scientific rationale and a comprehensive scientific and operational plan for the clinical trial. The Clinical Coordinating Center is expected to be responsible for project management, participant recruitment and retention strategies, performance milestones, scientific</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a two-phase, milestone-driven, cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data Coordinating Center application, submitted under PAR-20-219, proposing a data analysis and data management plan for the clinical project is required. Both a Clinical Coordinating Center application and a corresponding Data Coordinating Center (DCC) application need to be submitted simultaneously for consideration by NCCIH.

094934	<a href="#">Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-219	07-Jan-2022	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Wendy Weber, N.D., Ph.D, M.P.H.
Contact Telephone	301-402-1272
Contact Email	<a href="mailto:weberwj@mail.nih.gov">weberwj@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023
Synopsis	This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-20-215 The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: ( <a href="http://www.nccih.nih.gov">http://www.nccih.nih.gov</a> ). Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

091405	<a href="#">Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)</a>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-154	07-Jan-2022	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Lanay Mudd, Ph.D
Contact Telephone	301-594-9346

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:lanay.mudd@mail.nih.gov">lanay.mudd@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH designated areas of high research priority. Applications submitted under this FOA are expected to propose a remotely delivered and conducted clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. To justify the proposed remotely delivered efficacy or effectiveness clinical trial, applications must have sufficient preliminary data that includes: demonstration of feasibility of remote recruitment and accrual of participants; demonstration of participant adherence to the intervention as well as retention of participants throughout the study; completion of final data collection from any related studies; demonstration of the safety of the intervention; and evidence that the intervention has promise of clinical benefit. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.</p>				
102903	<p><a href="#">Notice of Special Interest (NOSI): Fundamental Science Research on Complementary and Integrative Health Approaches</a></p>	National Center for Complementary and Integrative Health/NIH/DHHS	NOT-AT-21-006	07-Jan-2022	Not Specified
	<p>Contact Name Wen Chen, M.M.Sc., Ph.D.</p> <p>Contact Telephone 301-451-3989</p> <p>Contact Email <a href="mailto:chenw@mail.nih.gov">chenw@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to describe NCCIH priorities in innovative basic and mechanistic research or technology/method development research relevant to complementary and integrative health approaches.</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
105041	<a href="#">NEI Vision Research Epidemiology Grant (UG1 Clinical Trial Not Allowed)</a>	National Eye Institute/NIH/DHHS	PAR-21-204	07-Jan-2022	Not Specified
	<p>Contact Name   Sangeeta Bhargava, PhD,</p> <p>Contact Telephone   301-451-2020</p> <p>Contact Email   <a href="mailto:bhargavas@mail.nih.gov">bhargavas@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023 , 25-May-2023 , 07-Sep-2023 , 25-Sep-2023 , 07-Jan-2024 , 25-Jan-2024 , 07-May-2024 , 25-May-2024 , 07-Sep-2024</p> <p>Synopsis   The National Eye Institute (NEI) supports investigator-initiated, complex, multi-center and other high resource risk epidemiologic studies under the cooperative agreement mechanism, UG1 activity code. Specifically, the purpose of this Funding Opportunity Announcement (FOA) is to support new and innovative ocular epidemiology research.</p>				
100802	<a href="#">NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required)</a>	National Eye Institute/NIH/DHHS	PAR-21-042	07-Jan-2022	Not Specified
	<p>Contact Name   Donald Everett, MA</p> <p>Contact Telephone   301-451-2020</p> <p>Contact Email   <a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023</p> <p>Synopsis   The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer, stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chair's Grant, the Coordinating Center, and Resource Centers, when appropriate. Specifically, this FOA encourages applications for</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| the Coordinating Center grant, which provides details of the Coordinating Center's responsibilities and operations.

100803	<a href="#">NEI Collaborative Clinical Vision Project: Resource Center Grant (UG1- Clinical Trial Required)</a>	National Eye Institute/NIH/DHHS	PAR-21-043	07-Jan-2022	Not Specified
--------	---	---------------------------------	------------	-------------	---------------

Contact Name	Donald Everett, MA
Contact Telephone	301-451-2020
Contact Email	<a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023
Synopsis	The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer, stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chair's Grant, the Coordinating Center, and Resource Centers, when appropriate. Specifically, this FOA encourages applications for the Resource Center grant which provides imaging, laboratory, or other requisite services for a multi-center clinical trial or other complex or high-risk clinical trial

100798	<a href="#">NEI Collaborative Clinical Vision Research : Chair's Grant (UG1-Clinical Trial Required)</a>	National Eye Institute/NIH/DHHS	PAR-21-041	07-Jan-2022	Not Specified
--------	--	---------------------------------	------------	-------------	---------------

Contact Name	Donald Everett, MA
Contact Telephone	301-451-2020
Contact Email	<a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer, stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chair's Grant, the Coordinating Center, and Resource Centers, when appropriate. Specifically, this FOA encourages applications for the Chair's grant, which includes the scientific rationale, study aims and significance of the research project.</p>			
081084	<a href="#">NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)</a>	National Eye Institute/NIH/DHHS	PAR-19-231	07-Jan-2022	300,000 USD
	Contact Name	Donald Everett, MA			
	Contact Telephone	301-451-2020			
	Contact Email	<a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022			
	Synopsis	<p>The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a well-documented Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This FOA is designed to facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed MOP. The NEI Clinical Study Planning Grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.</p>			
101324	<a href="#">Notice of Special Interest (NOSI): NEI Anterior Segment Initiative (ASI): Identification and Development of New Biomarkers and Effective Methods to Diagnose Dry Eye Disease.</a>	National Eye Institute/NIH/DHHS	NOT-EY-21-007	05-Jan-2022	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jan-2022 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of the NEI in research to identify new biomarkers and develop effective methods that can be used for the early diagnosis of dry eye disease (DED) and its subtypes, prognosis of disease progression, and monitoring of treatment response.</p>				
081744	<p><a href="#">NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)</a></p>	National Eye Institute/NIH/DHHS	PAR-19-260	07-Jan-2022	275,000 USD
	<p>Contact Name Donald Everett, M.A.</p> <p>Contact Telephone 301-451-2020</p> <p>Contact Email <a href="mailto:everettd@mail.nih.gov">everettd@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis This FOA encourages applications from institutions/organizations that propose to conduct vision-related secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
103977	<a href="#">RFA-HL-23-004 -- NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 23-004	16-Jan-2022 [Optional][LOI/Pre-App]	4,900,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Narasimhan Danthi, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-451-5170</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:ndanthi@nhlbi.nih.gov">ndanthi@nhlbi.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>16-Jan-2022 [Optional][LOI/Pre-App], 15-Feb-2022 , 26-Mar-2022 [Optional][LOI/Pre-App], 25-Apr-2022 , 16-Jan-2023 [Optional][LOI/Pre-App], 15-Feb-2023 , 26-Mar-2023 [Optional][LOI/Pre-App], 25-Apr-2023 , 16-Jan-2024 [Optional][LOI/Pre-App], 15-Feb-2024 , 26-Mar-2024 [Optional][LOI/Pre-App], 25-Apr-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td> <p>The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. The OIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe.</p> <p>Research supported by the OIA must be within the scope of the NHLBI mission. It is anticipated that the OIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs' commitment to research through increased stability of funding; and Enable PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service.</p> </td> </tr> </table>					Contact Name	Narasimhan Danthi, Ph.D.	Contact Telephone	301-451-5170	Contact Email	<a href="mailto:ndanthi@nhlbi.nih.gov">ndanthi@nhlbi.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	16-Jan-2022 [Optional][LOI/Pre-App], 15-Feb-2022 , 26-Mar-2022 [Optional][LOI/Pre-App], 25-Apr-2022 , 16-Jan-2023 [Optional][LOI/Pre-App], 15-Feb-2023 , 26-Mar-2023 [Optional][LOI/Pre-App], 25-Apr-2023 , 16-Jan-2024 [Optional][LOI/Pre-App], 15-Feb-2024 , 26-Mar-2024 [Optional][LOI/Pre-App], 25-Apr-2024	Synopsis	<p>The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. The OIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe.</p> <p>Research supported by the OIA must be within the scope of the NHLBI mission. It is anticipated that the OIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs' commitment to research through increased stability of funding; and Enable PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service.</p>
Contact Name	Narasimhan Danthi, Ph.D.																		
Contact Telephone	301-451-5170																		
Contact Email	<a href="mailto:ndanthi@nhlbi.nih.gov">ndanthi@nhlbi.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	16-Jan-2022 [Optional][LOI/Pre-App], 15-Feb-2022 , 26-Mar-2022 [Optional][LOI/Pre-App], 25-Apr-2022 , 16-Jan-2023 [Optional][LOI/Pre-App], 15-Feb-2023 , 26-Mar-2023 [Optional][LOI/Pre-App], 25-Apr-2023 , 16-Jan-2024 [Optional][LOI/Pre-App], 15-Feb-2024 , 26-Mar-2024 [Optional][LOI/Pre-App], 25-Apr-2024																		
Synopsis	<p>The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. The OIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe.</p> <p>Research supported by the OIA must be within the scope of the NHLBI mission. It is anticipated that the OIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs' commitment to research through increased stability of funding; and Enable PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service.</p>																		
103978	<a href="#">RFA-HL-23-005 -- NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 23-005	16-Jan-2022 [Optional][LOI/Pre-App]	4,900,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Narasimhan Danthi, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-451-5170</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:ndanthi@nhlbi.nih.gov">ndanthi@nhlbi.nih.gov</a></td> </tr> </table>					Contact Name	Narasimhan Danthi, Ph.D.	Contact Telephone	301-451-5170	Contact Email	<a href="mailto:ndanthi@nhlbi.nih.gov">ndanthi@nhlbi.nih.gov</a>								
Contact Name	Narasimhan Danthi, Ph.D.																		
Contact Telephone	301-451-5170																		
Contact Email	<a href="mailto:ndanthi@nhlbi.nih.gov">ndanthi@nhlbi.nih.gov</a>																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	16-Jan-2022 [Optional][LOI/Pre-App], 15-Feb-2022 , 26-Mar-2022 [Optional][LOI/Pre-App], 25-Apr-2022 , 16-Jan-2023 [Optional][LOI/Pre-App], 15-Feb-2023 , 26-Mar-2023 [Optional][LOI/Pre-App], 25-Apr-2023 , 16-Jan-2024 [Optional][LOI/Pre-App], 15-Feb-2024 , 26-Mar-2024 [Optional][LOI/Pre-App]			
	Synopsis	<p>The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrate their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. The EIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the EIA must be within the scope of the NHLBI mission. It is anticipated that the EIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs' commitment to research through increased stability of funding; and Enable PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service</p>			
100058	<a href="#">Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets (R01 Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-21-027	07-Jan-2022	1,920,000 USD
	Contact Name	Shimian Zou, Ph.D.			
	Contact Telephone	301-827-8301			
	Contact Email	<a href="mailto:zous@mail.nih.gov">zous@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 07-May-2022 , 07-Jan-2023			
	Synopsis	This Funding Opportunity Announcement (FOA) seeks applications for comprehensive systems biology studies using multidisciplinary team science to identify common, overlapping etiologies of HIV-associated comorbidities. Ultimately, the			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	goal is to identify targets for intervention to mitigate multiple comorbidities associated with HIV infection.																		
100990	<a href="#">NHLBI Program Project Applications (P01 Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-21-088	25-Jan-2022	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Denis Buxton, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-435-0515</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:denis.buxton@nih.gov">denis.buxton@nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023 , 25-May-2023 , 25-Sep-2023</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA), issued by the National Heart, Lung, and Blood Institute (NHLBI) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NHLBI mission including the biology and diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders. Programs may also include implementation science, health disparities, and translation research that addresses the mission of the Institute. Each application submitted in response to this FOA must include at least three related research projects that share a common central theme, focus, and/or overall objective. Higher budgets may be requested for applications that include at least four projects, one of which includes an Early Stage Investigator as Project Leader.</td> </tr> </table>					Contact Name	Denis Buxton, Ph.D.	Contact Telephone	301-435-0515	Contact Email	<a href="mailto:denis.buxton@nih.gov">denis.buxton@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023 , 25-May-2023 , 25-Sep-2023	Synopsis	This Funding Opportunity Announcement (FOA), issued by the National Heart, Lung, and Blood Institute (NHLBI) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NHLBI mission including the biology and diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders. Programs may also include implementation science, health disparities, and translation research that addresses the mission of the Institute. Each application submitted in response to this FOA must include at least three related research projects that share a common central theme, focus, and/or overall objective. Higher budgets may be requested for applications that include at least four projects, one of which includes an Early Stage Investigator as Project Leader.
Contact Name	Denis Buxton, Ph.D.																		
Contact Telephone	301-435-0515																		
Contact Email	<a href="mailto:denis.buxton@nih.gov">denis.buxton@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023 , 25-May-2023 , 25-Sep-2023																		
Synopsis	This Funding Opportunity Announcement (FOA), issued by the National Heart, Lung, and Blood Institute (NHLBI) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NHLBI mission including the biology and diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders. Programs may also include implementation science, health disparities, and translation research that addresses the mission of the Institute. Each application submitted in response to this FOA must include at least three related research projects that share a common central theme, focus, and/or overall objective. Higher budgets may be requested for applications that include at least four projects, one of which includes an Early Stage Investigator as Project Leader.																		
104079	<a href="#">RFA-HL-22-001 -- T32 Training Program for Institutions That Promote Diversity (T32 Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-22-001	29-Jan-2022 [Optional][LOI/Pre-App]	1,610,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Traci Mondoro, PhD</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-435-0050</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:NHLBI_Blood_Training@nhlbi.nih.gov">NHLBI_Blood_Training@nhlbi.nih.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>29-Jan-2022 [Optional][LOI/Pre-App], 28-Feb-2022 , 14-Aug-2022 [Optional][LOI/Pre-App], 13-Sep-2022 , 29-Jan-2023 [Optional][LOI/Pre-App], 28-Feb-2023 , 14-Aug-2023 [Optional][LOI/Pre-App], 13-Sep-2023 , 29-Jan-2024 [Optional][LOI/Pre-App], 28-Feb-2024</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of this funding opportunity announcement (FOA) is to enhance the participation of individuals from diverse</td> </tr> </table>					Contact Name	Traci Mondoro, PhD	Contact Telephone	301-435-0050	Contact Email	<a href="mailto:NHLBI_Blood_Training@nhlbi.nih.gov">NHLBI_Blood_Training@nhlbi.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	29-Jan-2022 [Optional][LOI/Pre-App], 28-Feb-2022 , 14-Aug-2022 [Optional][LOI/Pre-App], 13-Sep-2022 , 29-Jan-2023 [Optional][LOI/Pre-App], 28-Feb-2023 , 14-Aug-2023 [Optional][LOI/Pre-App], 13-Sep-2023 , 29-Jan-2024 [Optional][LOI/Pre-App], 28-Feb-2024	Synopsis	The purpose of this funding opportunity announcement (FOA) is to enhance the participation of individuals from diverse
Contact Name	Traci Mondoro, PhD																		
Contact Telephone	301-435-0050																		
Contact Email	<a href="mailto:NHLBI_Blood_Training@nhlbi.nih.gov">NHLBI_Blood_Training@nhlbi.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	29-Jan-2022 [Optional][LOI/Pre-App], 28-Feb-2022 , 14-Aug-2022 [Optional][LOI/Pre-App], 13-Sep-2022 , 29-Jan-2023 [Optional][LOI/Pre-App], 28-Feb-2023 , 14-Aug-2023 [Optional][LOI/Pre-App], 13-Sep-2023 , 29-Jan-2024 [Optional][LOI/Pre-App], 28-Feb-2024																		
Synopsis	The purpose of this funding opportunity announcement (FOA) is to enhance the participation of individuals from diverse																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>backgrounds, including those from groups that are nationally underrepresented in cardiovascular, pulmonary, hematologic and sleep disorders research across the career development continuum by providing support to institutions that promote diversity. The NHLBI's T32 Training Program for Institutions That Promote Diversity is a Ruth L. Kirschstein National Research Service Award Program intended to support training of predoctoral and health professional students and individuals in postdoctoral training institutions with an institutional mission focused on serving health disparity populations not well represented in scientific research, or institutions that have been identified by federal legislation as having an institutional mission focused on these populations, with the potential to develop meritorious training programs in cardiovascular, pulmonary, and hematologic diseases, and sleep disorders. These institutions are uniquely positioned to engage minority and other health disparity populations in research, translation, and implementation of research advances that impact health outcomes, as well as provide health care for these populations. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>			
104783	<a href="#">RFA-HL-22-012 -- Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL- 24-Jan-2022	22-012 [Optional][LOI/Pre-App]	770,000 USD
	<p>Contact Name   Paul Cotton, Ph.D., RDN</p> <p>Contact Telephone   301-435-0202</p> <p>Contact Email   <a href="mailto:paul.cotton@nih.gov">paul.cotton@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   24-Jan-2022 [Optional][LOI/Pre-App], 23-Feb-2022 , 10-Jul-2022 [Optional][LOI/Pre-App], 09-Aug-2022 , 24-Jan-2023 [Optional][LOI/Pre-App], 23-Feb-2023 , 10-Jul-2023 [Optional][LOI/Pre-App], 09-Aug-2023 , 24-Jan-2024 [Optional][LOI/Pre-App], 23-Feb-2024</p> <p>Synopsis   The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHLBI R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by providing research experiences and related opportunities that can enrich the pool of individuals from diverse backgrounds, including nationally underrepresented groups, who will be available to compete for research opportunities in the mission areas of importance to NHLBI. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences</p>				
101704	<a href="#">NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-21-119	07-Jan-2022	Not Specified



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Traci Heath Mondoro, Ph.D.</p> <p>Contact Telephone   301-435-0065</p> <p>Contact Email   <a href="mailto:xxxx@mail.nih.gov">xxxx@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 04-Jun-2022 , 07-Sep-2022 , 02-Oct-2022 , 07-Jan-2023 , 04-Jun-2023 , 07-Sep-2023 , 02-Oct-2023 , 07-Jan-2024</p> <p>Synopsis   The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This FOA will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.</p>				
101703	<a href="#">NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R33 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-21-118	07-Jan-2022	4,545,000 USD
	<p>Contact Name   Traci Heath Mondoro, Ph.D.</p> <p>Contact Telephone   301-435-0050</p> <p>Contact Email   <a href="mailto:mondorot@nhlbi.nih.gov">mondorot@nhlbi.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 04-Jun-2022 , 07-Sep-2022 , 02-Oct-2022 , 07-Jan-2023 , 04-Jun-2023 , 07-Sep-2023 , 02-Oct-2023 , 07-Jan-2024</p> <p>Synopsis   The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this FOA should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion FOA, PAR-21-119, which utilizes an R61/R33 phased approach.</p>				
079552	<a href="#">Implementation of Shared Decision Making for HLBS Diseases and Conditions</a>	National Heart, Lung, and Blood	PA-19-	07-Jan-2022	2,499,995

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">(R01 Clinical Trial Optional)</a>		Institute/NIH/DHHS	166	USD
	<p>Contact Name: Susan T. Shero, BSN, MS</p> <p>Contact Telephone: 301-496-1051</p> <p>Contact Email: <a href="mailto:sheros@nih.gov">sheros@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-Jan-2022 , 05-Feb-2022 , 07-May-2022</p> <p>Synopsis: The purpose of this initiative is to support research that uses evidence-based, practical approaches to increase the uptake of shared decision making (SDM) into routine clinical practice. Objectives are to improve patient-centered care for heart, lung, blood, and sleep (HLBS) diseases and conditions; and to address barriers and facilitators related to SDM strategies used to improve quality of care, adherence, and informed consent; reduce health disparities; and deliver treatments best suited for individual patients. Investigators and multidisciplinary research teams with expertise in clinical implementation research, health information technology, behavioral science, behavioral economics, workflow design, and organizational engineering are encouraged to apply.</p>				
106202	<a href="#">Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-015	07-Jan-2022	Not Specified
	<p>Contact Name: Alison G.M. Brown, PhD, MS, RDN</p> <p>Contact Telephone: 301-435-0583</p> <p>Contact Email: <a href="mailto:Alison.brown@nih.gov">Alison.brown@nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025 , 05-Feb-2025 , 07-May-2025 , 05-Jun-2025 , 07-Sep-2025 , 05-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 07-May-2026 , 05-Jun-2026</p> <p>Synopsis: This Notice of Special Interest (NOSI) calls for research to understand and promote cardiovascular and cardiometabolic health during transitional phases across the lifecourse, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years). This initiative would support research to: 1) understand the mechanisms and the</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitional phases from pre-adolescence into adolescence and adolescence into young adulthood, and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitional phases.				
084638	<a href="#">Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19-329	14-Jan-2022	Not Specified
	Contact Name	Nancy DiFronzo, PhD			
	Contact Telephone	301-435-0065			
	Contact Email	<a href="mailto:difronzon@nhlbi.nih.gov">difronzon@nhlbi.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	14-Jan-2022 , 11-Feb-2022 , 11-May-2022 , 10-Jun-2022 , 08-Sep-2022			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015) . For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (DCC) ( PAR-19-330 ). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating DCC application must be submitted on the same application due date for consideration by NHLBI.</p>			
084646	<a href="#">Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19-330	14-Jan-2022	Not Specified
	Contact Name	Nancy DiFronzo, PhD			
	Contact Telephone	301-435-0065			
	Contact Email	<a href="mailto:difronzon@nhlbi.nih.gov">difronzon@nhlbi.nih.gov</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Jan-2022 , 11-Feb-2022 , 11-May-2022 , 10-Jun-2022 , 08-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA ( PAR-19-329 ) that encourages applications for a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI.</p>				
084637	<a href="#">Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19-328	14-Jan-2022	Not Specified
	<p>Contact Name Nahed El Kassar, MD</p> <p>Contact Telephone 301-435-0065</p> <p>Contact Email <a href="mailto:nahed.elkassar@nih.gov">nahed.elkassar@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Jan-2022 , 11-Feb-2022 , 11-May-2022 , 10-Jun-2022 , 08-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention,</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination.

104361	<a href="#">RFA-HL-22-010 -- Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Required)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-22-010	07-Jan-2022	750,000 USD
--------	--	--	---------------	-------------	-------------

Contact Name	Jane D. Scott, ScD, MSN, FAHA
Contact Telephone	301-435-0535
Contact Email	<a href="mailto:scottj2@nhlbi.nih.gov">scottj2@nhlbi.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 11-Feb-2022 , 07-May-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Oct-2023 , 07-Jan-2024 , 13-Feb-2024 , 07-May-2024
Synopsis	<p>This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-HL-22-011).</p>

104360	<a href="#">RFA-HL-22-011 -- Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-22-011	07-Jan-2022	750,000 USD
--------	---	--	---------------	-------------	-------------

Contact Name	Jane D. Scott, ScD, MSN, FAHA
Contact Telephone	301-435-0535
Contact Email	<a href="mailto:scottj2@nhlbi.nih.gov">scottj2@nhlbi.nih.gov</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 11-Feb-2022 , 07-May-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Oct-2023 , 07-Jan-2024 , 13-Feb-2024 , 07-May-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from Institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator should apply to the companion FOA (RFA-HL-22-010).</p>				
099803	<a href="#">Notice of Special Interest (NOSI): Palliative Care in Heart, Lung, Blood, and Sleep Diseases</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-20-737	07-Jan-2022	Not Specified
	<p>Contact Name Lora Reineck, MD, MS</p> <p>Contact Telephone 301-435-0222</p> <p>Contact Email <a href="mailto:lora.reineck@nih.gov">lora.reineck@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023</p> <p>Synopsis Providing care that is consistent with a patient’s values, preferences, and goals is a cornerstone of palliative care, an interdisciplinary patient-centered approach that aims to improve quality of life for persons with advanced illness and their families. Palliative care focuses on several objectives including relief of symptoms and suffering, communication of prognosis</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and treatment options in the context of patients’ goals, and coordination of care within and across healthcare settings. Palliative care is not synonymous with hospice or end-of-life care. Rather, palliative care addresses the spectrum of care for serious illness from diagnosis through terminal stages of diseases. Moreover, palliative care does not necessarily entail withholding or curbing treatment. Relief of symptoms, enhancing quality of life, and many other specific aspects of goal-concordant care may, in fact, involve optimal medical or surgical treatment of diseases. The expected outcome of integrating palliative care into the management of the patient’s disease is a better quality of life, a realistic understanding of risks and benefits of treatment and interventions, and medical treatment decisions that align with the patient’s goals, preferences, and values. Many heart, lung, blood, and sleep (HLBS) diseases, including heart failure, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pulmonary hypertension, cystic fibrosis, myelodysplastic syndromes, and aplastic anemia are life-limiting, non-curable illnesses. These and other HLBS diseases may benefit from care focused on improvement of symptoms and quality of life, in addition to care focused on slowing or halting progression of diseases. Integration of palliative care into cardiology, pulmonary, hematology, and critical care practice is recommended by multiple professional societies. Additionally, symptoms of HLBS diseases such as cough, shortness of breath, and fatigue may be especially burdensome, even in diseases that are not life-limiting. Research to improve burdensome symptoms has the potential to greatly improve the quality of life for all patients with HLBS diseases, not just those with life-limiting disease.

100447	<a href="#">Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-20-815	07-Jan-2022	Not Specified
--------	--	--	---------------	-------------	---------------

Contact Name	Rebecca A. Roper, MS, MPH
Contact Telephone	301-496-1051
Contact Email	<a href="mailto:Rebecca.Roper@nih.gov">Rebecca.Roper@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024
Synopsis	NHLBI is issuing this Notice of Special Interest (NOSI) to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
100825	<a href="#">Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent RO1 Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-20-823	07-Jan-2022	Not Specified
	<p>Contact Name   Weiniu Gan, Ph.D.</p> <p>Contact Telephone   301-435-0202</p> <p>Contact Email   <a href="mailto:ganw2@mail.nih.gov">ganw2@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023</p> <p>Synopsis   The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has recently created the Trans Omics for Precision Medicine (TOPMed) program, which aims to utilize high throughput omics to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whole genome sequence from over 130,000 well-phenotyped individuals and is currently generating high-throughput expression and other “omics” data (e.g. RNA, DNA methylation, metabolites, and proteins) from many of these individuals to complement whole genome sequence information. Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource through novel systems biology analyses to uncover disease pathobiology. Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights from them remains challenging. Systems level models incorporating trans-omics analyses will be an important step in uncovering the underlying biological networks, gene-gene and gene-environment interactions influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of individuals are required to move TOPMed to the next phase of discovery.</p>				
085478	<a href="#">RFA-HL-20-006--Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38 Independent Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-006	14-Jan-2022	Not Specified
	<p>Contact Name   Neil Aggarwal, M.D.</p> <p>Contact Telephone   301-827-7820</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:neil.aggarwal@nih.gov">neil.aggarwal@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Jan-2022</p> <p>Synopsis The purpose of the Stimulating Access to Research in Residency Transition Scholar (StARRTS) K38 Career Development program is to retain and support clinician investigators who have successfully completed the Stimulating Access to Research in Residency (StARR) R38 Program (RFA-HL-18-023) as resident-investigators. Individuals who are awarded K38 grants described in this FOA will be referred to as Transition Scholars. The intent of this FOA is to provide Transition Scholars with opportunities for additional research and career development during subsequent clinical fellowship or early career faculty appointments (as defined in Section III. 3. Additional Information on Eligibility). It is anticipated that the StARRTS K38 program will provide a pathway to retain the newly-created pool of clinician-investigators generated through the StARR R38 program. Transition Scholar grantees will receive support for continued research and career development opportunities in basic, clinical and/or translational research thereby providing enhanced potential to accelerate the transition to independent research careers.</p>				

105201	<a href="#">Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-017	07-Jan-2022	Not Specified
--------	--	--	---------------	-------------	---------------

	<p>Contact Name James Luo, Ph.D.</p> <p>Contact Telephone 301-435-0533</p> <p>Contact Email <a href="mailto:luoja@nih.gov">luoja@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023</p> <p>Synopsis The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has recently created the Trans Omics for Precision Medicine (TOPMed) program, which aims to utilize high throughput omics to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whole genome sequence from over 130,000 well-phenotyped individuals and is currently generating high-throughput expression and other</p>				
--	---	--	--	--	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>“omics” data (e.g. RNA, DNA methylation, metabolites, and proteins) from many of these individuals to complement whole genome sequence information. Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource through novel systems biology analyses to uncover disease pathobiology. Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights from them remains challenging. Systems level models incorporating trans-omics analyses will be an important step in uncovering the underlying biological networks, gene-gene and gene-environment interactions influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of individuals are required to move TOPMed to the next phase of discovery.</p>				
106714	<a href="#">Notice of Special Interest (NOSI): Resilience and Vulnerability following Acute Heart, Lung, Blood, and Sleep Insults in People with HIV (R01, Clinical Trial Not Allowed)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-22-002	07-Jan-2022	Not Specified
	<p>Contact Name   Shimian Zou, PhD            Contact Telephone   301-827-8301            Contact Email   <a href="mailto:shimian.zou@nih.gov">shimian.zou@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024            Synopsis   This NOSI encourages the submission of research project applications focused on understanding the long-term manifestations of acute HLBS illnesses with an emphasis on host response, viral pathways, and mechanisms that contribute to long-term manifestations in the context of HIV. Proposals considered responsive to the NOSI may address questions across the spectrum of basic science to population science.</p>				
086465	<a href="#">RFA-HL-20-029 -- Limited Competition: Small Grant Program for NHLBI K01/K08/K23 Recipients (R03 - Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-029	10-Jan-2022	100,000 USD
	<p>Contact Name   Roya Kalantari, PhD            Contact Telephone   301-480-1989            Contact Email   <a href="mailto:roya.kalantari@nih.gov">roya.kalantari@nih.gov</a>            Sponsor Website  </p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 10-Jan-2022</p> <p>Synopsis: The purpose of this FOA is to solicit current or recently completed NHLBI K01, K08, and K23 awardees for grant support to expand their current research objectives or to branch out to a study that resulted from the research conducted under the K award. Active NHLBI K01, K08, and K23 awardees may apply for R03 support to run concurrently with the final two years of their K award. Recently completed NHLBI K01, K08, and K23 awardees are eligible to apply for the R03 if the earliest possible R03 start date falls within 2 years of their prior NHLBI K award Project Period end date. Thus, this FOA is intended to enhance the capability of NHLBI K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. For current and previous K23 awardees, research proposed in the R03 application may or may not include patient-oriented research. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide preliminary data to support a subsequent R01, or equivalent, application.</p>				
100811	<a href="#">NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-21-079	07-Jan-2022	450,000 USD
	<p>Contact Name Patrice Desvigne-Nickens, MD</p> <p>Contact Telephone 301-435-0504</p> <p>Contact Email <a href="mailto:gweinmann@nih.gov">gweinmann@nih.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024</p> <p>Synopsis: This Funding Opportunity Announcement (FOA) supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this FOA will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this FOA will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

for clinical trials (as described at <https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization>), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.

106072	<a href="#">Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue)</a>	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-21-024	07-Jan-2022	Not Specified
--------	---	--	---------------	-------------	---------------

Contact Name	Narasimhan Danthi, Ph.D.
Contact Telephone	301-435-5170
Contact Email	<a href="mailto:ndanthi@mail.nih.gov">ndanthi@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025
Synopsis	This Notice of Special Interest is a reissue of NOT-HL-20-796. The purpose of this NOSI is to advise potential applicants to the National Heart, Lung and Blood Institute (NHLBI) of an area of special interest to support early phases of innovative bioengineering projects which are expected to transition their research into future follow-on funding, technologies, or commercial products. Please note that this R21 program does not overlap with projects which are expected to transition their research into future follow-on funding, technologies, or commercial products. Please note that this R21 program does not overlap with the NHLBI Catalyze Program, and it does focus on new investigator-initiated ideas that will feed into the Catalyze pipeline.

090720	<a href="#">RFA-HG-20-016 -- Novel Synthetic Nucleic Acid Technology Development (R43/R44) (Clinical Trial Not Allowed)</a>	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-016	05-Jan-2022 [Optional][LOI/Pre-App]	Not Specified
--------	---	---	---------------	--	---------------

Contact Name	Michael W. Smith, Ph.D.
Contact Telephone	301-480-3413
Contact Email	<a href="mailto:smithmw@nih.gov">smithmw@nih.gov</a>
Sponsor Website	

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jan-2022 [Optional][LOI/Pre-App], 04-Feb-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in commercial synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of commercial nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Applicants may propose to develop novel complete synthesis and/or synthetic constructs systems, investigate challenges underlying key novel system components, or propose substantive improvements of at least an order of magnitude improvement to existing commercial systems. Exploration of methods other than those currently commercially in use is highly encouraged.</p>				
090719	<a href="#">RFA-HG-20-015 -- Novel Synthetic Nucleic Acid Technology Development (R21)</a> <a href="#">(Clinical Trial not allowed)</a>	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-015	05-Jan-2022 [Optional][LOI/Pre-App]	400,000 USD
	<p>Contact Name Michael W. Smith, Ph.D.</p> <p>Contact Telephone 301-480-3413</p> <p>Contact Email <a href="mailto:smithmw@nih.gov">smithmw@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jan-2022 [Optional][LOI/Pre-App], 04-Feb-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits R21 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Applicants may propose to develop novel complete synthesis and/or synthetic constructs systems, investigate challenges underlying key novel system components, or propose substantive improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.</p>				
090708	<a href="#">RFA-HG-20-014 -- Novel Synthetic Nucleic Acid Technology Development (R01)</a> <a href="#">(Clinical Trial not allowed)</a>	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-014	05-Jan-2022 [Optional][LOI/Pre-App]	2,100,000 USD
	Contact Name Michael W. Smith, Ph.D.				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-480-3413</p> <p>Contact Email   <a href="mailto:smithmw@nih.gov">smithmw@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jan-2022 [Optional][LOI/Pre-App], 04-Feb-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) solicits R01 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Large progress in this area has the potential to catalyze scientific advances relevant to the mission of NIH, NHGRI and the field of genomics.</p>				
103017	<a href="#">NHGRI Predoctoral to Postdoctoral Transition Award for a Diverse Genomics Workforce (F99/K00)</a>	National Human Genome Research Institute/NIH/DHHS	PAR-21-143	08-Dec-2021	Not Specified
	<p>Contact Name   Tina Gatlin, Ph.D.</p> <p>Contact Telephone   301-480-2280</p> <p>Contact Email   <a href="mailto:gatlincl@nih.gov">gatlincl@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   08-Dec-2021 , 25-Jan-2022 , 08-Apr-2022 , 25-May-2022 , 08-Aug-2022 , 08-Dec-2022 , 08-Apr-2023 , 08-Aug-2023 , 08-Dec-2023 , 08-Apr-2024</p> <p>Synopsis   The purpose of the NHGRI Predoctoral to Postdoctoral Transition Award for a Diverse Genomics Workforce (F99/K00) is to support a defined pathway across career stages for talented graduate students from diverse backgrounds, including those from groups underrepresented in biomedical, clinical, behavioral and social sciences. This two-phased award will facilitate completion of a doctoral dissertation (F99) and transition to a strong postdoctoral research position (K00) focused on the scientific, medical, ethical, social and/or legal areas of genomics research. It is anticipated that successful completion of this phased award program will provide students sufficient scientific and career development activities to set them on the path to becoming independent genomics researchers.</p>				
106172	<a href="#">Notice of Special Interest (NOSI): Genomics Education Interactive Digital Media Resources (SBIR/STTR)</a>	National Human Genome Research Institute/NIH/DHHS	NOT-HG-21-038	05-Jan-2022	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Tina Gatlin, Ph.D.</p> <p>Contact Telephone   301-480-2280</p> <p>Contact Email   <a href="mailto:gatlincl@nih.gov">gatlincl@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jan-2022 , 05-Apr-2022 , 05-Sep-2022 , 05-Jan-2023 , 05-Apr-2023 , 05-Sep-2023 , 05-Jan-2024 , 05-Apr-2024 , 05-Sep-2024</p> <p>Synopsis   The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing genomics education interactive digital media products that address the needs of high school, college, advanced degree students and professionals and provide a new avenue for entry and pursuit of genomics careers.</p>				
100053	<p><a href="#">Notice of Special Interest (NOSI): Clarification of the Objectives and Program Elements in NHGRI Applications Submitted in Response to the "Ruth L. Kirschstein NRSA Institutional Research Training Grants (Parent T32)"</a></p>	National Human Genome Research Institute/NIH/DHHS	NOT-HG-21-010	07-Jan-2022	Not Specified
	<p>Contact Name   Luis A. Cubano, Ph.D.</p> <p>Contact Telephone   301-480-3435</p> <p>Contact Email   <a href="mailto:luis.cubano@nih.gov">luis.cubano@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023</p> <p>Synopsis   The National Human Genome Research Institute (NHGRI) is issuing this Notice to highlight interest in receiving grant applications focused in the following area(s): Genome sciences to support training with a focus on the quantitative sciences, bioinformatics, and technology development; Genomic medicine to support training with a focus on innovation and understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care; Ethical, Legal and Social Implications (ELSI) of Genomic Research to support training with a focus on developing multi-disciplinary conceptual and methodological skills necessary to pursue independent careers as ELSI researchers.</p>				
079894	<p><a href="#">Initiative to Maximize Research Education in Genomics: Courses (R25 Clinical Trial Not Allowed)</a></p>	National Human Genome Research Institute/NIH/DHHS	PAR-19-185	25-Jan-2022	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Bettie J. Graham, Ph.D.</p> <p>Contact Telephone   301-496-7531</p> <p>Contact Email   <a href="mailto:bettie_graham@nih.gov">bettie_graham@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   25-Jan-2022</p> <p>Synopsis   The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development.</p>				
085902	<a href="#">Initiative to Maximize Research Education in Genomics: Diversity Action Plan (R25)</a>	National Human Genome Research Institute/NIH/DHHS	PAR-19-380	25-Jan-2022	1,500,000 USD
	<p>Contact Name   Tina Gatlin, Ph.D.</p> <p>Contact Telephone   301-480-2280</p> <p>Contact Email   <a href="mailto:gatlincl@nih.gov">gatlincl@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   25-Jan-2022 , 25-May-2022 , 25-Sep-2022</p> <p>Synopsis   The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI Diversity Action Plan (DAP) R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral, social and clinical research workforce in genomics. This funding opportunity announcement seeks to expose students at the undergraduate, post-baccalaureate and graduate levels who are from diverse backgrounds, including those from underrepresented groups, to the foundational sciences relevant to genomics to enable them to pursue careers that span all areas of interest to NHGRI - genome sciences, genomic medicine and genomics and society. For the purposes of this FOA, the term "genomics" encompasses issues and activities in these three areas.</p>				
104968	<a href="#">Notice of Special Interest (NOSI): Clarification of the Objectives and Program Elements in NHGRI Applications Submitted in Response to the "Ruth L. Kirschstein NRSA Institutional Research Training Grants (Parent T32)"</a>	National Human Genome Research Institute/NIH/DHHS	NOT-HG-21-032	07-Jan-2022	Not Specified



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 301-945-7573</p> <p>Contact Email <a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023 , 25-May-2023</p> <p>Synopsis The National Human Genome Research Institute (NHGRI) is issuing this Notice to highlight interest in receiving grant applications focused in the following area(s): Genome sciences to support training with a focus on the quantitative sciences, bioinformatics, and technology development; Genomic medicine to support training with a focus on innovation and understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care; Ethical, Legal and Social Implications (ELSI) of Genomic Research to support training with a focus on developing multi-disciplinary conceptual and methodological skills necessary to pursue independent careers as ELSI researchers.</p>				
103150	<a href="#">RFA-HG-21-007 -- Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial not Allowed)</a>	National Human Genome Research Institute/NIH/DHHS	RFA-HG-21-007	30-Jan-2022 [Optional][LOI/Pre-App]	400,000 USD
	<p>Contact Name Michael W. Smith, Ph.D.</p> <p>Contact Telephone 301-480-3413</p> <p>Contact Email <a href="mailto:smithmw@nih.gov">smithmw@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 30-Jan-2022 [Optional][LOI/Pre-App], 01-Mar-2022 , 02-Jan-2023 [Optional][LOI/Pre-App], 01-Feb-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits R21 grant applications to innovate and develop the early stages of novel technologies that will enable greater than a one order of magnitude improvement in 1) DNA sequencing, and 2) methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been greatly facilitated by cycles of technology innovation and disruption that have driven significant and sustained nucleic acid sequencing throughput and assembly quality increases combined with cost decreases and read quality improvements. The goal now is to dramatically advance DNA sequencing and direct RNA sequencing technologies at reasonable costs with the anticipation that significant exploratory innovation in any of these and related</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRI's other technology development goals.			
103144	<a href="#">RFA-HG-21-006 -- Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R01 Clinical Trial not Allowed)</a>	National Human Genome Research Institute/NIH/DHHS	RFA-HG-21-006	30-Jan-2022 [Optional][LOI/Pre-App]	2,800,000 USD
	<p>Contact Name   Michael W. Smith, Ph.D.</p> <p>Contact Telephone   301-480-3413</p> <p>Contact Email   <a href="mailto:smithmw@nih.gov">smithmw@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   30-Jan-2022 [Optional][LOI/Pre-App], 01-Mar-2022 , 03-Jan-2023 [Optional][LOI/Pre-App], 01-Feb-2023</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) solicits R01 grant applications to innovate and develop the early stages of novel technologies that will enable greater than a one order of magnitude improvement in 1) DNA sequencing, and 2) methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been greatly facilitated by cycles of technology innovation and disruption that have driven significant and sustained nucleic acid sequencing throughput and assembly quality increases combined with cost decreases and read quality improvements. The goal now is to dramatically advance DNA sequencing and direct RNA sequencing technologies at reasonable costs with the anticipation that significant innovation in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRI's other technology development goals.</p>				
103218	<a href="#">RFA-HG-21-008 -- Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44 Clinical Trial not Allowed)</a>	National Human Genome Research Institute/NIH/DHHS	RFA-HG-21-008	30-Jan-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name   Michael W. Smith, Ph.D.</p> <p>Contact Telephone   301-480-3413</p> <p>Contact Email   <a href="mailto:smithmw@nih.gov">smithmw@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   30-Jan-2022 [Optional][LOI/Pre-App], 01-Mar-2022 , 02-Jan-2023 [Optional][LOI/Pre-App], 01-Feb-2023</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications to innovate and develop the early stages of novel commercial technologies that will enable greater than a one order of magnitude improvement in 1) DNA sequencing, and 2) methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been greatly facilitated by the business sector with cycles of technology innovation and disruption that have driven significant and sustained nucleic acid sequencing throughput and assembly quality increases combined with cost decreases and read quality improvements. The goal now is to dramatically advance commercial DNA sequencing and direct RNA sequencing technologies at reasonable costs with the anticipation that significant innovation in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRI's other technology development goals.

101174	<a href="#">Notice of Special Interest (NOSI): Advancing Genomic Technology Development for Research and Clinical Application</a>	National Human Genome Research Institute/NIH/DHHS	NOT-HG-21-018	05-Jan-2022	Not Specified
--------	---	---	---------------	-------------	---------------

Contact Name	Michael W. Smith, Ph.D.
Contact Telephone	301-480-3413
Contact Email	<a href="mailto:smithmw@mail.nih.gov">smithmw@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Jan-2022 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Jan-2024 , 07-Jan-2024
Synopsis	The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing novel laboratory-focused tools and technologies that enable new lines of scientific inquiry and clinical applications in human genomics.

101030	<a href="#">Notice of Special Interest (NOSI): High-throughput Molecular and Cellular Phenotyping</a>	National Human Genome Research Institute/NIH/DHHS	NOT-HG-21-004	08-Jan-2022	Not Specified
--------	---	---	---------------	-------------	---------------

Contact Name	Colin Fletcher, Ph.D.
Contact Telephone	301-496-7531
Contact Email	<a href="mailto:fletcher2@mail.nih.gov">fletcher2@mail.nih.gov</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-Jan-2022 , 05-Feb-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 05-Oct-2023 , 07-Jan-2024			
	Synopsis	The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing novel methods to perform high-throughput molecular and cellular phenotyping in order to elucidate the functional consequences of DNA variation.			
090119	<a href="#">Research Towards Developing a Cure for HBV in HIV/HBV Co-Infection (R21 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAS-20-121	07-Jan-2022	275,000 USD
	Contact Name	Chris Lambros, PhD			
	Contact Telephone	240-627-3093			
	Contact Email	<a href="mailto:clambros@niaid.nih.gov">clambros@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative basic, translational, and clinical research to identify and address the challenges to achieving hepatitis B virus (HBV) cure in the presence of human immunodeficiency virus (HIV).			
087230	<a href="#">NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-063	07-Jan-2022	Not Specified
	Contact Name	Martin Gutierrez, Ph.D.			
	Contact Telephone	240-292-4844			
	Contact Email	<a href="mailto:mgutierrez@niaid.nih.gov">mgutierrez@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023			
	Synopsis	This Funding Opportunity Announcement (FOA), issued by the National Institute of Allergy and Infectious Diseases (NIAID),			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. Under rare circumstances, this mechanism may be used to support development of a new resource to the broader scientific community of the NIAID. It is anticipated that the request for resource support through the R24 activity code will occur on an infrequent basis and only in circumstances where other mechanisms of support from the NIAID are not appropriate. The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases.</p>				
106623	<a href="#">RFA-AI-21-065 -- Systems Biology for Infectious Diseases (U19 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-065	15-Dec-2021 [Optional][LOI/Pre-App]	7,500,000 USD
	<p>Contact Name   Reed Shabman, Ph.D.            Contact Telephone   301-761-6433            Contact Email   <a href="mailto:reed.shabman@nih.gov">reed.shabman@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   15-Dec-2021 [Optional][LOI/Pre-App], 14-Jan-2022            Synopsis   The purpose of the Funding Opportunity Announcement (FOA) is to support research that employs systems biology approaches to human pathogens. The approach will generate and integrate large datasets into models that guide in vitro, in vivo and clinical studies, with the goals of predicting disease severity, predicting responses to vaccines and therapeutics, and identifying candidate targets for interventions.</p>				
097705	<a href="#">NIAID Clinical Trial Planning Grant (R34 Clinical Trials Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-270	12-Jan-2022	150,000 USD
	<p>Contact Name   Greg Deye, M.D.            Contact Telephone   240-627-3371            Contact Email   <a href="mailto:gregory.deye@nih.gov">gregory.deye@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   12-Jan-2022 , 13-May-2022 , 14-Sep-2022 , 13-Jan-2023 , 12-May-2023</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (<a href="https://www.niaid.nih.gov/research/role">https://www.niaid.nih.gov/research/role</a>).</p>				
101688	<a href="#">NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-21-083	14-Jan-2022	Not Specified
	<p>Contact Name   Greg Deye, M.D.</p> <p>Contact Telephone   240-627-3371</p> <p>Contact Email   <a href="mailto:gregory.deye@nih.gov">gregory.deye@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   14-Jan-2022 , 13-May-2022 , 13-Sep-2022 , 13-Jan-2023 , 13-May-2023 , 14-Sep-2023 , 13-Jan-2024</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (<a href="https://www.niaid.nih.gov/research/role">https://www.niaid.nih.gov/research/role</a>). Only one clinical trial may be proposed in each NIAID Clinical Trial Implementation Cooperative Agreement (U01) application.</p>				
101691	<a href="#">NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-21-082	14-Jan-2022	Not Specified
	<p>Contact Name   Natalia Kruchinin, Ph.D.</p> <p>Contact Telephone   240-669-2919</p> <p>Contact Email   <a href="mailto:NIAIDU44@mail.nih.gov">NIAIDU44@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   14-Jan-2022 , 13-May-2022 , 13-Sep-2022 , 13-Jan-2023 , 13-May-2023 , 14-Sep-2023 , 13-Jan-2024</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis: This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials related to the research mission of the NIAID. This program provides support for hypothesis-driven, milestone-driven clinical trials. Although clinical trials not considered high-risk may be proposed, this program encourages high-risk clinical studies. High-risk does not imply human subject or patient risk, but rather defines a study that contains one or more of the following unique features: involves non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged and may be proposed under this program.</p>				
105511	<a href="#">NIAID Research Education Program Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-21-258	25-Jan-2022	1,625,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email: <a href="mailto:AITrainingHelpDesk@niaid.nih.gov">AITrainingHelpDesk@niaid.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Jan-2023 , 07-May-2023 , 25-May-2023 , 07-Sep-2023</p> <p>Synopsis: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities related to NIAID's mission areas with a primary focus on: Courses for Skills Development Research Experiences Mentoring Activities</p>				
085408	<a href="#">Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19-364	10-Jan-2022	275,000 USD
	<p>Contact Name: Daniel Frank, Ph.D.</p> <p>Contact Telephone: 301-761-6256</p> <p>Contact Email: <a href="mailto:Daniel.Frank@nih.gov">Daniel.Frank@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 10-Jan-2022</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical, preclinical and non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis.</p>			
102836	<a href="#">RFA-AI-21-020 -- Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases (U01 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-020	18-Jan-2022 [Optional][LOI/Pre-App]	900,000 USD
	Contact Name	Steve Tsang, PhD			
	Contact Telephone	240-627-3330			
	Contact Email	<a href="mailto:AI-DSFOAinquiries@nih.gov">AI-DSFOAinquiries@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	18-Jan-2022 [Optional][LOI/Pre-App], 17-Feb-2022 , 01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 18-Jan-2023 [Optional][LOI/Pre-App], 17-Feb-2023 , 06-Jun-2023 [Optional][LOI/Pre-App], 06-Jul-2023			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the development of enabling data science technologies to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge for immune-mediated and infectious diseases including disease mechanism, risk prediction, epidemiology, detection and diagnosis, treatment and vaccines across the allergy, immune-mediated, and infectious-disease research continuum, aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID data science program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. This contrasts with exploratory (R21) and enhancement/sustainment (U24) efforts to generate these tools and resources that are supported by the companion FOAs.</p>			
102837	<a href="#">RFA-AI-21-035-- Exploratory Data Science Methods and Algorithm Development in Infectious and Immune-mediated Diseases (R21 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-035	18-Jan-2022 [Optional][LOI/Pre-App]	275,000 USD
	Contact Name	Steve Tsang, PhD			
	Contact Telephone	240-627-3330			
	Contact Email	<a href="mailto:AI-DSFOAinquiries@nih.gov">AI-DSFOAinquiries@nih.gov</a>			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	18-Jan-2022 [Optional][LOI/Pre-App], 17-Feb-2022 , 01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 18-Jan-2023 [Optional][LOI/Pre-App], 17-Feb-2023 , 06-Jun-2023 [Optional][LOI/Pre-App], 06-Jul-2023			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory research focused on developing innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the infectious or immune-mediated disease research continuum aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID Data Science program, this R21 FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods, including artificial intelligence and machine learning approaches, that can considerably improve acquisition, management, analysis, visualization, and dissemination of relevant data and/or knowledge. This contrasts with early-stage development (U01) and enhancement/sustainment (U24) efforts to generate these tools and resources that are supported by the companion FOAs.</p>			
102838	<a href="#">RFA-AI-21-021 -- Enhancement or Sustainment of Data Science Tools for Infectious and Immune-Mediated diseases (U24 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-021	18-Jan-2022 [Optional][LOI/Pre-App]	3,000,000 USD
	Contact Name	Steve Tsang, PhD			
	Contact Telephone	240-627-3330			
	Contact Email	<a href="mailto:AI-DSFOAinquiries@nih.gov">AI-DSFOAinquiries@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	18-Jan-2022 [Optional][LOI/Pre-App], 17-Feb-2022 , 01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 18-Jan-2023 [Optional][LOI/Pre-App], 17-Feb-2023 , 06-Jun-2023 [Optional][LOI/Pre-App], 06-Jul-2023			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to support exploratory research focused on developing innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the infectious or immune-mediated disease research continuum aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID Data Science program, this R21 FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods, including artificial intelligence and machine learning approaches, that can considerably improve acquisition, management,</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		analysis, visualization, and dissemination of relevant data and/or knowledge. This contrasts with early-stage development (U01) and enhancement/sustainment (U24) efforts to generate these tools and resources that are supported by the companion FOAs.			
085477	<a href="#">NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19-371	07-Jan-2022	Not Specified
	Contact Name	Shawn Drew Gaillard, Ph.D.			
	Contact Telephone	240-627-3857			
	Contact Email	<a href="mailto:Shawn.Gaillard@nih.gov">Shawn.Gaillard@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	National Institute of Allergy and Infectious Diseases (NIAID) provides support for the NIAID Research Scholar Development Award (RSDA), which is intended to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) will utilize the NIH Career Transition Award (K22) mechanism.			
094378	<a href="#">NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-209	07-Jan-2022	Not Specified
	Contact Name	Deborah Philip, Ph.D.			
	Contact Telephone	301-761-7776			
	Contact Email	<a href="mailto:AITrainingHelpDesk@niaid.nih.gov">AITrainingHelpDesk@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023			
	Synopsis	The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-20-210).</p>			
094380	<a href="#">NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-210	07-Jan-2022	Not Specified
	Contact Name	Shawn Drew Gaillard, Ph.D.			
	Contact Telephone	301-761-7776			
	Contact Email	<a href="mailto:AITrainingHelpDesk@niaid.nih.gov">AITrainingHelpDesk@niaid.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023			
	Synopsis	<p>The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-20-209).</p>			
105630	<a href="#">Notice of Special Interest (NOSI): Understanding the Immune Functions of DEAD/H-box Helicases</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-066	07-Jan-2022	Not Specified
	Contact Name	Qian "Joy" Liu, M.D., M.Sc.			
	Contact Telephone	301-761-6621			
	Contact Email	<a href="mailto:liujoy@niaid.nih.gov">liujoy@niaid.nih.gov</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	This Notice of Special Interest (NOSI) supports research aimed at gaining a comprehensive understanding of the expression, function, and regulation of DEAD/H-box helicases in immune homeostasis, activation, and/or function. Knowledge obtained from such studies may be applied to the design of improved vaccines and immunotherapies to combat pathogenic infections or treat/prevent immune-mediated diseases.			
078717	<a href="#">Novel Approaches to Understand, Prevent, Treat, and Diagnose coccidioidomycosis (Valley Fever) and Other Select Endemic Fungal Infections (R21 Clinical Trial Not Allowed)</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-083	07-Jan-2022	275,000 USD
	Contact Name	Dona Love, Ph.D.			
	Contact Telephone	301-761-7788			
	Contact Email	<a href="mailto:dona.love@nih.gov">dona.love@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement is to support research activities that will contribute to the overall understanding of coccidioidomycosis, commonly known as Valley Fever, and other select endemic fungal diseases including histoplasmosis and blastomycosis. This research opportunity encourages studies that address diverse scientific areas such as: 1) pathogenesis; 2) host response; 3) disease transmission; 4) natural history and environmental factors contributing to disease; 5) vaccines; 6) diagnostics; and 7) therapeutics; with the ultimate goal of advancing the field towards solutions for the improved detection, prevention and treatment of select endemic mycoses.			
102961	<a href="#">Notice of Special Interest (NOSI): Investigations on Inborn Errors of Immunity/Primary Immunodeficiencies</a>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-21-032	07-Jan-2022	Not Specified
	Contact Name	Frosso Voulgaropoulou, PhD			
	Contact Telephone	240-627-3205			
	Contact Email	<a href="mailto:fvoulgaropoulou@niaid.nih.gov">fvoulgaropoulou@niaid.nih.gov</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024
Synopsis	This Notice of Special Interest (NOSI) is to support the discovery and characterization of Inborn Errors of Immunity, also referred to as Primary Immunodeficiencies, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
102539	<a href="#">Notice of Special Interest (NOSI): Advancing Health Communication Research on HIV Prevention, Treatment and Cure</a>	National Institute of Mental Health/NIH/DHHS	NOT-MH-21-105	25-Oct-2021	Not Specified

Contact Name	Collene Lawhorn, Ph.D.
Contact Telephone	301-828-7186
Contact Email	<a href="mailto:collene.lawhorn@nih.gov">collene.lawhorn@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	25-Oct-2021 , 08-Dec-2021 , 07-Jan-2022 , 25-Jan-2022 , 05-Feb-2022 , 12-Feb-2022 , 16-Feb-2022 , 25-Feb-2022 , 08-Apr-2022 , 07-May-2022 , 25-May-2022 , 05-Jun-2022 , 12-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 08-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 08-Dec-2022 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 25-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 08-Aug-2023 , 07-Sep-2023 , 25-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 08-Dec-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 08-Apr-2024
Synopsis	The National Institute of Mental Health is issuing this Notice to highlight interest in research applications to optimize health communication strategies that advance HIV prevention, treatment and cure.

104058	<a href="#">NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PA-21-235	07-Jan-2022	275,000 USD
--------	--	--	-----------	-------------	-------------

Contact Name	Susan Koester, Ph.D.
--------------	----------------------

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-443-3563</p> <p>Contact Email   <a href="mailto:koesters@mail.nih.gov">koesters@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis   The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care.</p>				
106961	<a href="#">RFA-MH-22-125 -- Enhanced Interpersonal Focused Strategies for Suicide Prevention Interventions (R34 Clinical Trial Required)</a>	National Institute of Mental Health/NIH/DHHS	RFA-MH-22-125	19-Jan-2022 [Optional][LOI/Pre-App]	450,000 USD
	<p>Contact Name   Stephen O'Connor, Ph.D.</p> <p>Contact Telephone   301-480-8366</p> <p>Contact Email   <a href="mailto:stephen.o'connor2@nih.gov">stephen.o'connor2@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   19-Jan-2022 [Optional][LOI/Pre-App], 18-Feb-2022</p> <p>Synopsis   NIMH seeks applications to evaluate the preliminary effectiveness of therapeutic and service delivery interventions that utilize interpersonal treatment strategies to reduce risk among suicidal individuals following acute care by enhancing perceived social supports and connections that contribute to life-affirming beliefs, intentions, and behaviors and/or by promoting adherence/sustained engagement in appropriate mental health services. Intervention strategies and targets are intended to enhance and/or compliment effectiveness of existing evidenced-based treatments by addressing interpersonal factors that have been empirically associated with suicide risk and/or problematic adherence/engagement and are not adequately addressed by existing evidence based approaches. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					study, practical trial) designed to definitively test the effectiveness of the intervention.
079331	<a href="#">Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-19-146	07-Jan-2022	275,000 USD
	Contact Name	Enrique Michelotti, PhD			
	Contact Telephone	301-443-5415			
	Contact Email	<a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability in the discovery of novel compounds for the prevention and treatment of nervous system disorders. This FOA is designed to stimulate research in 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics, 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest, 3) Later stage lead optimization to improve efficacy and pharmacokinetics ,and 4) Initial drug metabolism and pharmacokinetics (DMPK). Emphasis will be placed on projects that provide novel approaches to identify potential therapeutic agents. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high payoff projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may wish to apply to the companion R01 mechanism ( PAR-19-147)</p>			
106403	<a href="#">Mental Health Research Dissertation Grant to Enhance Workforce Diversity (R36 Independent Clinical Trial Not Allowed)</a>	National Institute of Mental Health/NIH/DHHS	PAR-21-325	07-Jan-2022	Not Specified
	Contact Name	Mark Chavez, Ph.D.			
	Contact Telephone	301-443-8942			
	Contact Email	<a href="mailto:mchavez1@nih.gov">mchavez1@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to enhance the diversity of the mental health research			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		workforce by providing dissertation awards in all research areas within the strategic priorities of the NIMH to individuals from groups underrepresented in biomedical, behavioral, clinical and social sciences research. This FOA provides support to complete a mental health-related doctoral research project and includes funds not readily available in NRSA predoctoral (F31) awards, which limit support to stipends, tuition and fees, and institutional allowance.			
103959	<a href="#">NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-224	05-Jan-2022	Not Specified
	Contact Name	Codrin Lungu, MD			
	Contact Telephone	301-496-9135			
	Contact Email	<a href="mailto:lunguci@ninds.nih.gov">lunguci@ninds.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jan-2022 , 05-Apr-2022 , 05-Sep-2022 , 05-Jan-2023 , 05-Apr-2023 , 05-Sep-2023 , 05-Jan-2024 , 05-Apr-2024			
	Synopsis	This Funding Opportunity Announcement (FOA) encourages small business applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing clinical studies. Diseases chosen for study should be based on the NINDS strategic plan and clinical research interests ( <a href="http://www.ninds.nih.gov/funding/areas/index.htm">www.ninds.nih.gov/funding/areas/index.htm</a> ). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure.			
101794	<a href="#">NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-114	05-Jan-2022	Not Specified
	Contact Name	Emily Caporello, Ph.D.			
	Contact Telephone	301-496-1778			
	Contact Email	<a href="mailto:Emily.caporello@nih.gov">Emily.caporello@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jan-2022 , 05-Apr-2022 , 05-Sep-2022 , 05-Jan-2023 , 05-Apr-2023 , 05-Sep-2023 , 05-Jan-2024			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis Some projects initiated with SBIR or STTR funding require considerable financing beyond the SBIR/STTR Phase II award to achieve commercialization. The development of medical biotechnology products is often impeded by a significant funding gap (known as the “Valley of Death”) between the end of the SBIR/STTR Phase II award and the commercialization stage. The goal of this FOA is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product/technology that requires Federal regulatory approval or to bring a complex research tool to market. This opportunity aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by promoting partnerships between NINDS SBIR or STTR awardees and third-party investors and/or strategic partners in the Phase IIB competing renewal. Applicants are strongly encouraged to secure independent third-party funding throughout the Phase IIB project period.</p>				
105509	<a href="#">NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-265	05-Jan-2022	Not Specified
	<p>Contact Name Emily Caporello, Ph.D.            Contact Telephone 301-496-1778            Contact Email <a href="mailto:Emily.caporello@nih.gov">Emily.caporello@nih.gov</a>            Sponsor Website            Program URL <a href="#">Link to program URL</a>            Deadline Dates (ALL) 05-Jan-2022 , 05-Apr-2022 , 05-Sep-2022 , 05-Jan-2023 , 05-Apr-2023 , 05-Sep-2023 , 05-Jan-2024 , 05-Apr-2024</p> <p>Synopsis Some projects initiated with SBIR or STTR funding require considerable financing beyond the SBIR/STTR Phase II award to achieve commercialization. The development of medical biotechnology products is often impeded by a significant funding gap (known as the “Valley of Death”) between the end of the SBIR/STTR Phase II award and the commercialization stage. The goal of this FOA is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product/technology that requires Federal regulatory approval or to bring a complex research tool to market. This opportunity aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by promoting partnerships between NINDS SBIR or STTR awardees and third-party investors and/or strategic partners in the Phase IIB competing renewal. Applicants are strongly encouraged to secure independent third-party funding throughout the Phase IIB project period.</p>				
105508	<a href="#">NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-266	05-Jan-2022	Not Specified
	<p>Contact Name Emily Caporello, Ph.D.            Contact Telephone 301-496-1778</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:Emily.caporello@nih.gov">Emily.caporello@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jan-2022 , 05-Apr-2022 , 05-Sep-2022 , 05-Jan-2023 , 05-Apr-2023 , 05-Sep-2023 , 05-Jan-2024 , 05-Apr-2024</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies.</p>				
105507	<a href="#">NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-267	05-Jan-2022	Not Specified
	<p>Contact Name Emily Caporello, Ph.D.</p> <p>Contact Telephone 301-496-1778</p> <p>Contact Email <a href="mailto:Emily.caporello@nih.gov">Emily.caporello@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jan-2022 , 05-Apr-2022 , 05-Sep-2022 , 05-Jan-2023 , 05-Apr-2023 , 05-Sep-2023 , 05-Jan-2024 , 05-Apr-2024</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites Small Business Technology Transfer (STTR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. This FOA will utilize the R41/R42 Small Business Technology Transfer (STTR) Grant - Phase I, Phase II and Fast-Track only.</p>				
103276	<a href="#">NINDS Program Project Grant (P01 Clinical Trial Optional)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-181	07-Jan-2022	Not Specified
	<p>Contact Name David Owens, Ph.D.</p> <p>Contact Telephone 301-496-9248</p> <p>Contact Email <a href="mailto:do47h@nih.gov">do47h@nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023 , 25-May-2023 , 07-Sep-2023 , 25-Sep-2023 , 07-Jan-2024 , 25-Jan-2024 , 07-May-2024</p> <p>Synopsis This funding opportunity announcement (FOA) is issued by the National Institute of Neurological Disorders and Stroke to enable submission of program project grant applications that propose to conduct innovative, interactive research to answer significant scientific questions that are important for the mission of NINDS, via a synergistic collaboration between outstanding scientists who might not otherwise collaborate. The program project grant is designed to support research in which the funding of several interdependent highly meritorious projects as a group offers significant scientific advantages over support of these same projects as individual research grants.</p>				
104027	<a href="#">NINDS Exploratory Clinical Trials (U01 - Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-236	07-Jan-2022	Not Specified
	<p>Contact Name Jeremy Brown, MD</p> <p>Contact Telephone 301-496-9135</p> <p>Contact Email <a href="mailto:Jeremy.brown@nih.gov">Jeremy.brown@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (<a href="https://www.ninds.nih.gov/">https://www.ninds.nih.gov/</a>).</p>				
086929	<a href="#">NINDS Postdoctoral Mentored Career Development Award (K01 - No Independent Clinical Trial Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20-049	07-Jan-2022	Not Specified
	<p>Contact Name Stephen Korn, PhD</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:korns@mail.nih.gov">korns@mail.nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent small clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing an independent small clinical trial as lead investigator, should apply to the companion FOA (PAR-20-050).</p>				
086932	<a href="#">NINDS Postdoctoral Mentored Career Development Award (K01 - Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20-050	07-Jan-2022	Not Specified
	<p>Contact Name Stephen Korn, PhD</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:korns@mail.nih.gov">korns@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent small clinical trial as part of their research and career development. Applicants not planning an independent small clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-20-049).

104258	<a href="#">NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-237	07-Jan-2022	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Jeremy Brown, MD
Contact Telephone	301-496-9135
Contact Email	<a href="mailto:Jeremy.brown@nih.gov">Jeremy.brown@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 09-Feb-2022 , 07-May-2022 , 09-Jun-2022 , 07-Sep-2022 , 11-Oct-2022 , 07-Jan-2023 , 09-Feb-2023 , 07-May-2023 , 09-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024 , 09-Feb-2024 , 07-May-2024
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website ( <a href="https://www.ninds.nih.gov/">https://www.ninds.nih.gov/</a> ).

086471	<a href="#">NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20-021	07-Jan-2022	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Stephen Korn, Ph.D.
Contact Telephone	301-496-4188
Contact Email	<a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 09-Feb-2022 , 07-May-2022 , 08-Jun-2022 , 07-Sep-2022 , 11-Oct-2022 , 07-Jan-2023

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 3 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of "mentored training" within a particular lab or environment. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
079593	<a href="#">Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-19-171	07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Adam L. Hartman, MD</p> <p>301-496-9135</p> <p><a href="mailto:adam.hartman@nih.gov">adam.hartman@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-Jan-2022 , 18-Mar-2022</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered)). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.</p>			
106266	<a href="#">NINDS Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-022	07-Jan-2022	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Amelie Gubitz, Ph.D.</p> <p>Contact Telephone   301-451-7966</p> <p>Contact Email   <a href="mailto:gubitz@ninds.nih.gov">gubitz@ninds.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024</p> <p>Synopsis   The purpose of the NINDS Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of new and talented, independent investigators from diverse backgrounds (e.g. see NOT-OD-20-031, Notice of NIH’s Interest in Diversity) conducting AD/ADRD research. The program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees establish independent research programs in the AD/ADRD field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experiences in a clinical trial led by a mentor or co-mentor.</p>				
103393	<a href="#">NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-153	07-Jan-2022	Not Specified
	<p>Contact Name   Michelle Jones-London, Ph.D.</p> <p>Contact Telephone   301-451-7966</p> <p>Contact Email   <a href="mailto:jonesmiche@ninds.nih.gov">jonesmiche@ninds.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p> <p>Synopsis   The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>Individuals from diverse backgrounds, including those from groups underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-152).</p>			
100306	<a href="#">NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-032	07-Jan-2022	Not Specified
	Contact Name	Stephen Korn, Ph.D.			
	Contact Telephone	301-496-4188			
	Contact Email	<a href="mailto:korns@ninds.nih.gov">korns@ninds.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 09-Feb-2022 , 07-May-2022 , 08-Jun-2022 , 07-Sep-2022 , 11-Oct-2022 , 07-Jan-2023 , 09-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024			
	Synopsis	<p>The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 4 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of “mentored training” within a particular lab or environment. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106818	<a href="#">RFA-RM-21-024 -- SPARC Human Open Research Neural Engineering Technologies (HORNET) Initiative (U41 Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-RM-21-024	13-Dec-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Eric Hudak, Ph. D</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email <a href="mailto:SPARC-O@od.nih.gov">SPARC-O@od.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 13-Dec-2021 [Optional][LOI/Pre-App], 12-Jan-2022</p> <p>Synopsis This U41 opportunity will fund Centers to create interoperable open-source modules that can be combined into custom profiles for new exploratory and clinical neuromodulation studies in the peripheral nervous system, and for potential applicability in the central nervous system. The centers will disseminate the open-source neuromodulation resources broadly. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (<a href="http://commonfund.nih.gov/">http://commonfund.nih.gov/</a>) through the NIH Office of the NIH Director, Office of Strategic Coordination (<a href="https://dpcpsi.nih.gov/">https://dpcpsi.nih.gov/</a>). All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Institute of Neurological Disorders and Stroke (NINDS), (<a href="http://www.ninds.nih.gov">http://www.ninds.nih.gov</a> on behalf of the NIH.</p>				
103724	<a href="#">NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)</a>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-234	07-Jan-2022	Not Specified
	<p>Contact Name Michelle Jones-London, Ph.D.</p> <p>Contact Telephone 301-451-7966</p> <p>Contact Email <a href="mailto:jonesmiche@ninds.nih.gov">jonesmiche@ninds.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from diverse backgrounds, including those from groups underrepresented in biomedical research are eligible for</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-21-153).

079184	<a href="#">Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-135	25-Oct-2021	300,000 USD
--------	--	---	------------	-------------	-------------

Contact Name | Michelle R.J. Hamlet, PhD  
 Contact Telephone | 301-496-9623  
 Contact Email | [hamletm@mail.nih.gov](mailto:hamletm@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 25-Oct-2021 , 07-Jan-2022

Synopsis | The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and health professional institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools to meritorious research projects, and to strengthen the research environment of the applicant institution. Eligible institutions (e.g., the university or college with a unique identifier number (such as DUNS) and a unique NIH Institutional Profile File (IPF) number)) must award NIH-relevant baccalaureate or advanced degrees in health professions and have received no more than \$6 million per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by the institution as a whole (meaning all schools and colleges within an institution). In other words, the funding for all the institution's health professional schools, graduate schools, and colleges and all the institution's non-health professional schools and colleges that are part of the institution are considered together and summed as total NIH funding when determining institutional eligibility. For institutions with multiple campuses, eligibility can be considered for each individual campus (e.g. main, satellite, etc.) only if a unique identifier number or NIH IPF number is established for each campus. For institutions that use one identifier number or

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>NIH IPF number for all campuses, eligibility is determined for all campuses (e.g. main, satellite, etc.) together. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.</p>			
102700	<a href="#">Notice of Special Interest (NOSI): NINR Priority Areas for Training and Career Development Awards</a>	National Institute of Nursing Research/NIH/DHHS	NOT-NR-21-001	07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 25-Jan-2022 , 12-Feb-2022 , 08-Apr-2022 , 07-May-2022 , 25-May-2022 , 12-Jun-2022 , 08-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 12-Oct-2022 , 08-Dec-2022 , 07-Jan-2023 , 25-Jan-2023 , 12-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 25-May-2023 , 12-Jun-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis The National Institute of Nursing Research (NINR) is committed to training the next generation of nurse scientists at all levels of education and encouraging training in important new areas of nursing research.</p>				
078635	<a href="#">Telomeres in Wellness and Disease: A Biobehavioral Approach (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-19-074	07-Jan-2022	Not Specified
	<p>Contact Name Lois A. Tully, PhD</p> <p>Contact Telephone 301-594-5968</p> <p>Contact Email <a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioral programs of research. A body of research has demonstrated the contribution of telomeres to health-related outcomes; however,</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		additional studies are needed to achieve the full potential for incorporating telomere-guided approaches for maintaining wellness, reducing the risk and burden of disease, and for advancing symptom and self-management strategies.			
079185	<a href="#">End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-136	07-Jan-2022	Not Specified
	Contact Name	Lynn S. Adams, Ph.D.			
	Contact Telephone	301-594-8911			
	Contact Email	<a href="mailto:lynn.adams@nih.gov">lynn.adams@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.			
078345	<a href="#">End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-045	07-Jan-2022	Not Specified
	Contact Name	Karen A. Kehl, Ph.D.			
	Contact Telephone	301-594-8010			
	Contact Email	<a href="mailto:kehlka@nih.gov">kehlka@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.			
077785	<a href="#">Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-944	07-Jan-2022	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Lois A. Tully, PhD</p> <p>Contact Telephone   301-594-5968</p> <p>Contact Email   <a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022</p> <p>Synopsis   The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual's chronic pain experience. Research relating biology and behavior is needed to better define the individual-specific burden of chronic pain and to better understand the mechanisms underlying differences in pain experiences among individuals afflicted with the same chronic illness.</p>				
078411	<p><a href="#">Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R01 Clinical Trial Optional)</a></p>	National Institute of Nursing Research/NIH/DHHS	PAR-19-057	07-Jan-2022	Not Specified
	<p>Contact Name   Lynn S. Adams, Ph.D.</p> <p>Contact Telephone   301-594-8911</p> <p>Contact Email   <a href="mailto:adamsls@nih.gov">adamsls@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022</p> <p>Synopsis   The purpose of this funding opportunity announcement (FOA) is to encourage research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care (EOLPC) for American Indian/Alaska Native (AI/AN) individuals with advanced illness and their families and communities.</p>				
077788	<p><a href="#">Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional)</a></p>	National Institute of Nursing Research/NIH/DHHS	PA-18-945	07-Jan-2022	Not Specified
	<p>Contact Name   Martha Matocha, PhD</p> <p>Contact Telephone   301-594-2775</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:matocham@mail.nih.gov">matocham@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022</p> <p>Synopsis The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.</p>				
077972	<a href="#">Addressing Caregiver Symptoms through Technological Tools (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-19-023	07-Jan-2022	Not Specified
	<p>Contact Name Augie Diana, Ph.D.</p> <p>Contact Telephone 301-402-6423</p> <p>Contact Email <a href="mailto:dianaa@mail.nih.gov">dianaa@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022</p> <p>Synopsis The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community that develop and test tools to address symptoms in caregivers. The key to this announcement is the focus on the caregiver, regardless of patient symptoms or conditions. Research is needed to enhance symptom recognition and assessment in caregivers, and to promote technological strategies to alleviate distress in caregiver symptoms. These studies are needed to advance the science related to caregiver experience of symptoms, caregiving contexts that promote these symptoms, and viable tools to address the symptoms experienced by caregivers.</p>				
084549	<a href="#">Palliative Care in Home and Community Settings (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-321	07-Jan-2022	Not Specified
	<p>Contact Name Karen A. Kehl, PhD, RN, FPCN</p> <p>Contact Telephone 301-594-8010</p> <p>Contact Email <a href="mailto:karen.kehl@mail.nih.gov">karen.kehl@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.			
085700	<a href="#">Omics-guided Biobehavioral Interventions for Improved Health Outcomes: A Step Forward in Translation (R01 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-377	07-Jan-2022	Not Specified
	Contact Name	Lois A. Tully, PhD			
	Contact Telephone	301-594-5968			
	Contact Email	<a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that harnesses the wealth of advances in the fields of genomics and other omics (e.g., metabolomics, microbiomics, proteomics, transcriptomics, epigenomics, etc.) to incorporate these advances into translatable, personalized biobehavioral interventions for improved health outcomes.			
078362	<a href="#">End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-044	07-Jan-2022	275,000 USD
	Contact Name	Karen A. Kehl, Ph.D.			
	Contact Telephone	301-594-8010			
	Contact Email	<a href="mailto:kehlka@nih.gov">kehlka@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.			
077787	<a href="#">Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-	07-Jan-2022	275,000

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Research/NIH/DHHS	943		USD
	<p>Contact Name   Lois A. Tully, PhD</p> <p>Contact Telephone   301-594-5968</p> <p>Contact Email   <a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022</p> <p>Synopsis   The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual's chronic pain experience. Research relating biology and behavior is needed to better define the individual-specific burden of chronic pain and to better understand the mechanisms underlying differences in pain experiences among individuals afflicted with the same chronic illness.</p>				
077789	<a href="#">Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-18-946	07-Jan-2022	275,000 USD
	<p>Contact Name   Martha Matocha, PhD</p> <p>Contact Telephone   301-594-2775</p> <p>Contact Email   <a href="mailto:matocham@mail.nih.gov">matocham@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022</p> <p>Synopsis   The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.</p>				
077974	<a href="#">Addressing Caregiver Symptoms through Technological Tools (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-19-024	07-Jan-2022	275,000 USD
	<p>Contact Name   Augie Diana, Ph.D.</p> <p>Contact Telephone   301-402-6423</p> <p>Contact Email   <a href="mailto:dianaa@mail.nih.gov">dianaa@mail.nih.gov</a></p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community that develop and test tools to address symptoms in caregivers. The key to this announcement is the focus on the caregiver, regardless of patient symptoms or conditions. Research is needed to enhance symptom recognition and assessment in caregivers, and to promote technological strategies to alleviate distress in caregiver symptoms. These studies are needed to advance the science related to caregiver experience of symptoms, caregiving contexts that promote these symptoms, and viable tools to address the symptoms experienced by caregivers.			
084550	<a href="#">Palliative Care in Home and Community Settings (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-320	07-Jan-2022	275,000 USD
	Contact Name	Karen A. Kehl, PhD, RN, FPCN			
	Contact Telephone	301-594-8010			
	Contact Email	<a href="mailto:karen.kehl@mail.nih.gov">karen.kehl@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022			
	Synopsis	The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.			
078414	<a href="#">Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-058	07-Jan-2022	275,000 USD
	Contact Name	Lynn S. Adams, Ph.D.			
	Contact Telephone	301-594-8911			
	Contact Email	<a href="mailto:adamsls@nih.gov">adamsls@nih.gov</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to encourage research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care (EOLPC) for American Indian/Alaska Native (AI/AN) individuals with advanced illness and their families and communities.			
078636	<a href="#">Telomeres in Wellness and Disease: A Biobehavioral Approach (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PA-19-073	07-Jan-2022	Not Specified
	Contact Name	Lois A. Tully, PhD			
	Contact Telephone	301-594-5968			
	Contact Email	<a href="mailto:tullyla@mail.nih.gov">tullyla@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioral programs of research. A body of research has demonstrated the contribution of telomeres to health-related outcomes; however, additional studies are needed to achieve the full potential for incorporating telomere-guided approaches for maintaining wellness, reducing the risk and burden of disease, and for advancing symptom and self-management strategies.			
079344	<a href="#">End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional)</a>	National Institute of Nursing Research/NIH/DHHS	PAR-19-153	07-Jan-2022	275,000 USD
	Contact Name	Lynn S. Adams, Ph.D.			
	Contact Telephone	301-594-8911			
	Contact Email	<a href="mailto:lynn.adams@nih.gov">lynn.adams@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs,			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.			
084210	<a href="#">Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAS-19-317	05-Jan-2022	Not Specified
	Contact Name	Zane Martin, Ph.D.			
	Contact Telephone	301-827-7130			
	Contact Email	<a href="mailto:zane.martin@nih.gov">zane.martin@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jan-2022 , 05-Apr-2022 , 05-Sep-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) supports applications to NIA's Small Business Technology Transfer Research (STTR) program to conduct research leading to the development of innovative products and/or services that may advance progress in preventing and treating Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD) and/or caring for and treating AD/ADRD patients.			
088437	<a href="#">Harmonization of Alzheimer's Disease and Related Dementias (AD/ADRD) Genetic, Epidemiologic, and Clinical Data to Enhance Therapeutic Target Discovery (U24 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-20-099	25-Jan-2022	13,855,000 USD
	Contact Name	Marilyn Miller, Ph.D.			
	Contact Telephone	301-496-9350			
	Contact Email	<a href="mailto:millerem@nia.nih.gov">millerem@nia.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023			
	Synopsis	The National Institute on Aging (NIA) invites applications specific to infrastructure that will support, under a single cooperative agreement (U24), phenotypic data harmonization on subjects with Alzheimer's Disease Sequencing Project (ADSP) genetic and genomic data. These data will become a long-lived "legacy" data set that will be perpetually curated. The			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		FOA will fund a single vanguard network of researchers with expertise in genetics, epidemiology, and clinical specialties who will work with the ADSP and with study cohort leads on data harmonization efforts to optimize the ability to identify well-targeted therapeutic approaches for Alzheimer's disease and related dementias (AD/ADRD).			
088853	<a href="#">National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (U24 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-20-110	25-Jan-2022	Not Specified
	Contact Name	Marilyn M. Miller, Ph.D.			
	Contact Telephone	301-496-9350			
	Contact Email	<a href="mailto:millerm@nia.nih.gov">millerm@nia.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023			
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications specific to infrastructure that will support the storage, analysis, and sharing of primary and secondary data for the genetics and genomics of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).			
088306	<a href="#">Development of Research Education Resources for Geriatrics-Related Translational and Clinical Scientists (R25 Independent Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-20-095	25-Jan-2022	900,000 USD
	Contact Name	Basil Eldadah, MD, Ph.D.			
	Contact Telephone	301-496-6761			
	Contact Email	<a href="mailto:basil.eldadah@nih.gov">basil.eldadah@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023			
	Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Curriculum or Methods Development Courses for Skills Development Research Experiences			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
083966	<a href="#">NIA Program Project Applications (P01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-19-314	07-Jan-2022	Not Specified
	<p>Contact Name   Robin A. Barr, D.Phil</p> <p>Contact Telephone   301-496-9322</p> <p>Contact Email   <a href="mailto:BarrR@mail.nih.gov">BarrR@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022</p> <p>Synopsis   The National Institute on Aging (NIA) invites the submission of investigator-initiated program project (P01) applications addressing scientific areas relevant to the NIA mission. Each application submitted to this FOA must include at least three related research projects that share a common central theme, focus, and/overall objective and an administrative core to lead the project. Revision applications should include expansion of an existing, or proposal of a new, project or projects within a program project. Revision applications may not request support beyond the end date of the parent P01 award.</p>				
082792	<a href="#">Limited Competition: NIA Genome Center for Alzheimer's Disease (GCAD) (U54 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-19-288	25-Jan-2022	Not Specified
	<p>Contact Name   Marilyn Miller, Ph.D.</p> <p>Contact Telephone   301-496-9350</p> <p>Contact Email   <a href="mailto:millerm@nia.nih.gov">millerm@nia.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   25-Jan-2022 , 25-May-2022 , 25-Sep-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites applications to continue the operations of the NIA Genome Center for Alzheimer's Disease (GCAD) to facilitate and support the Alzheimer's Disease Sequencing Project (ADSP) activities. GCAD will serve as the focal point for all phases of ADSP quality control checking, data harmonization, and meta-analysis. The FOA is intended to support a major component of the full range of analysis for the ADSP. The spectrum of the Center's activities comprises a multidisciplinary attack on Alzheimer's disease (AD) and AD-related dementias (ADRD), in keeping with NIA's programmatic needs. The Center will serve as a national resource for the specific purpose of identifying potential avenues for therapeutic approaches and prevention of the disease.</p>				
085643	<a href="#">Complex Integrated Multi-Component Projects in Aging Research (U19)</a>	National Institute on	PAR-19-	25-Jan-2022	Not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	<a href="#">Clinical Trial Optional</a>		Aging/NIH/DHHS	374	Specified	
	<p>Contact Name   Sanoj Suneja, PhD</p> <p>Contact Telephone   301-402-7710</p> <p>Contact Email   <a href="mailto:sunejas@mail.nih.gov">sunejas@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   25-Jan-2022 , 25-May-2022 , 25-Sep-2022</p> <p>Synopsis   National Institute on Aging (NIA) invites applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions. This FOA will use the NIH U19 Research Program – Cooperative Agreements award mechanism.</p>					
084181	<a href="#">Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)</a>		National Institute on Aging/NIH/DHHS	PAS-19-316	05-Jan-2022	Not Specified
	<p>Contact Name   Stephanie Fertig, M.B.A.</p> <p>Contact Telephone   301-496-1447</p> <p>Contact Email   <a href="mailto:fertigs@ninds.nih.gov">fertigs@ninds.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jan-2022 , 05-Apr-2022 , 05-Sep-2022</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) is to support applications to NIA's Small Business Innovation Research (SBIR) program to conduct research leading to the development of innovative products and/or services that may advance progress in preventing and treating Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD) and/or caring for and treating AD/ADRD patients.</p>					
103307	<a href="#">Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer's Disease and Related Dementias (AD/ADRD) (R01 Clinical Trial Optional)</a>		National Institute on Aging/NIH/DHHS	PAR-21-207	26-Jan-2022	Not Specified
	<p>Contact Name   Luke Stoeckel, Ph.D.</p> <p>Contact Telephone   301-496-3136</p>					

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:luke.stoeckel@nih.gov">luke.stoeckel@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 26-Jan-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites R01 applications for ancillary studies that address psychological and interpersonal mechanisms driving adherence to behavior or lifestyle change relevant to the prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Successful applications will seek to identify malleable, mechanistic, psychological, or interpersonal targets that – if modified – will strengthen adherence to, maintenance of, and continued/renewed engagement in behaviors that may promote cognitive health and prevent AD/ADRD. This FOA will specifically support ancillary studies to ongoing, early- to late-stage clinical intervention trials. Ancillary studies should provide the opportunity to explore novel psychological and interpersonal mechanisms by collecting new data from participants enrolled in the ongoing parent study.</p>				
101790	<a href="#">NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-21-106	07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:NIATraining@nih.gov">NIATraining@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024</p> <p>Synopsis The objective of the NIA Academic Leadership Career Award (K07) is to provide support for senior investigators who have the expertise and leadership skills to enhance aging and geriatric research capacity within their academic institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator.</p>				
075498	<a href="#">Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)</a>	National Institute on Aging/NIH/DHHS	PAR-18-820	07-Jan-2022	5,000,000 USD
	Contact Name	Lorenzo M. Refolo, Ph.D.			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-594-7576</p> <p>Contact Email   <a href="mailto:refolol@nia.nih.gov">refolol@nia.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022</p> <p>Synopsis   National Institute on Aging's (NIA) invites applications for pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.</p>				
097636	<p><a href="#">Notice of Special Interest (NOSI): Basic and Translational Research on Affective, Motivational, and Social Function in Normative Aging and/or Alzheimer's Disease and Related Dementias (AD/ADRD)</a></p>	National Institute on Aging/NIH/DHHS	NOT-AG-20-040	07-Jan-2022	Not Specified
	<p>Contact Name   Janine Simmons, M.D., Ph.D.</p> <p>Contact Telephone   301-480-8959</p> <p>Contact Email   <a href="mailto:janine.simmons@nih.gov">janine.simmons@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022</p> <p>Synopsis   This Notice of Special Interest (NOSI) is intended to underscore NIA's continued commitment to psychological and neuroscientific research on affective, motivational, and social functions in midlife and aging. NIA supports research to further clarify the changes in and trajectories of these processes in adults who are aging normally and/or in individuals with mild cognitive impairment (MCI), Alzheimer's disease (AD), and AD-related dementias (ADRD). NIA also seeks to understand how changes in the structure and function of neurobiological and neuromodulatory systems mediate or moderate affective, motivational, and social behaviors and interact with other psychological functions, including cognition. NIA's goals are three-</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>fold: (1) to advance understanding of normative maturational changes in affective, motivational, and social processes, their role in behavior and cognition, and their underlying integrative neural-behavioral mechanisms; (2) to elucidate how dysfunction in these processes might manifest in MCI and the early stages of AD/ADRD; and/or (3) to determine how dysfunction in these processes might account for any of the Behavioral and Psychological Symptoms of Dementia (BPSD) observed in AD/ADRD. Such studies may identify novel targets for preventative or therapeutic interventions to promote social, emotional, and cognitive well-being; facilitate adaptive function in aging; normalize social or emotional dysregulation; and/or strengthen social or emotional resilience at different stages of the life course and at different disease stages in AD/ADRD.</p>			
102443	<a href="#">Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration</a>	National Institute on Aging/NIH/DHHS	NOT-AG-21-016	07-Jan-2022	Not Specified
	<p>Contact Name   Mirosław Mackiewicz, Ph.D.            Contact Telephone   301-496-9350            Contact Email   <a href="mailto:miroslaw.mackiewicz@nih.gov">miroslaw.mackiewicz@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a>            Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023            Synopsis   The purpose of this Notice of Special Interest (NOSI) is to inform applicants to the National Institute on Aging (NIA) of NIA's interest in basic and clinical mechanistic research on neurological and neurocognitive sequelae originating from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and Coronavirus Disease 2019 (COVID-19) in aging and age-related neurodegeneration.</p>				
086469	<a href="#">Aging Research Dissertation Awards to Increase Diversity (R36 Clinical Trial Not Allowed)</a>	National Institute on Aging/NIH/DHHS	PAR-19-394	07-Jan-2022	Not Specified
	<p>Contact Name   Shahrooz Vahedi, Ph.D.            Contact Telephone   301-496-9322            Contact Email   <a href="mailto:shahrooz.vahedi@nih.gov">shahrooz.vahedi@nih.gov</a>            Sponsor Website              Program URL   <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to provide dissertation awards in all areas of research within NIA's strategic priorities to increase the diversity of the scientific research workforce engaged in research on aging and aging-related health conditions.			
100297	<a href="#">Notice of Special Interest (NOSI): Integrative Studies of Neural Mechanisms Underlying Fundamental Affective Processes in Aging</a>	National Institute on Aging/NIH/DHHS	NOT-AG-21-012	07-Jan-2022	Not Specified
	Contact Name	Luci Roberts, Ph.D.			
	Contact Telephone				
	Contact Email	<a href="mailto:roberlu@mail.nih.gov">roberlu@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to inform applicants of NIA's interest in research on the neural mechanisms underlying fundamental affective processes in aging. Grant applications are encouraged to 1) extend research on neural mechanisms underlying affective processes into aging models; and/or 2) seek to "reverse translate" clinical research results on affective processes in aging into model systems that support elucidation of fundamental neural mechanisms. NIA also wishes to encourage collaboration among cognitive and affective neuroscientists and/or investigators working at different levels of neurobiological and behavioral analysis.			
100731	<a href="#">NIAAA Resource-Related Research Projects (R24 Clinical Trial Not Allowed)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-21-072	25-Jan-2022	Not Specified
	Contact Name	Gary J Murray, Ph.D.			
	Contact Telephone	301-443-9940			
	Contact Email	<a href="mailto:gary.murray@nih.gov">gary.murray@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023 , 25-May-2023 , 25-Sep-2023			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis	<p>The purpose of the Resource-Related Research Projects (R24) grant is to support investigator-initiated resources designed to provide materials and services to support and advance biomedical research on a national basis. An R24 resource grant mechanism is a non-hypothesis-driven activity to provide data, materials, tools, or services that are essential to making timely, high quality, and cost-efficient progress in a field. Hypothesis-driven research applications should not be submitted in response to this program announcement but to another mechanism that encourages this type of research. The resource should be available to any qualified investigator, and should be highly quality controlled, and not duplicate resources available commercially or through other sources. Resources should be designed to provide services to the broad alcohol research community and should not be limited by any specific regional focus.</p>
----------	--

076327	<a href="#">Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R03 - Clinical Trial Optional)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-861	07-Jan-2022	100,000 USD
--------	--	---	-----------	-------------	-------------

Contact Name	Robert Freeman, Ph.D.
Contact Telephone	301-443-8820
Contact Email	<a href="mailto:rfreeman@mail.nih.gov">rfreeman@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022
Synopsis	<p>National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R03 Small Grant Program award mechanism.</p>

083915	<a href="#">Mechanisms of Tolerance (R21/R33 - Clinical Trial Required)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-19-311	07-Jan-2022	1,775,000 USD
--------	---	---	------------	-------------	---------------

Contact Name	Elizabeth M Powell, PhD
Contact Telephone	301-443-0786
Contact Email	<a href="mailto:elizabeth.powell3@nih.gov">elizabeth.powell3@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial required, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase. Applicants interested in animal studies on the mechanisms of tolerance may consider FOA (PAR-18-659) or in the genetic basis of tolerance may consider FOA (PA-18-660).</p>			
097916	<a href="#">Notice of Special Interest (NOSI): Secondary Analyses of Existing Alcohol Research Data</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-018	07-Jan-2022	Not Specified
	Contact Name	Wenxing Zha, Ph.D.			
	Contact Telephone	301-443-0633			
	Contact Email	<a href="mailto:zhaw@mail.nih.gov">zhaw@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023			
	Synopsis	<p>The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary analyses of existing data sets with the goal of enhancing our understanding of the following: 1) the patterns and trajectories of alcohol consumption, 2) the epidemiology and etiology, including genetics, of alcohol-related problems and disorders, and 3) alcohol-related health services and health systems, including access, quality, and efficiency. This Notice encourages applications proposing innovative analyses of existing alcohol research data, answering novel research hypotheses and questions, and developing and testing advanced analytical methodologies applicable to alcohol related epidemiological, behavioral and genetics research.</p>			
098270	<a href="#">Notice of Special Interest (NOSI): Alcohol and Aging</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-019	07-Jan-2022	Not Specified
	Contact Name	Andras Orosz, Ph.D.			
	Contact Telephone	301-443-2193			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:orosza@mail.nih.gov">orosza@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to promote research to improve our understanding of the effects of alcohol consumption on aging across different levels of biological organization including the molecular, cellular, tissue, organ, organism, and societal levels. The following broad research areas will be encouraged: 1) Basic and clinical research defining the effects of alcohol consumption on lifespan, health span, and age-related diseases depending on level of alcohol consumption, drinking pattern, and duration of drinking; 2) Research to inform evidence-based guidance for identifying risk for alcohol use disorder (AUD) among older adults as well as prevention, diagnosis, and treatment of AUD in this population; and 3) Research to extend the health span of older adults who drink and decrease the health care burden of age-related diseases associated with alcohol use.</p>				
101458	<a href="#">Notice of Special Interest (NOSI): Alcohol-induced Tissue-specific and Organ System Diseases (R01/R21/R03)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-024	07-Jan-2022	Not Specified
	<p>Contact Name Li Lin</p> <p>Contact Telephone 301-827-7749</p> <p>Contact Email <a href="mailto:linli@mail.nih.gov">linli@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of this Notice is to inform potential applicants of the NIAAA's special interest in research project applications studying the harmful effects of alcohol on the body's tissues, organs, and systems in diverse populations across the lifespan.</p>				
105028	<a href="#">Notice of Special Interest (NOSI): Genetics of Alcohol Sensitivity and Tolerance</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-21-029	07-Jan-2022	Not Specified
	<p>Contact Name Hemin Chin, PhD</p> <p>Contact Telephone 301-443-1282</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:hemin.chin@nih.gov">hemin.chin@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024</p> <p>Synopsis The purpose of this notice of special interest (NOSI) is to provide enhanced understanding of genetic, genomic, and epigenetic factors contributing to biological processes for individual variation in sensitivity, the development of tolerance, and progression to AUD. NIAAA is interested in projects that will develop innovative strategies integrating both experimental and bioinformatics approaches to establish causality for candidate genes from GWAS and linkage studies and to provide insights into genetic mechanisms of alcohol sensitivity and the development of tolerance through investigation of genomic, epigenetic, or transcriptional variation, and gene network and pathway analyses. Applicants are encouraged to consider model systems in which these complex relationships can be better studied under defined genetic backgrounds and well-controlled environmental conditions.</p>				
100945	<a href="#">Notice of Special Interest (NOSI): Advances in Research for the Treatment, Services, and Recovery of Alcohol Use Disorder</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-022	07-Jan-2022	Not Specified

	<p>Contact Name Brett T. Hagman, Ph.D.</p> <p>Contact Telephone 301-443-0638</p> <p>Contact Email <a href="mailto:brett.hagman@nih.gov">brett.hagman@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to advance research on various topics that fall within NIAAA's Division of Treatment and Recovery Research (DTRR). DTRR's research interests are wide-ranging and encompass broad categories such as health services, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for alcohol use disorder (AUD) treatment and sustaining recovery. Other areas of interest include topics focusing on special-emphasis and underserved populations, including NIH-designated U.S. health disparity populations, as well as those with co-occurring disorders; and fetal alcohol spectrum disorders (FASD). In all studies, at all levels from FASD to elderly, efforts will be made to include participants that reflect the diversity of the population at</p>				
--	---	--	--	--	--

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

large.

090099	<a href="#">Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-20-127	07-Jan-2022	2,499,995 USD
--------	---	---	------------	-------------	---------------

Contact Name	Trinh T. Ly, MD
Contact Telephone	301-435-4085
Contact Email	<a href="mailto:trinh.ly@nih.gov">trinh.ly@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications Disorders (NIDCD). Applications should address high priority HIV/AIDS research outlined by the NIH Office of AIDS Research (OAR) [ <a href="https://www.oar.nih.gov/hiv-policy-and-research/research-priorities">https://www.oar.nih.gov/hiv-policy-and-research/research-priorities</a> ] in the areas of hearing, balance, taste, smell, voice, speech, and language. For applications with a clinical trial, only low risk clinical trials will be supported.

101187	<a href="#">NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-093	08-Dec-2021	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	<a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023 , 08-Dec-2023 , 07-Jan-2024
Synopsis	The purpose of the NIDCD Research Dissertation Fellowship for Au.D. Audiologists (F32) program is to support a comprehensive, rigorous biomedical research training, and dissertation research leading to a research doctorate (i.e., Ph.D.) in the biomedical, behavioral, or clinical sciences. This Funding Opportunity Announcement (FOA) does not allow applicants

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

090106	<a href="#">Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-20-123	07-Jan-2022	275,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Trinh T. Ly, MD
Contact Telephone	301-435-4085
Contact Email	<a href="mailto:trinh.ly@nih.gov">trinh.ly@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications Disorders (NIDCD). Applications should address high priority HIV/AIDS research outlined by the NIH Office of AIDS Research (OAR) [ <a href="https://www.oar.nih.gov/hiv-policy-and-research/research-priorities">https://www.oar.nih.gov/hiv-policy-and-research/research-priorities</a> ] in the areas of hearing, balance, taste, smell, voice, speech, and language. For applications with a clinical trial, only low risk clinical trials will be supported.

103278	<a href="#">Research Experiences to Enhance Clinician-Scientists' Participation in NIDCD's Research (R25 Clinical Trial Not Allowed)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-188	27-Jan-2022	1,250,000 USD
--------	--	---	------------	-------------	---------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	<a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	27-Jan-2022 , 27-May-2022 , 21-Sep-2022 , 27-Jan-2023 , 26-May-2023 , 26-Sep-2023 , 29-Jan-2024
Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated over-



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences

101155	<a href="#">NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-063	07-Jan-2022	2,499,995 USD
--------	---	---	------------	-------------	---------------

Contact Name	Trinh T. Ly, M.D.
Contact Telephone	301-435-4085
Contact Email	<a href="mailto:trinh.ly@nih.gov">trinh.ly@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024
Synopsis	The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This funding opportunity announcement (FOA) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this FOA, not require FDA oversight, are not intended to formally establish efficacy and have low risks to potentially cause physical or psychological harm. This FOA also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred companion U01 FOA PAR-21-064, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.

101736	<a href="#">NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-096	07-Jan-2022	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	<a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>07-Jan-2022 , 08-Feb-2022 , 07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 06-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024</p> <p>The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under PAR-21-094 "NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required)" Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to companion FOA PAR-21-095 "NIDCD Research Career Enhancement Award for Established Investigators (K18Independent Clinical Trial Not Allowed)" .</p>			
101734	<p><a href="#">NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Clinical Trial Not Allowed)</a></p>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-095	07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Alberto L. Rivera-Rentas, Ph.D.</p> <p>301-496-1804</p> <p><a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-Jan-2022 , 08-Feb-2022 , 07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 06-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024</p> <p>The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study or an ancillary study to a clinical trial. proposing to serve as the lead</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

investigator of an independent clinical trial, as part of their research and career development. Those planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA PAR-21-094 or for PAR-21-096 for Independent Basic Experimental Studies with Humans Required.

101733	<a href="#">NIDCD Research Career Enhancement Award for Established Investigators (K18 Clinical Trial Required)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-094	07-Jan-2022	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	<a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 08-Feb-2022 , 07-May-2022 , 07-Jun-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 06-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024
Synopsis	The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-095). Applicants not planning an independent clinical trial, but planning a basic experimental study with humans, must apply to companion FOA PAR-21-096 - NIDCD Research Career Enhancement Award for Established Investigators (K18 Independent Basic Experimental Studies with Humans Required)

078310	<a href="#">Advancing Research in Augmentative and Alternative Communication (AAC) (R01 Clinical Trial Optional)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PA-19-047	07-Jan-2022	Not Specified
--------	--	---	-----------	-------------	---------------

Contact Name	Lana Shekim, Ph.D.
Contact Telephone	301-496-5061
Contact Email	<a href="mailto:shekiml@nidcd.nih.gov">shekiml@nidcd.nih.gov</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	This funding opportunity announcement (FOA) seeks Research Project Grants (R01) applications on Augmentative and Alternative Communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with severe speech and physical impairments (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. This FOA is for R01s only and encourages a range of research inclusive of basic, clinical, and translational.			
101085	<a href="#">NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-087	07-Jan-2022	315,000 USD
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.			
	Contact Telephone	301-496-1804			
	Contact Email	<a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 17-Feb-2022 , 07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep-2023 , 13-Oct-2023 , 07-Jan-2024			
	Synopsis	The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Independent Clinical Trial Required’ (PAR-21-085). Applicants not planning an independent			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

clinical trial, or proposing to gain research in a clinical trial led by another investigator must apply to the companion 'Independent Clinical Trial Not Allowed' (PAR-21-086) FOA.

101080	<a href="#">NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 No Independent Clinical Trials)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-086	07-Jan-2022	315,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	<a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 17-Feb-2022 , 07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep-2023 , 13-Oct-2023 , 07-Jan-2024
Synopsis	The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-085 for Clinical Trial Required or for PAR-21-087 for Independent Basic Experimental Studies with Humans Required..

101078	<a href="#">NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Clinical Trial Required)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-085	07-Jan-2022	315,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	<a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-Jan-2022 , 17-Feb-2022 , 07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep-2023 , 13-Oct-2023 , 07-Jan-2024			
	Synopsis	The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-086). Observational Studies involving humans should submit under PAR-21-087 - NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required).			
078368	<a href="#">Advancing Research in Augmentative and Alternative Communication (AAC) (R21 Clinical Trial Optional)</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PA-19-046	07-Jan-2022	275,000 USD
	Contact Name	Lana Shekim, Ph.D.			
	Contact Telephone	301-496-5061			
	Contact Email	<a href="mailto:shekiml@nidcd.nih.gov">shekiml@nidcd.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	This funding opportunity announcement (FOA) solicits Research Project Grants (R21) applications on augmentative and alternative communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with complex communication needs (CCN) or with severe speech and physical impairments (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. This FOA is for R21s only and encourages a range of research inclusive of basic, clinical, and translational.			
102240	<a href="#">Notice of Special Interest (NOSI): Hearing Healthcare for Adults: Improving Access and Affordability</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-21-001	05-Jan-2022	Not Specified
	Contact Name	Kelly King, Au.D, Ph.D.			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-402-3458</p> <p>Contact Email   <a href="mailto:kingke@nidcd.nih.gov">kingke@nidcd.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jan-2022 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to encourage applications for research on hearing health care in adults in support of improving access and affordability. Further research is needed to strengthen the evidence base with a goal of delivering better hearing health care outcomes in adults.</p>				
104661	<a href="#">Notice of Special Interest (NOSI): NIDCD Health Disparities and Inequities Research</a>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	NOT-DC-21-003	08-Dec-2021	Not Specified
	<p>Contact Name   Kelly King, Au.D, Ph.D.</p> <p>Contact Telephone   301-402-3458</p> <p>Contact Email   <a href="mailto:kingke@nidcd.nih.gov">kingke@nidcd.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   08-Dec-2021 , 07-Jan-2022 , 05-Feb-2022 , 12-Feb-2022 , 16-Feb-2022 , 08-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 12-Jun-2022 , 16-Jun-2022 , 08-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 08-Dec-2022 , 07-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 08-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 08-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 08-Dec-2023 , 07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 08-Apr-2024 , 07-May-2024</p> <p>Synopsis   This Notice of Special Interest (NOSI) encourages applications that advance the understanding or reduce the impact of health disparities and inequities in communication disorders among racial/ethnic minority and other underrepresented populations. Applications that address the influence or reduction of racism or discrimination in causing or sustaining health disparities and inequities are also encouraged. The research must address one or more of the NIDCD mission areas of hearing, balance, taste, smell, voice, speech, and language.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
104056	<a href="#">Development &amp; Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)</a>	National Institute on Drug Abuse/NIH/DHHS	PA-21-205	07-Jan-2022	450,000 USD
	<p>Contact Name: Richard A. Jenkins, PhD</p> <p>Contact Telephone: 301-443-1923</p> <p>Contact Email: <a href="mailto:jenkinsri@mail.nih.gov">jenkinsri@mail.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023 , 07-May-2023 , 07-Sep-2023 , 07-Jan-2024 , 07-May-2024</p> <p>Synopsis: This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions for people who use drugs. Primary outcomes of interest include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research. "Intervention" here may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition or transmission of HIV infection, or improve clinical outcomes for persons living with HIV.</p>				
104989	<a href="#">RFA-DA-22-003 -- Elucidating the Effects of ART on Neuronal Function in the Context of SUD and HIV (R01 - Clinical Trials Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-22-003	02-Jan-2022 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name: Roger G Sorensen, PhD, MPA</p> <p>Contact Telephone: 301-443-3205</p> <p>Contact Email: <a href="mailto:rsorens@mail.nih.gov">rsorens@mail.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 02-Jan-2022 [Optional][LOI/Pre-App], 02-Feb-2022</p> <p>Synopsis: The National Institute on Drug Abuse [NIDA] seeks research applications to identify the effects of anti-retroviral therapy (ART) used for the treatment of HIV/AIDS on neuronal and glial structure and function, particularly when occurring in a background of chronic exposure to addictive substances including opioids, cocaine and other stimulants, cannabinoids, and nicotine. The overall goal of this funding opportunity is to determine the contributions of ART in the neurological and neurocognitive deficits that are linked to HIV-Associated Neurocognitive Disorders [HAND] in people living with HIV (PLWH) and substance use disorders (SUD).</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
105619	<a href="#">RFA-DA-22-033--Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-22-033	17-Jan-2022 [Optional][LOI/Pre-App]	1,000,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Peter Hartsock, PhD</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-402-1964</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:peter.hartsock@nih.gov">peter.hartsock@nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>17-Jan-2022 [Optional][LOI/Pre-App], 17-Feb-2022</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of substance use and SUD. These cohorts provide a strong resource platform for addressing imminent questions related to HIV prevention, treatment, HIV-associated comorbidities and coinfections in people who use drugs (PWUD). This FOA aims to support a single coordinating center (CC). The CC is charged with the task of enhancing collaborations and innovation in research to address NIH's high priority HIV research areas among the cohort investigators and other researchers engaged in the HIV and addiction research field by leveraging the rich data and biospecimen resources available through the cohorts program. The center coordinator(s) will lead the CC, and is responsible for the overall performance of the project, including the development, tracking, and reporting of performance metrics by all the currently funded U01 cohort program sites. The CC will establish and maintain a virtual repository for all the behavioral, clinical, and laboratory data including virologic, immunologic, genetics and other relevant biological data collected from the NIDA-funded cohort studies that can be shared widely among the cohort investigators and their collaborators. The CC will also identify new research opportunities, approaches to addressing methodological and/or technical challenges, and strategies to disseminate information and research findings from the cohort research sites.</td> </tr> </table>					Contact Name	Peter Hartsock, PhD	Contact Telephone	301-402-1964	Contact Email	<a href="mailto:peter.hartsock@nih.gov">peter.hartsock@nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	17-Jan-2022 [Optional][LOI/Pre-App], 17-Feb-2022	Synopsis	The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of substance use and SUD. These cohorts provide a strong resource platform for addressing imminent questions related to HIV prevention, treatment, HIV-associated comorbidities and coinfections in people who use drugs (PWUD). This FOA aims to support a single coordinating center (CC). The CC is charged with the task of enhancing collaborations and innovation in research to address NIH's high priority HIV research areas among the cohort investigators and other researchers engaged in the HIV and addiction research field by leveraging the rich data and biospecimen resources available through the cohorts program. The center coordinator(s) will lead the CC, and is responsible for the overall performance of the project, including the development, tracking, and reporting of performance metrics by all the currently funded U01 cohort program sites. The CC will establish and maintain a virtual repository for all the behavioral, clinical, and laboratory data including virologic, immunologic, genetics and other relevant biological data collected from the NIDA-funded cohort studies that can be shared widely among the cohort investigators and their collaborators. The CC will also identify new research opportunities, approaches to addressing methodological and/or technical challenges, and strategies to disseminate information and research findings from the cohort research sites.
Contact Name	Peter Hartsock, PhD																		
Contact Telephone	301-402-1964																		
Contact Email	<a href="mailto:peter.hartsock@nih.gov">peter.hartsock@nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	17-Jan-2022 [Optional][LOI/Pre-App], 17-Feb-2022																		
Synopsis	The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of substance use and SUD. These cohorts provide a strong resource platform for addressing imminent questions related to HIV prevention, treatment, HIV-associated comorbidities and coinfections in people who use drugs (PWUD). This FOA aims to support a single coordinating center (CC). The CC is charged with the task of enhancing collaborations and innovation in research to address NIH's high priority HIV research areas among the cohort investigators and other researchers engaged in the HIV and addiction research field by leveraging the rich data and biospecimen resources available through the cohorts program. The center coordinator(s) will lead the CC, and is responsible for the overall performance of the project, including the development, tracking, and reporting of performance metrics by all the currently funded U01 cohort program sites. The CC will establish and maintain a virtual repository for all the behavioral, clinical, and laboratory data including virologic, immunologic, genetics and other relevant biological data collected from the NIDA-funded cohort studies that can be shared widely among the cohort investigators and their collaborators. The CC will also identify new research opportunities, approaches to addressing methodological and/or technical challenges, and strategies to disseminate information and research findings from the cohort research sites.																		
084606	<a href="#">Grand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-19-327	01-Jan-2022	15,000,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Ivan D. Montoya, M.D., M.P.H.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-827-5936</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td><a href="mailto:imontoya@mail.nih.gov">imontoya@mail.nih.gov</a></td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> </table>					Contact Name	Ivan D. Montoya, M.D., M.P.H.	Contact Telephone	301-827-5936	Contact Email	<a href="mailto:imontoya@mail.nih.gov">imontoya@mail.nih.gov</a>	Sponsor Website		Program URL	<a href="#">Link to program URL</a>				
Contact Name	Ivan D. Montoya, M.D., M.P.H.																		
Contact Telephone	301-827-5936																		
Contact Email	<a href="mailto:imontoya@mail.nih.gov">imontoya@mail.nih.gov</a>																		
Sponsor Website																			
Program URL	<a href="#">Link to program URL</a>																		

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	01-Jan-2022 , 01-May-2022 , 01-Sep-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to \$5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.			
106310	<a href="#">RFA-DA-22-028 -- Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R01 - Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-22-028	09-Jan-2022 [Optional][LOI/Pre-App]	2,500,000 USD
	Contact Name	Kiran Vemuri, Ph.D.			
	Contact Telephone	301-435-4446			
	Contact Email	<a href="mailto:kiran.vemuri@nih.gov">kiran.vemuri@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	09-Jan-2022 [Optional][LOI/Pre-App], 09-Feb-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support human and animal research on the pharmacokinetic (PK) and pharmacodynamic (PD) effects of Δ9-tetrahydrocannabinol (THC) that is present in cannabis and cannabis products. Applications testing a fully conceptualized premise founded with adequate preliminary data are appropriate for this FOA. Exploratory research projects should consider applying to the companion R21 announcement RFA-DA-22-039.			
106311	<a href="#">RFA-DA-22-039 -- Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R21 - Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-22-039	09-Jan-2022 [Optional][LOI/Pre-App]	200,000 USD
	Contact Name	Kiran Vemuri, Ph.D.			
	Contact Telephone	301-435-4446			
	Contact Email	<a href="mailto:kiran.vemuri@nih.gov">kiran.vemuri@nih.gov</a>			
	Sponsor Website				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-Jan-2022 [Optional][LOI/Pre-App], 09-Feb-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support human and animal research on the pharmacokinetic (PK) and pharmacodynamic (PD) effects of Δ9-tetrahydrocannabinol (THC) that is present in cannabis and cannabis products. Exploratory projects are appropriate for this FOA. Applicants with projects testing a fully conceptualized premise founded with adequate preliminary data should consider applying to the companion R01 announcement RFA-DA-22-028.</p>				
084960	<a href="#">NIDA Program Project Grant Applications (P01 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-19-345	07-Jan-2022	Not Specified
	<p>Contact Name Kevin Walton, Ph.D.</p> <p>Contact Telephone 301-827-5980</p> <p>Contact Email <a href="mailto:waltonkm@nida.nih.gov">waltonkm@nida.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) announces the availability of support for collaborative research by multi-disciplinary teams which is of high priority to NIDA and leads to synergistic outcomes based on the synthesis of multiple research approaches. The NIDA Program Projects funding opportunity will support research in which the funding of three or more highly meritorious projects as a group enriches both the component projects and the overall program to offer significant scientific advantages over supporting the same projects as individual research grants (i.e., synergy). For the duration of the award, each Program must consist of a minimum of three research projects focused on issues critical to advance the mission and goals of NIDA.</p>				
101989	<a href="#">Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-018	07-Jan-2022	Not Specified
	<p>Contact Name Raul Mandler, MD</p> <p>Contact Telephone 301-480-2541</p> <p>Contact Email <a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a></p> <p>Sponsor Website</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis NIDA is interested in receiving research applications focusing on studying the long-term neurocognitive consequences of the COVID-19/HIV/SUDs syndemic.</p>				
102988	<a href="#">Notice of Special Interest (NOSI): Basic Research on Fentanyl and Synthetic Fentanyl Analogs: Signaling, Neurobiology, and Pharmacology</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-033	07-Jan-2022	Not Specified
	<p>Contact Name Pamela G. Fleming</p> <p>Contact Telephone 301-480-1159</p> <p>Contact Email <a href="mailto:pfleming@nih.gov">pfleming@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Notice informs potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in basic research on fentanyl and synthetic fentanyl analogs. Of particular interest is research that is focused on elucidating chemical, cellular, signaling, and neurobiological mechanisms underlying abuse potential, physical dependence, addiction liability and deaths due to overdose of fentanyl and fentanyl analogs.</p>				
103015	<a href="#">Notice of Special Interest (NOSI): Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-028	07-Jan-2022	Not Specified
	<p>Contact Name Pamela G. Fleming</p> <p>Contact Telephone 301-480-1159</p> <p>Contact Email <a href="mailto:pfleming@nih.gov">pfleming@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This Notice informs potential applicants to the National Institute on Drug Abuse (NIDA) about a special interest in research on</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

chemistry, pharmacology, biological targets and biochemical mechanisms that contribute to the effects of synthetic psychoactive substances.

079379	<a href="#">Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-19-162	07-Jan-2022	1,250,000 USD
--------	--	---	------------	-------------	---------------

Contact Name	Karen Sirocco
Contact Telephone	301-451-8661
Contact Email	<a href="mailto:siroccok@nida.nih.gov">siroccok@nida.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022
Synopsis	The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page ( <a href="http://www.abcdstudy.org">www.abcdstudy.org</a> ).

106362	<a href="#">AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAS-21-270	07-Jan-2022	200,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Richard A. Jenkins, Ph.D.
Contact Telephone	301-443-1923
Contact Email	<a href="mailto:jenkinsri@mail.nih.gov">jenkinsri@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023 , 07-May-2023 , 07-Sep-2023 , 07-Jan-2024 , 07-May-2024 , 07-Sep-2024
Synopsis	This funding opportunity announcement (FOA) seeks to facilitate the entry of both newly independent and early career investigators to the area of drug use and use disorder research and HIV/AIDS. This FOA, the AIDS-Science Track Award for

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug use and/or use disorder and HIV/AIDS that can be carried out in a short period of time with limited resources. This FOA welcomes applications integrating substance use and/or substance use disorder (SUD) and HIV/AIDS across all areas of research supported by NIDA.			
085474	<a href="#">Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-19-368	07-Jan-2022	2,499,995 USD
	Contact Name	Marsha F. Lopez, Ph.D., M.H.S.			
	Contact Telephone	301-443-6504			
	Contact Email	<a href="mailto:marsha.lopez@nih.gov">marsha.lopez@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV.			
082413	<a href="#">Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-19-282	07-Jan-2022	Not Specified
	Contact Name	Vani Pariyadath, Ph.D.			
	Contact Telephone	301-443-3209			
	Contact Email	<a href="mailto:vani.pariyadath@nih.gov">vani.pariyadath@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 11-Jul-2022 , 07-Sep-2022 , 10-Mar-2023 , 07-May-2023			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying Substance Use Disorders (SUD), including fundamental brain function relevant to substance use. For projects not requiring a phased research approach, applicants are encouraged to apply under a different funding mechanism (e.g., Neuroscience Research on Drug Abuse (R01 Clinical Trial Optional)).

091070	<a href="#">Extracellular RNA Carrier Subclasses in Processes Relevant to Substance Use Disorders or HIV infection (R21- Clinical Trial Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-20-148	07-Jan-2022	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	John Satterlee, Ph.D
Contact Telephone	301-435-1020
Contact Email	<a href="mailto:satterleej@nida.nih.gov">satterleej@nida.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 15-Mar-2022 , 07-May-2022 , 13-Oct-2022 , 07-Jan-2023 , 15-Mar-2023 , 07-May-2023
Synopsis	The purpose of this FOA is to encourage research investigating the roles of extracellular RNA (exRNA) carrier subclasses in biological processes relevant to substance use disorders (SUDs) and/or HIV infection, latency, or pathogenesis in the CNS. Applicants may propose to investigate biological mechanisms involving exRNA carrier subclasses, or propose to develop improved technologies to investigate extracellular vesicles or other exRNA carriers.

091068	<a href="#">Extracellular RNA Carrier Subclasses in Processes Relevant to Substance Use Disorders or HIV infection (R01- Clinical Trial Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-20-147	07-Jan-2022	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	John Satterlee, Ph.D
Contact Telephone	301-435-1020
Contact Email	<a href="mailto:satterleej@nida.nih.gov">satterleej@nida.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 15-Mar-2022 , 07-May-2022 , 13-Oct-2022 , 07-Jan-2023 , 15-Mar-2023 , 07-May-2023
Synopsis	The purpose of this FOA is to encourage research investigating the roles of extracellular RNA (exRNA) carrier subclasses in biological processes relevant to substance use disorders (SUDs) and/or HIV infection, latency, or pathogenesis in the CNS. Applicants may propose to investigate biological mechanisms involving exRNA carrier subclasses, or propose to develop improved technologies to investigate extracellular vesicles or other exRNA carriers.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					improved technologies to investigate extracellular vesicles or other exRNA carriers.
083682	<a href="#">Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-19-310	07-Jan-2022	75,000 USD
	Contact Name	Holly Moore, Ph.D.			
	Contact Telephone	301-827-7376			
	Contact Email	<a href="mailto:holly.moore@nih.gov">holly.moore@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	<p>This Funding Opportunity from the National Institute on Drug Abuse (NIDA) will use a NIH Small Research Grant (R03) award mechanism to support studies that apply affective, cognitive and behavioral science approaches to research questions relevant to substance use disorders (SUD). With this R03 mechanism, NIDA aims to seed innovative affective, cognitive and behavioral hypotheses, models, and methods in preclinical and clinical SUD research. The B/START R03 is intended for recently-independent investigators with expertise in behavioral science as well as established investigators who are using behavioral science approaches to SUD for the first time. Studies supported by B/START are expected to produce a coherent set of preliminary findings that would inform the design of a more complete study and serve as preliminary data supporting feasibility or scientific rationale in an R01, R21 or similar application.</p>			
094123	<a href="#">Substance Use/Substance Use Disorder Dissertation Research Award (R36 - Clinical Trials Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PA-20-208	07-Jan-2022	100,000 USD
	Contact Name	Aria Crump, Sc.D.			
	Contact Telephone	301-435-0881			
	Contact Email	<a href="mailto:acrump@nida.nih.gov">acrump@nida.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023			
	Synopsis	<p>The goal of this FOA is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with NIDA funding priorities detailed</p>			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>here (<a href="https://www.drugabuse.gov/funding/funding-priorities">https://www.drugabuse.gov/funding/funding-priorities</a>) or within the NIDA Strategic Plan (<a href="https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan">https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan</a>). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from those who can contribute to diversifying the research workforce as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031).</p>			
101618	<a href="#">Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PA-21-110	07-Jan-2022	450,000 USD
	Contact Name	Amy B. Goldstein, PhD			
	Contact Telephone	301-827-4124			
	Contact Email	<a href="mailto:amy.goldstein@nih.gov">amy.goldstein@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage theoretically-driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest for the research supported through this FOA include a reduction in negative sequelae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.</p>			
103874	<a href="#">Notice of Special Interest (NOSI): Leveraging Transformative Connectome Resources in Model Organisms to Elucidate the Neurobiology of Substance Abuse Disorders</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-006	07-Jan-2022	Not Specified
	Contact Name	Olivier Berton, Ph.D.			
	Contact Telephone	301-827-7771			
	Contact Email	<a href="mailto:olivier.berton@nih.gov">olivier.berton@nih.gov</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this notice is to encourage research project submissionsthat leverage whole-brain or large connectome resources in genetically tractable model organisms to investigate the role of distributed neuronal circuits in behaviors relevant to substance use disorders (SUD).</p>				
103870	<a href="#">Notice of Special Interest (NOSI): Leveraging Longitudinal Studies in Animal Models to Identify Neural Mechanisms of Vulnerability and Resilience to Substance Use Disorder</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-003	25-Oct-2021	Not Specified
	<p>Contact Name Holly Moore</p> <p>Contact Telephone 301-827-7376</p> <p>Contact Email <a href="mailto:Holly.Moore@nih.gov">Holly.Moore@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 25-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 25-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024</p> <p>Synopsis NIDA seeks to stimulate research in non-human species aimed at modeling environmental and/or biological risk factors for SUD to elucidate neural and cognitive developmental mechanisms that may mediate, moderate, or predict the effects of these factors on subsequent emergence of SUD-related behaviors. Use of longitudinal designs and developmental-stage-appropriate paradigms are strongly encouraged.</p>				
090993	<a href="#">NIDA Small Research Grant Program (R03 Clinical Trial Required)</a>	National Institute on Drug Abuse/NIH/DHHS	PA-20-146	07-Jan-2022	100,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Katrina L Foster, PhD</p> <p>Contact Telephone   301-827-5815</p> <p>Contact Email   <a href="mailto:fosterkl@nih.gov">fosterkl@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis   The NIDA Small Research Grant Program supports small clinical trials that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot, feasibility, or small clinical trials with medications, behavioral interventions, immunotherapies, therapeutic devices, therapeutic digital applications, health services, prevention interventions, biomarkers, and development of research methodology. This Funding Opportunity Announcement requires that a clinical trial be proposed. The proposed project must be related to the programmatic interests of NIDA.</p>				
103071	<a href="#">Notice of Special Interest (NOSI): Deciphering the Mosaic of Glia in the Addicted Brain</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-001	25-Oct-2021	Not Specified
	<p>Contact Name   Shang-Yi Anne Tsai, Ph.D</p> <p>Contact Telephone   301-827-5842</p> <p>Contact Email   <a href="mailto:stsai@nih.gov">stsai@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   25-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 25-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform potential applicants of its interest in research project grant submissions that examine the effects of drug use on the structural and functional diversity and plasticity of glia and non-neuronal cells on nervous system process in the context of drug misuse and substance use disorders (SUD). Glial and other non-neuronal cells include astrocytes, microglia, oligodendrocytes and ependymal cells.</p>				
102446	<a href="#">Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic</a>	National Institute on Drug Abuse	NOT-DA-	07-Jan-2022	Not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	<a href="#">Knowledge and Program Planning</a>		Abuse/NIH/DHHS	21-007	Specified	
	<p>Contact Name Richard A. Jenkins PhD</p> <p>Contact Telephone 301-443-1923</p> <p>Contact Email <a href="mailto:jenkinsri@mail.nih.gov">jenkinsri@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this Notice is to encourage grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. Data may be from NIDA-funded or co-funded projects as well as from other sources. This Notice is expected to increase the utilization of existing data including epidemiologic and clinic cohorts, longitudinal follow-up studies of interventions, as well as other publicly available data including those provided by government bodies, data warehouses and commercial data sources. Existing data may include data from completed projects as well as those that are ongoing. Results from studies supported by this NOSI are expected to generate knowledge that can be used to answer significant questions about HIV epidemics, promote efficient provision of services, and address limitations of existing models that have guided public policy. NIDA is particularly interested in research that integrates substance use considerations into program planning and policy to increase the quality of HIV services and their responsiveness to substance using populations.</p>					
104862	<a href="#">Notice of Special Interest (NOSI): Advancing HIV/AIDS Research through Computational Neuroscience</a>		National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-030	25-Oct-2021	Not Specified
	<p>Contact Name Yu (Woody) Lin</p> <p>Contact Telephone 301-435-1318</p> <p>Contact Email <a href="mailto:ylin1@mail.nih.gov">ylin1@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 25-Oct-2021 , 07-Jan-2022 , 25-Jan-2022 , 05-Feb-2022 , 12-Feb-2022 , 16-Feb-2022 , 25-Feb-2022 , 07-May-2022 , 25-May-2022 , 05-Jun-2022 , 12-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 15-Aug-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 12-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 12-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 ,</p>					

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
106279	<a href="#">Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-22-027	11-Jan-2022	275,000 USD

07-May-2023 , 25-May-2023 , 05-Jun-2023 , 12-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 07-Sep-2023 , 25-Sep-2023 , 05-Oct-2023 , 12-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 25-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024 , 25-Sep-2024 , 12-Oct-2024 , 25-Oct-2024 , 07-Jan-2025

**Synopsis** This Notice of Special Interest [NOSI] is to support computational HIV/AIDS research as it relates to NIDA’s mission through collaborative research between investigators with experimental expertise related to HIV/AIDS and those with computational proficiency, including scientists from statistics, physics, mathematics, engineering, and computer science. The NOSI will support meritorious and innovative research built on well-established computational strategies (theory, models, and methods) to investigate HIV-related neurocognitive deficits and neuropathogenesis in the context of substance use or substance use disorder (SUD). Investigators are expected to have complementary and integrated expertise in their field(s), but an ongoing collaboration or record of co-authorship is not required.

**Contact Name** Marsha F. Lopez, PhD, MHS  
**Contact Telephone** 301-443-6504  
**Contact Email** [lopezmar@mail.nih.gov](mailto:lopezmar@mail.nih.gov)  
**Sponsor Website**  
**Program URL** [Link to program URL](#)  
**Deadline Dates (ALL)** 11-Jan-2022 , 03-May-2022 , 08-Sep-2022 , 11-Jan-2023 , 03-May-2023 , 08-Sep-2023 , 11-Jan-2024 , 03-May-2024 , 08-Sep-2024

**Synopsis** This Funding Opportunity Announcement (FOA) will support pilot, feasibility or exploratory research in 7 priority areas in substance use epidemiology, prevention, and health services, including: 1) responses to sudden and severe emerging drug issues (e.g. the ability to look into a large and sudden spike in opioid or synthetic cannabinoid use/overdoses in a particular community); 2) responses to emerging marijuana trends and topics related to the shifting policy landscape; 3) responses to unexpected and time-sensitive prescription drug abuse research opportunities (e.g., new state or local efforts); 4) responses to unexpected and time-sensitive medical system issues (e.g. opportunities to understand addiction services in the evolving health care system); 5) responses to unexpected and time-sensitive criminal or juvenile justice opportunities (e.g. new system and/or structural level changes) that relate to drug abuse and access and provision of health care service;6) partnerships between researchers and state or local organizations to support the evaluation of new local policies, programs, or practices in response to public health emergencies (e.g., the opioid crisis); 7) research examining how the COVID-19 pandemic has impacted drug markets and overdose risk. It should be clear that the knowledge gained from the proposed study is time-

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		sensitive and that an expedited rapid review and funding are required in order for the scientific question to be answered (i.e. an imminent policy change will not allow for standard review and funding timeline).			
101829	<a href="#">Notice of Special Interest (NOSI): Effects of Smoking and Vaping on the Risk and Outcome of COVID-19 Infection</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-011	07-Jan-2022	Not Specified
	Contact Name	Raul Mandler, MD; FAAN; FANA			
	Contact Telephone	301-480-2541			
	Contact Email	<a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	The purpose of this notice is to communicate NIDA's interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection. This Notice is a reissuance of NOT-DA-20-084.			
102016	<a href="#">Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-017	07-Jan-2022	Not Specified
	Contact Name	Raul Mandler, MD			
	Contact Telephone	301-480-2541			
	Contact Email	<a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.			
102120	<a href="#">Notice of Special Interest (NOSI): Telehealth Strategies for Individuals</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-	07-Jan-2022	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">with HIV and Substance Use Disorders</a>	Abuse/NIH/DHHS	21-019		Specified
	<p>Contact Name   Raul Mandler, MD</p> <p>Contact Telephone   301-480-2541</p> <p>Contact Email   <a href="mailto:mandlerr@nih.gov">mandlerr@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   The National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) inviting research applications to explore and develop telehealth methods and strategies for diagnosis, prevention, treatment, and population analysis in individuals living with HIV and Substance Use Disorder (SUD).</p>				
104182	<a href="#">Notice of Special Interest (NOSI): Advanced Computational Approaches to Elucidate Disease Pathology and Identify Novel Therapeutics for Addiction</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-004	07-Jan-2022	Not Specified
	<p>Contact Name   Susan Wright, Ph.D.</p> <p>Contact Telephone   301-402-6683</p> <p>Contact Email   <a href="mailto:susan.wright@nih.gov">susan.wright@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 16-Oct-2024 , 07-Jan-2025</p> <p>Synopsis   The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) of NIDA's interest in grant applications that will develop or utilize advanced computational approaches to describe complex drug-disease relationships in ways that will rapidly advance the development of new treatments, allow for targeted funding of substance use disorder (SUD) drug discovery and improve health care. NIDA has a particular interest in applications that include approaches in one or more of the following categories: 1) artificial intelligence, including machine learning and deep learning,</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					2) supercomputing/parallel computing, and/or 3) quantum computing.
105778	<a href="#">Imaging - Science Track Award for Research Transition (I/START) (R03-Basic Experimental Studies with Humans Required)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-21-309	07-Jan-2022	150,000 USD
	Contact Name	John Fedota, PhD			
	Contact Telephone	301-402-0812			
	Contact Email	<a href="mailto:john.fedota@mail.nih.gov">john.fedota@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	This Funding Opportunity Announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both newly independent investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources.			
105780	<a href="#">Imaging - Science Track Award for Research Transition (I/START) (R03-Clinical Trial Optional)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-21-310	07-Jan-2022	150,000 USD
	Contact Name	John Fedota, PhD			
	Contact Telephone	301-402-0812			
	Contact Email	<a href="mailto:john.fedota@mail.nih.gov">john.fedota@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	This Funding Opportunity Announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both newly independent investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					limited resources.
079380	<a href="#">Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)</a>	National Institute on Drug Abuse/NIH/DHHS	PAR-19-163	07-Jan-2022	275,000 USD
	Contact Name	Karen Sirocco			
	Contact Telephone	301-451-8661			
	Contact Email	<a href="mailto:siroccok@nida.nih.gov">siroccok@nida.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page ( <a href="http://www.abcdstudy.org">www.abcdstudy.org</a> ).			
100294	<a href="#">Notice of Special Interest (NOSI): Neuroimmune Signaling and Function in Substance Use Disorders</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-20-046	25-Oct-2021	Not Specified
	Contact Name	Roger G Sorensen, Ph.D., MPA			
	Contact Telephone	301-443-3205			
	Contact Email	<a href="mailto:rsorensen@nida.nih.gov">rsorensen@nida.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	25-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 25-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 01-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 07-Sep-2023			
	Synopsis	The purpose of this notice is to encourage research project submissions examining the role of neuroimmune signaling in the CNS in relation to: the trajectory (i.e. initiation, escalation, and maintenance) of drug misuse; consequences of chronic			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		exposure to misused drugs; abstinence and withdrawal from prolonged use; and relapse or reinstatement of drug taking at molecular, cellular, circuit, or behavioral levels.			
106007	<a href="#">Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-064	07-Jan-2022	Not Specified
	Contact Name	Steve Gust, Ph.D.			
	Contact Telephone	301-402-1118			
	Contact Email	<a href="mailto:sgust@nida.nih.gov">sgust@nida.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the United States. Applications examining all areas of NIDA-supported research addressing the causes, consequences, treatment, recovery, and prevention of drug use, misuse, and addiction are encouraged. Projects may be conducted through newly formed or well-established partnerships between investigators in a U.S.-based institution and scientists working in another country. All NIH grant applications for research to be conducted outside the United States must establish that the proposal takes advantage of unique research opportunities in other countries, speeds scientific discovery, and advances U.S. health science.			
091370	<a href="#">NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)</a>	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-20-150	07-Jan-2022	275,000 USD
	Contact Name				
	Contact Telephone	301-402-1366			
	Contact Email	<a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.			
087977	<a href="#">RFA-NS-20-006 -- BRAIN Initiative: Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials Optional)</a>	National Institutes of Health/DHHS	RFA-NS-20-006	02-Jan-2022 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Sahana N. Kukke, PhD			
	Contact Telephone	301-496-1447			
	Contact Email	<a href="mailto:BRAIN-FOAs@nih.gov">BRAIN-FOAs@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	02-Jan-2022 [Optional][LOI/Pre-App], 01-Feb-2022 , 03-Sep-2022 [Optional][LOI/Pre-App], 03-Oct-2022			
	Synopsis	A central goal of the BRAIN Initiative is to develop new and improved technologies suitable for recording from as well as controlling specified cell types and circuits to modulate and understand function in the central nervous system. In order to accomplish these goals, further information is needed to understand the function of current technologies used for recording or stimulating the nervous system. This RFA accepts grant applications in two related but distinct areas. The first is to systematically characterize, model, and validate the membrane, cellular, circuit, and adaptive-biological responses of neuronal and non-neuronal cells to various types of stimulation technologies. The second is to understand the biological and bioinformatic content of signals recorded from neuronal and non-neuronal cells and circuits. Development of new technologies, therapies and disease models is outside the scope of this FOA. Activities related to enabling the simultaneous use of multiple recording or stimulation technologies are allowed.			
104244	<a href="#">Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAR-21-154	25-Oct-2021	300,000 USD
	Contact Name	Minna Liang, Ph.D.			
	Contact Telephone	301-827-5708			
	Contact Email	<a href="mailto:liangm@nida.nih.gov">liangm@nida.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   25-Oct-2021 , 07-Jan-2022 , 25-Feb-2022 , 07-May-2022 , 25-Jun-2022 , 07-Sep-2022 , 25-Oct-2022 , 07-Jan-2023 , 25-Feb-2023 , 07-May-2023 , 25-Jun-2023 , 07-Sep-2023 , 25-Oct-2023 , 07-Jan-2024 , 25-Feb-2024 , 07-May-2024</p> <p>Synopsis   The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than \$6 million per year of NIH support (in both direct and F&amp;A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. Help determining the Organization Funding Level can be found here.</p>				
104245	<a href="#">Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-155	25-Oct-2021	300,000 USD
	<p>Contact Name   Alexandra M. Ainsztein, Ph.D.</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:alexandra.ainsztein@nih.gov">alexandra.ainsztein@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   25-Oct-2021 , 07-Jan-2022 , 25-Feb-2022 , 07-May-2022 , 25-Jun-2022 , 07-Sep-2022 , 25-Oct-2022 , 07-Jan-2023 , 25-Feb-2023 , 07-May-2023 , 25-Jun-2023 , 07-Sep-2023 , 25-Oct-2023 , 07-Jan-2024 , 25-Feb-2024 , 07-May-2024</p> <p>Synopsis   The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than \$6 million dollars per year of NIH support (in both direct and F&amp;A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. Help determining the Organization Funding Level can be found here.</p>				
102333	<a href="#">Notice of Special Interest (NOSI): National Research Service Award (NRSA) F32 Postdoctoral Fellowship Applications from Individuals from Diverse Backgrounds, Including Under-Represented Minorities</a>	National Institutes of Health/DHHS	NOT-EY-21-001	08-Dec-2021	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023 , 08-Dec-2023</p> <p>Synopsis The institutes participating in the Notice seek to promote diversity in all of our training and research programs and to increase the participation of underrepresented groups. As the US population becomes increasingly diverse, reflection of that diversity among the biomedical research workforce is vital to our science enterprise and the NIH research mission (See NOT-OD-20-031). Evidence from several reports demonstrates that an intervention designed to facilitate successful transitions along this pathway would benefit the research community (Expanding Underrepresented Minority Participation: America's Science and Technology Talent at the Crossroads, National Academy of Sciences, National Academy of Engineering, and Institute of Medicine 2011;and Advancing the Nation's Health Needs: NIH Research Training Programs).</p>				
106078	<a href="#">RFA-MD-22-001 -- Innovative Multi-Level Approaches and Strategies to Prevent, Test and Treat HIV in Primary Care Settings in Health Disparity Populations in Geographic Hot Spots in the United States (R01 - Clinical Trial Required)</a>	National Institutes of Health/DHHS	RFA-MD-22-001	14-Dec-2021 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Rick Berzon, DrPH, PA</p> <p>Contact Telephone 301-594-8949</p> <p>Contact Email <a href="mailto:Rick.berzon@nih.gov">Rick.berzon@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Dec-2021 [Optional][LOI/Pre-App], 14-Jan-2022</p> <p>Synopsis This initiative will support research projects that examine innovative approaches and strategies to prevent, test and treat HIV among health disparity populations or subgroups within primary care settings located in geographic areas with a high rate of new infections in the United States.</p>				
106064	<a href="#">Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote</a>	National Institutes of Health/DHHS	PAR-21-273	27-Oct-2021	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Diversity \(K99/R00 - Independent Basic Experimental Studies with Humans Required \(BESH\)\)](#)

Contact Name	Lanay M. Mudd, Ph.D., FACSM
Contact Telephone	301-594-9346
Contact Email	<a href="mailto:lanay.mudd@nih.gov">lanay.mudd@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	27-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024
Synopsis	<p>The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees.</p> <p>This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>

106063	<a href="#">Maximizing Opportunities for Scientific and Academic Independent</a>	National Institutes of Health/DHHS	PAR-21-	27-Oct-2021	Not
--------	--	------------------------------------	---------	-------------	-----

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Required)</a>			272	Specified
	<p>Contact Name   Lanay M. Mudd, Ph.D., FACSM</p> <p>Contact Telephone   301-594-9346</p> <p>Contact Email   <a href="mailto:lanay.mudd@nih.gov">lanay.mudd@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   27-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024</p> <p>Synopsis   The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA PAR-21-271.</p>				
106062	<a href="#">Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-271	27-Oct-2021	Not Specified
	<p>Contact Name   Kenneth D. Gibbs, Jr., Ph.D.</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:kenneth.gibbs@nih.gov">kenneth.gibbs@nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 27-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 , 12-Jun-2023 , 07-Sep-2023 , 12-Oct-2023 , 07-Jan-2024 , 12-Feb-2024 , 07-May-2024 , 12-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas. The long-term goal of this program is to enhance diversity in the biomedical research workforce. The MOSAIC K99/R00 program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see Notice of NIH's Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent research-intensive faculty positions. The MOSAIC K99/R00 program will provide independent NIH research support before and after this transition to help awardees launch successful, independent research careers. Additionally, MOSAIC K99/R00 scholars will be part of organized scientific cohorts and will be expected to participate in mentoring, networking, and professional development activities coordinated by MOSAIC Institutionally-Focused Research Education Award to Promote Diversity (UE5) grantees. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA PAR-21-272.</p>				
105313	<p><a href="#">PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)</a></p>	National Institutes of Health/DHHS	PA-21-259	05-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-435-2688</p> <p>Contact Email <a href="mailto:sbir@od.nih.gov">sbir@od.nih.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jan-2022 , 05-Apr-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2021-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement does not accept clinical trials.			
105314	<a href="#">PHS 2020 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-21-260	05-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-435-2688</p> <p>Contact Email <a href="mailto:sbir@od.nih.gov">sbir@od.nih.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jan-2022 , 05-Apr-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R&amp;D mission(s) of the NIH and CDC awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2021-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH and CDC Institutes and Centers (ICs) based on their scientific missions.</p>				
105321	<a href="#">PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-21-261	05-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-435-2688</p> <p>Contact Email <a href="mailto:sbir@od.nih.gov">sbir@od.nih.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jan-2022 , 05-Apr-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH) invites eligible United States small businesses to submit Small Business Technology Transfer (STTR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R&amp;D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2021-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>				
102356	<p><a href="#">Notice of Special Interest (NOSI): Small Business Initiatives for Innovative Diagnostic Technology for Improving Outcomes for Maternal Health</a></p>	National Institutes of Health/DHHS	NOT-EB-21-001	05-Jan-2022	Not Specified
	<p>Contact Name Ilana Goldberg, Ph.D.</p> <p>Contact Telephone 301-402-3465</p> <p>Contact Email <a href="mailto:ilana.goldberg@nih.gov">ilana.goldberg@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jan-2022 , 05-Apr-2022 , 05-Sep-2022 , 05-Jan-2023 , 05-Apr-2023</p> <p>Synopsis The purpose of this trans-NIH Notice of Special Interest (NOSI) is to inform potential applicants that the National Institute of Biomedical Imaging and Bioengineering and participating Institutes and Centers (ICs) invite SBIR/STTR applications to develop technologies or tools to quantitatively predict or indicate an increased risk for maternal morbidity and mortality (MMM). This NOSI is part of the Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE) initiative, which supports research to reduce preventable causes of maternal deaths and improve health for women before, during, and after delivery.</p>				
088051	<p><a href="#">Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44 Clinical Trial Not Allowed)</a></p>	National Institutes of Health/DHHS	PA-20-047	05-Jan-2022	Not Specified
	<p>Contact Name Dr. Margaret Grabb</p> <p>Contact Telephone 301-443-3563</p> <p>Contact Email <a href="mailto:mgrabb@mail.nih.gov">mgrabb@mail.nih.gov</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jan-2022 , 05-Apr-2022 , 05-Sep-2022 , 05-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) to develop and validate next-generation single cell analysis technologies and tools. The purpose is to foster the commercialization of innovative single cell analysis technologies for their broad use in biomedical research. The novel single-cell analysis technologies will aid in obtaining a fine-grained and dynamic view of heterogeneous cellular states and intercellular interactions, thereby providing new mechanistic insight into biological processes in health and disease. Applications should define the current state of technologies and tools as a benchmark against which the new approach(es) will be measured. The new approach(es) should provide substantially improved performance in sensitivity, selectivity, spatiotemporal resolution, scalability, multiplexing capability, or non-destructive analysis of molecular or functional measures of single cells. A companion FOA to support STTR Grants is also available see PA-20-025</p>				
096933	<a href="#">SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-129	05-Jan-2022	Not Specified
	<p>Contact Name Dr. Jerome Wujek</p> <p>Contact Telephone 301-451-2020</p> <p>Contact Email <a href="mailto:wujekjer@nei.nih.gov">wujekjer@nei.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Jan-2022 , 05-Apr-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R&amp;D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)/Investigational Device Exemption (IDE) enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R&amp;D throughout the award. Clinical trials are not accepted under this FOA.</p>				
088059	<a href="#">Development of Highly Innovative Tools and Technology for Analysis of</a>	National Institutes of Health/DHHS	PA-20-025	05-Jan-2022	Not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<a href="#">Single Cells (STTR) (R41/R42 Clinical Trial Not Allowed)</a>					Specified
	Contact Name   Rebecca Claycamp Contact Telephone   301-443-2811 Contact Email   <a href="mailto:rclaycam@mail.nih.gov">rclaycam@mail.nih.gov</a> Sponsor Website   Program URL   <a href="#">Link to program URL</a> Deadline Dates (ALL)   05-Jan-2022 , 05-Apr-2022 , 05-Sep-2022 , 05-Jan-2023 Synopsis   This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer Research (STTR) grant applications from small business concerns (SBCs) to develop and validate next-generation single cell analysis technologies and tools. The purpose is to foster the commercialization of innovative single cell analysis technologies for their broad use in biomedical research. The novel single-cell analysis technologies will aid in obtaining a fine-grained and dynamic view of heterogeneous cellular states and intercellular interactions, thereby providing new mechanistic insight into biological processes in health and disease. Applications should define the current state of technologies and tools as a benchmark against which the new approach(es) will be measured. The new approach(es) should provide substantially improved performance in sensitivity, selectivity, spatiotemporal resolution, scalability, multiplexing capability, or non-destructive analysis of molecular or functional measures of single cells. A companion FOA to support SBIR Grants is also available see PA-20-047				
084662	<a href="#">SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Required</a>	National Institutes of Health/DHHS	PAR-19-335	05-Jan-2022	Not Specified
	Contact Name   Dr. Jerome Wujek Contact Telephone   301-451-2020 Contact Email   <a href="mailto:wujekjer@nei.nih.gov">wujekjer@nei.nih.gov</a> Sponsor Website   Program URL   <a href="#">Link to program URL</a> Deadline Dates (ALL)   05-Jan-2022 , 05-Apr-2022 Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>additional support for technical assistance and later stage research and development (R&amp;D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R&amp;D throughout the award. This Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>			
088835	<a href="#">Non-Viral Technologies for in vivo Delivery of Genome Editors (R43/R44 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-098	05-Jan-2022	Not Specified
	Contact Name	P.J. Brooks, Ph.D.			
	Contact Telephone	301-443-0513			
	Contact Email	<a href="mailto:pjbrooks@mail.nih.gov">pjbrooks@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jan-2022			
	Synopsis	The purpose of this PAR is to support the development and evaluation of non-viral technologies to deliver genome editors to disease relevant somatic cells and tissues in vivo. The ultimate goal of these technologies is translation into clinical trials of genome editing to treat human disease.			
088840	<a href="#">Non-Viral Technologies for in vivo Delivery of Genome Editors (R41/R42 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-109	05-Jan-2022	Not Specified
	Contact Name	P.J. Brooks, Ph.D.			
	Contact Telephone	301-443-0513			
	Contact Email	<a href="mailto:pjbrooks@mail.nih.gov">pjbrooks@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jan-2022			
	Synopsis	The purpose of this PAR is to support the development and evaluation of non-viral technologies to deliver genome editors to disease relevant somatic cells and tissues in vivo. The ultimate goal of these technologies is translation into clinical trials of			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		genome editing to treat human disease.			
097262	<a href="#">Notice of Special Interest (NOSI): Improving Methods to Assess Body Composition in Infants and Young Children</a>	National Institutes of Health/DHHS	NOT-DK-20-036	05-Jan-2022	Not Specified
	Contact Name	Voula Osganian, M.D., Sc.D., M.P.H.			
	Contact Telephone	301-827-6939			
	Contact Email	<a href="mailto:voula.osganian@nih.gov">voula.osganian@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jan-2022 , 05-Apr-2022 , 05-Sep-2022			
	Synopsis	The purpose of this Notice is to inform potential applicants to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of an area of special interest in research to improve methods to assess body composition in infants and young children ages birth through 5 years.			
105329	<a href="#">PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-21-262	05-Jan-2022	Not Specified
	Contact Name				
	Contact Telephone	301-435-2688			
	Contact Email	<a href="mailto:sbir@od.nih.gov">sbir@od.nih.gov</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jan-2022 , 05-Apr-2022			
	Synopsis	This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH) invites eligible United States small businesses to submit Small Business Technology Transfer (STTR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2021-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement does not accept clinical trials.			
106167	<a href="#">Notice of Special Interest (NOSI): Supporting Women's Health Research</a>	National Institutes of Health/DHHS	NOT-GM-	27-Jan-2022	Not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	<a href="#">in the IDeA States through the Centers of Biomedical Research Excellence (COBRE) Phase I Program</a>			21-056	Specified	
	<p>Contact Name   Crina Frincu, Ph.D.</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:cfrincu@mail.nih.gov">cfrincu@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   27-Jan-2022</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the National Institutes of Health's interest in supporting women's health research in Institutional Development Award (IDeA)-eligible states through PAR-19-313 "Centers of Biomedical Research Excellence (COBRE) Phase 1 (P20 Clinical Trial Optional)".</p>					
100877	<a href="#">Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)</a>		National Institutes of Health/DHHS	PAR-21-068	07-Jan-2022	Not Specified
	<p>Contact Name   Basil A. Eldadah, MD, PhD</p> <p>Contact Telephone   301-496-6761</p> <p>Contact Email   <a href="mailto:eldadahb@nia.nih.gov">eldadahb@nia.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023 , 07-May-2023 , 07-Sep-2023 , 07-Jan-2024</p> <p>Synopsis   This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-20-018.</p>					
086223	<a href="#">RFA-NS-20-011 -- HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Not Allowed)</a>		National Institutes of Health/DHHS	RFA-NS-20-011	06-Jan-2022	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Stephanie Fertig, MBA</p> <p>Contact Telephone   301-496-1778</p> <p>Contact Email   <a href="mailto:fertigs@ninds.nih.gov">fertigs@ninds.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   06-Jan-2022 , 06-Apr-2022 , 08-Sep-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.</p>				
086216	<a href="#">RFA-NS-20-010 -- HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Required)</a>	National Institutes of Health/DHHS	RFA-NS-20-010	06-Jan-2022	Not Specified
	<p>Contact Name   Stephanie Fertig, MBA</p> <p>Contact Telephone   301-496-1778</p> <p>Contact Email   <a href="mailto:fertigs@ninds.nih.gov">fertigs@ninds.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   06-Jan-2022 , 06-Apr-2022 , 08-Sep-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.</p>				
086226	<a href="#">RFA-NS-20-009 -- HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical</a>	National Institutes of Health/DHHS	RFA-NS-20-009	06-Jan-2022	Not Specified



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Trial Not Allowed](#)

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis	Stephanie Fertig, MBA 301-496-1778 <a href="mailto:fertigs@ninds.nih.gov">fertigs@ninds.nih.gov</a>  <a href="#">Link to program URL</a> 06-Jan-2022 , 06-Apr-2022 , 08-Sep-2022  The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.
--	---

086288	<a href="#">Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-029	07-Jan-2022	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis	Marina Protopopova, Ph.D 301-761-7653 <a href="mailto:marina.protopopova@niaid.nih.gov">marina.protopopova@niaid.nih.gov</a>  <a href="#">Link to program URL</a> 07-Jan-2022  The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications that address the long term goal and objective of developing sustained release strategies for HIV treatment or prevention. Applications may propose treatment or prevention products delivered using sustained release platforms (oral, injection, implant or direct delivery to HIV target mucosa) that will provide a minimum of 1 week for oral (treatment) or a minimum of once a month for all other drug delivery systems for prevention and treatment.
--	--

100879	<a href="#">Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-069	07-Jan-2022	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Basil A. Eldadah, MD, PhD</p> <p>Contact Telephone   301-496-6761</p> <p>Contact Email   <a href="mailto:eldadahb@nia.nih.gov">eldadahb@nia.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023 , 07-May-2023 , 07-Sep-2023 , 07-Jan-2024</p> <p>Synopsis   This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Studies that move the science of HIV and aging into new directions with little or no preliminary data are appropriate for this activity code. Applications appropriate for this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-20-018.</p>				
086228	<a href="#">RFA-NS-20-008 -- HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Required)</a>	National Institutes of Health/DHHS	RFA-NS-20-008	06-Jan-2022	Not Specified
	<p>Contact Name   Stephanie Fertig, MBA</p> <p>Contact Telephone   301-496-1778</p> <p>Contact Email   <a href="mailto:fertigs@ninds.nih.gov">fertigs@ninds.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   06-Jan-2022 , 06-Apr-2022 , 08-Sep-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.</p>				
094281	<a href="#">HIV Infection of the Central Nervous System (R01 Clinical Trial Not</a>	National Institutes of Health/DHHS	PA-20-149	07-Jan-2022	Not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<a href="#">Allowed</a> )				Specified
	<p>Contact Name   Jeymohan Joseph, Ph.D.</p> <p>Contact Telephone   240-627-3869</p> <p>Contact Email   <a href="mailto:jjeymoha@mail.nih.gov">jjeymoha@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023 , 07-May-2023</p> <p>Synopsis   The goals of this Funding Opportunity Announcement (FOA) are to stimulate further research on delineating the pathophysiology of HIV-1 associated CNS disease in the setting of chronic viral suppression and ART. In addition, FOA also encourages research studies to aid in the identification/ validation of biomarkers and pre-clinical targets with quantifiable readouts in domestic and international settings. Multidisciplinary research teams and collaborative alliances are encouraged but not required.</p>				
094284	<a href="#">Eradication of HIV-1 from Central Nervous system Reservoirs (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-151	07-Jan-2022	Not Specified
	<p>Contact Name   Jeymohan Joseph, Ph.D.</p> <p>Contact Telephone   240-627-3869</p> <p>Contact Email   <a href="mailto:jjeymoha@mail.nih.gov">jjeymoha@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023 , 07-May-2023</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system (CNS) in the context of viral suppression. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required. Applications focused on HIV-associated CNS comorbidities and treatment should apply to the companion FOA PA-20-149.</p>				
090436	<a href="#">Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAR-20-139	13-Jan-2022	Not Specified
	Contact Name   Sergei Romashkan, M.D., Ph.D.				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-435-3047</p> <p>Contact Email   <a href="mailto:romashks@mail.nih.gov">romashks@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   13-Jan-2022 , 13-May-2022 , 13-Sep-2022 , 13-Jan-2023</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of one of the participating ICs. Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do not require an extended project period of 6 or 7 years.</p>				
100542	<p><a href="#">Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)</a></p>	National Institutes of Health/DHHS	PA-21-052	08-Dec-2021	Not Specified
	<p>Contact Name  </p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis   The purpose of this Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research award is to enhance the diversity of the health-related research workforce by supporting the research training of predoctoral students from diverse backgrounds including those from groups that are underrepresented in the biomedical, behavioral, or clinical research workforce. Through this award program, promising predoctoral students will obtain individualized, mentored research training from outstanding faculty sponsors while conducting well-defined research projects in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist. This Funding Opportunity Announcement (FOA) does not allow candidates to propose to lead an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
100438	<a href="#">Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)</a>	National Institutes of Health/DHHS	PA-21-050	08-Dec-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support students at institutions without NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Candidates must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential to develop into a productive, independent physician/clinician-scientist. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
100374	<a href="#">Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)</a>	National Institutes of Health/DHHS	PA-21-051	08-Dec-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p>	<p>2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31) award is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must reflect the candidate’s dissertation research project and is expected to clearly enhance the individual’s potential to develop into a productive, independent research scientist. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor. NOTE: Per NOT-DA-20-037 NIDA announces a special interest in the development of a scientific workforce engaged in research to develop treatments for substance use disorders and the associated medical consequences by providing support for research training and career development for talented investigators interested in addiction science. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements, and Staff Contacts website (<a href="https://grants.nih.gov/grants/guide/contacts/parent_F30b.html">https://grants.nih.gov/grants/guide/contacts/parent_F30b.html</a>) ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>			
100399	<p><a href="#">Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)</a></p>	National Institutes of Health/DHHS	PA-21-047	08-Dec-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p><a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a></p> <p><a href="#">Link to program URL</a></p> <p>08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial,</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.

090889	<a href="#">Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-20-145	07-Jan-2022	275,000 USD
--------	--	------------------------------------	-----------	-------------	-------------

Contact Name	Christopher Gordon, Ph.D.
Contact Telephone	240-627-3867
Contact Email	<a href="mailto:cgordon1@mail.nih.gov">cgordon1@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023
Synopsis	This Funding Opportunity Announcement (FOA) seeks innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches. Applicants are encouraged to read current Notices of Special Interests (NOSIs) from NIMH DAR for further information about the Division’s research priorities. PA-20-144 uses the R01 grant mechanism while this PA-20-145 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism, while applicants with preliminary data and/or including longitudinal analysis may apply using the R01 mechanism.

088347	<a href="#">Biomedical Knowledgebase (U24 - Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-097	07-Jan-2022	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Veerasamy Ravichandran, Ph.D.
Contact Telephone	
Contact Email	<a href="mailto:veerasamy.ravichandra@nih.gov">veerasamy.ravichandra@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 25-Jan-2022 , 06-May-2022 , 26-Sep-2022 , 06-Jan-2023 , 25-Jan-2023 , 08-May-2023
Synopsis	This funding opportunity announcement is designed to support biomedical knowledgebases. Biomedical knowledgebases under this announcement should have the primary function to extract, accumulate, organize, annotate, and link growing

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

bodies of information related to core datasets. Support for data curation should include efficient and effective methods of curation that scale to the needs of the community and include semi-automated methods. Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the knowledgebase. Applications that have a significant focus on software or tool development are not appropriate for this activity.

088346	<a href="#">Biomedical Data Repository (U24 - Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-089	07-Jan-2022	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Veerasamy Ravichandran, Ph.D.
Contact Telephone	
Contact Email	<a href="mailto:veerasamy.ravichandra@nih.gov">veerasamy.ravichandra@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 25-Jan-2022 , 06-May-2022 , 26-Sep-2022 , 06-Jan-2023 , 25-Jan-2023 , 08-May-2023
Synopsis	This funding opportunity announcement is designed to support biomedical data repositories. Biomedical data repositories under this announcement should have the primary function to ingest, archive, preserve, manage, distribute, and make accessible the data related to a particular system or systems. Support for data curation must be limited to that which improves the efficiency and accessibility of data ingestion, management, and use and reuse by the user communities. Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the repository. Applications that have a significant focus on software and tool development are not appropriate for this activity.

088438	<a href="#">Genomic Community Resources (U24 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-100	25-Jan-2022	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Christopher Wellington
Contact Telephone	301-480-3496
Contact Email	<a href="mailto:wellingtonc@mail.nih.gov">wellingtonc@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	To facilitate genomic research and the dissemination of its products, NHGRI supports genomic resources that are crucial for basic research, disease studies, model organism studies, and other biomedical research. Awards under this FOA will support the development and distribution of genomic resources that use cost-effective approaches and will be valuable for the broad research community. Such resources include (but are not limited to) databases and informatics resources (such as human and model organism databases, ontologies, and analysis toolsets), comprehensive identification and collections of genomic features (such as functional genomic elements), and standard data types produced using central sets of samples (such as structural variants in 1000 Genomes or GTEx samples).			
104540	<a href="#">Shared Personal Protective Equipment (PPE) Resources (S10 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-257	24-Jan-2022	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email				
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	24-Jan-2022 , 24-May-2022			
	Synopsis	The National Institutes of Health (NIH) hereby notifies the applicant community that funds may be available to provide Personal Protective Equipment (PPE) to directly support the needs of the NIH Clinical Trials and Clinical Research Activities. Only applications submitted in response to a Notice of Special Interest (NOSI) published by an IC will be allowed to apply to this FOA.			
103212	<a href="#">Mentoring Networks to Enhance Diversity in NIDCD's Extramural Research Workforce (R25 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-185	27-Jan-2022	1,250,000 USD
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.			
	Contact Telephone	301-496-1804			
	Contact Email	<a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	27-Jan-2022 , 27-May-2022 , 21-Sep-2022 , 27-Jan-2023 , 26-May-2023 , 26-Sep-2023 , 29-Jan-2024			
	Synopsis	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research . To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Mentoring Activities</p>			
103518	<a href="#">Enhancing NIDCD's Extramural Workforce Diversity through Research Experiences (R25 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-186	27-Jan-2022	1,250,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Alberto L. Rivera-Rentas, Ph.D.</p> <p>301-496-1804</p> <p><a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>27-Jan-2022 , 27-May-2022 , 21-Sep-2022 , 27-Jan-2023 , 26-May-2023 , 26-Sep-2023 , 29-Jan-2024</p>			
	Synopsis	<p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences The proposed research experiences may be targeted to undergraduates, graduate students, postdoctorates or early to mid-career faculty and should be designed to extend their research skills, experiences and knowledge base. . The nature of research experiences should be tailored to the needs and career levels of participants and engage them in NIDCD-funded research or expose them to skills, experiences and knowledge base related to NIDCD research. It is expected that mentoring will be provided in conjunction with planned research experiences and participants will design individualized development plans (IDPs) that are compatible with their needs and experience. Additionally, programs that provide educational/research experiences that enhance the participation and productivity of investigators from diverse backgrounds, including from underrepresented groups, in carrying out research on NIDCD mission-relevant health disparities will be considered.</p>			
103185	<a href="#">NIDCD's Mentoring Networks to Enhance Clinician-Scientists' Participation in Research (R25 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-187	27-Jan-2022	1,250,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p>	<p>Alberto L. Rivera-Rentas, Ph.D.</p> <p>301-496-1804</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:riverara@nidcd.nih.gov">riverara@nidcd.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 27-Jan-2022 , 27-May-2022 , 21-Sep-2022 , 27-Jan-2023 , 26-May-2023 , 26-Sep-2023 , 29-Jan-2024</p> <p>Synopsis The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on: Mentoring Activities</p>				
090787	<p><a href="#">Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)</a></p>	National Institutes of Health/DHHS	PA-20-142	07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023</p> <p>Synopsis The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible, domestic institutions to enhance predoctoral and postdoctoral research training, including short-term research training, and help ensure that a diverse and highly trained workforce is available to meet the needs of the Nation's biomedical, behavioral, and clinical research agenda. Research training programs are expected to incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. Programs proposing only short-term predoctoral research training should not apply to this announcement, but rather to the Kirschstein-NRSA Short-Term Institutional Research Training Grant Program (T35) exclusively reserved for predoctoral, short-term research training. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>				
091820	<p><a href="#">Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grant (Parent T35)</a></p>	National Institutes of Health/DHHS	PA-20-162	07-Jan-2022	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Jan-2023 , 07-Jan-2023 , 07-May-2023</p> <p>Synopsis The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grants (T35) to eligible, domestic institutions to develop and/or enhance research training opportunities for predoctoral students interested in careers in biomedical, behavioral, or clinical research. Many NIH Institutes and Centers (ICs) use this NRSA program exclusively to support intensive, short-term research training experiences for health professional students (medical students, veterinary students, and/or students in other health-professional programs) during the summer. This program is also intended to encourage training of graduate students in the physical or quantitative sciences to pursue research careers by short-term exposure to, and involvement in, the health-related sciences. The training should be of sufficient depth to enable the trainees, upon completion of the program, to have a thorough exposure to the principles underlying the conduct of biomedical research. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>				
092624	<a href="#">National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)</a>	National Institutes of Health/DHHS	PAR-20-169	07-Jan-2022	Not Specified
	<p>Contact Name Behrouz Shabestari, PhD</p> <p>Contact Telephone 301-451-6771</p> <p>Contact Email <a href="mailto:shabestb@mail.nih.gov">shabestb@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 25-Jan-2022 , 07-May-2022 , 25-May-2022 , 07-Sep-2022 , 25-Sep-2022 , 07-Jan-2023 , 25-Jan-2023 , 07-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages grant applications for National Centers for Biomedical Imaging and Bioengineering (NCBIB). NCBIB are national resource centers for conducting research and development on new</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		technologies that are driven by the needs of basic, translational, and/or clinical researchers. NCBIB also make their technologies available to other investigators, train members of the research community in the use of the technologies and disseminate the technologies broadly.			
086663	<a href="#">Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-20-036	07-Jan-2022	Not Specified
	<p>Contact Name   Robin E. Huebner, Ph.D., M.P.H.</p> <p>Contact Telephone   240-627-3216</p> <p>Contact Email   <a href="mailto:rhuebner@niaid.nih.gov">rhuebner@niaid.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 07-May-2022 , 07-Sep-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to support grants to improve understanding of viral suppression and HIV transmission in the United States (U.S.) using population-level epidemiology, novel tools from data science approaches and m/eHealth, and implementation science research. Data generated through this research will be used to inform and evaluate context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.</p>				
100882	<a href="#">SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance (SB1, Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-128	05-Jan-2022	Not Specified
	<p>Contact Name   Dr. Jerome Wujek</p> <p>Contact Telephone   301-451-2020</p> <p>Contact Email   <a href="mailto:wujekjer@nei.nih.gov">wujekjer@nei.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   05-Jan-2022 , 05-Apr-2022</p> <p>Synopsis   The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance not typically supported through Phase II or Phase IIB grants or contracts. This may include preparation of documents for a Food and Drug Administration (FDA) submission, development of an intellectual property</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		strategy, and/or planning for a clinical trial. Although a significant amount of the work in a CRP award may be subcontracted to other organizations, the SBC is expected to maintain oversight and management of the R&D throughout the award. Clinical trials are not accepted under this FOA.			
081709	<a href="#">Postdoctoral Fellowships</a>	National Institutes of Health/DHHS		01-Jan-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	301-496-2429 <a href="mailto:bioethics-inquiries@mail.nih.gov">bioethics-inquiries@mail.nih.gov</a> <a href="#">Link to sponsor website</a> <a href="#">Link to program URL</a> 01-Jan-2022 he NIH Department of Bioethics welcomes applications for fully funded two-year postdoctoral and postbaccalaureate research fellowships. Fellows are central to the activities and intellectual life of our interdisciplinary department. Fellowships begin in September 2022. Stipends are determined by NIH Intramural Research Training Award (IRTA) guidelines.			
085404	<a href="#">Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-19-357	10-Jan-2022	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Daniel Frank, Ph.D. 301-761-6256 <a href="mailto:Daniel.Frank@nih.gov">Daniel.Frank@nih.gov</a>  <a href="#">Link to program URL</a> 10-Jan-2022 The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical, preclinical and non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis.			
100434	<a href="#">Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)</a>	National Institutes of Health/DHHS	PA-21-048	08-Dec-2021	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 301-945-7573</p> <p>Contact Email <a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32) is to support research training of highly promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers. Applications are expected to incorporate exceptional mentorship. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
106478	<a href="#">RFA-AI-21-068 -- Development of Microbiome-Related Approaches for Diagnosis/Mitigation/Treatment of Radiation Injuries (U01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-AI-21-068	10-Jan-2022 [Optional][LOI/Pre-App]	1,750,000 USD
	<p>Contact Name Carmen I. Rios, Ph.D.</p> <p>Contact Telephone 240-627-3553</p> <p>Contact Email <a href="mailto:carmen.rios@nih.gov">carmen.rios@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 10-Jan-2022 [Optional][LOI/Pre-App], 09-Feb-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support research that will advance the understanding of how the microbiome affects radiation injury and to develop medical countermeasures (MCMs) that target the microbiome to prevent or mitigate radiation injury.</p>				
104041	<a href="#">RFA-NS-21-023 -- BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-NS-21-023	20-Oct-2021	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Brooks Gross, PhD
Contact Telephone	301-496-1447
Contact Email	<a href="mailto:NINDS-Devices@nih.gov">NINDS-Devices@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	20-Oct-2021 , 19-Jan-2022 [Optional][LOI/Pre-App], 18-Feb-2022 , 21-May-2022 [Optional][LOI/Pre-App], 20-Jun-2022 , 18-Sep-2022 [Optional][LOI/Pre-App], 18-Oct-2022 , 22-Jan-2023 [Optional][LOI/Pre-App], 21-Feb-2023 , 20-May-2023 [Optional][LOI/Pre-App], 19-Jun-2023 , 18-Sep-2023 [Optional][LOI/Pre-App], 18-Oct-2023 , 21-Jan-2024 [Optional][LOI/Pre-App], 20-Feb-2024
Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies for recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study, as well as a subsequent small clinical study. Only Significant Risk (SR) clinical studies that will require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants, will be supported by this FOA. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to RFA-NS-21-024 or this FOA. The BRAIN PPP includes agreements with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new FDA IDE and IRB approvals without need for significant additional non-clinical data. For more information on the BRAIN PPP, see <a href="https://braininitiative.nih.gov/brain-programs/public-private-partnerships">https://braininitiative.nih.gov/brain-programs/public-private-partnerships</a></p>

104043	<a href="#">RFA-NS-21-024 -- BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-NS-21-024	20-Oct-2021	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Brooks Gross, PhD
Contact Telephone	301-496-1447



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:NINDS-Devices@nih.gov">NINDS-Devices@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Oct-2021 , 19-Jan-2022 [Optional][LOI/Pre-App], 18-Feb-2022 , 21-May-2022 [Optional][LOI/Pre-App], 20-Jun-2022 , 18-Sep-2022 [Optional][LOI/Pre-App], 18-Oct-2022 , 22-Jan-2023 [Optional][LOI/Pre-App], 21-Feb-2023 , 20-May-2023 [Optional][LOI/Pre-App], 19-Jun-2023 , 18-Sep-2023 [Optional][LOI/Pre-App], 18-Oct-2023 , 21-Jan-2024 [Optional][LOI/Pre-App], 20-Feb-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue first-in-human or early stage clinical studies for recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain. Only Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants, will be supported by this FOA. The clinical study is expected to provide data to answer key questions about the function or final design of a device and is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is part of a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. As part of the BRAIN Initiative, NIH has initiated a Public-Private Partnership Program (BRAIN PPP) that includes agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general, it is expected that the devices' existing safety and utility data will be sufficient to enable new FDA IDE and IRB approvals without need for significant additional non-clinical data. For more information on the BRAIN PPP, see <a href="https://braininitiative.nih.gov/brain-programs/public-private-partnerships">https://braininitiative.nih.gov/brain-programs/public-private-partnerships</a> Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to RFA-NS-21-023 or this FOA.</p>				
102106	<a href="#">NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-21-151	12-Dec-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   12-Dec-2021 , 07-Jan-2022 , 12-Apr-2022 , 07-May-2022 , 12-Aug-2022 , 07-Sep-2022 , 12-Dec-2022 , 07-Jan-2023 , 12-Apr-2023 , 07-May-2023 , 12-Aug-2023 , 07-Sep-2023 , 12-Dec-2023 , 07-Jan-2024</p> <p>Synopsis   The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.</p>				
102904	<p><a href="#">Notice of Special Interest (NOSI): Conferences and Scientific Meetings Aimed at Supporting the National Eye Institute's Audacious Goals Initiative</a></p>	National Institutes of Health/DHHS	NOT-EY-21-009	12-Dec-2021	Not Specified
	<p>Contact Name   Houmam Araj, PhD</p> <p>Contact Telephone   301-451-2020</p> <p>Contact Email   <a href="mailto:arajh@mail.nih.gov">arajh@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   12-Dec-2021 , 07-Jan-2022 , 12-Apr-2022 , 07-May-2022 , 12-Aug-2022 , 07-Sep-2022 , 12-Dec-2022 , 07-Jan-2023 , 12-Apr-2023 , 07-May-2023 , 12-Aug-2023 , 07-Sep-2023 , 12-Dec-2023 , 07-Jan-2024 , 12-Apr-2024 , 07-May-2024</p> <p>Synopsis   This Notice of Special Interest (NOSI) is to solicit applications to support conferences, symposia, and workshops aimed at supporting the National Eye Institute's (NEI) Audacious Goals Initiative.</p>				
105886	<p><a href="#">RFA-HG-21-041 -- New Investigators to Promote Workforce Diversity in Genomics, Bioinformatics, or Bioengineering and Biomedical Imaging Research (R01 Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	RFA-HG-21-041	23-Jan-2022 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name   Jyoti Dayal, M.S.</p> <p>Contact Telephone   301-480-2307</p> <p>Contact Email   <a href="mailto:jyotig@mail.nih.gov">jyotig@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   23-Jan-2022 [Optional][LOI/Pre-App], 22-Feb-2022 , 23-Jan-2023 [Optional][LOI/Pre-App], 22-Feb-2023 , 23-Jan-2024 [Optional][LOI/Pre-App], 22-Feb-2024</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Human Genome Research Institute (NHGRI), National Institute of</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Biomedical Imaging and Bioengineering (NIBIB), and All of Us Research Program (All of Us). This program is intended to support Early Stage Investigators and New Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences.				
102907	<a href="#">Support for Research Excellence – First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-173	07-Jan-2022	500,000 USD
	<p>Contact Name   Irina N. Krasnova, Ph.D.</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:irina.krasnova@nih.gov">irina.krasnova@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 28-Sep-2022 , 07-Jan-2023 , 28-Sep-2023 , 07-Jan-2024</p> <p>Synopsis   SuRE is a research capacity building program designed to develop and sustain research excellence in U.S. higher education institutions that receive limited NIH research support and serve students from groups underrepresented in biomedical research (see NOT-OD-20-031) with an emphasis on providing students with research opportunities and enriching the research environment at the applicant institutions. The purpose of SuRE-First awards is to support research grants for faculty investigators who have not had prior independent external research grants.</p>				
100652	<a href="#">Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PAR-21-039	28-Dec-2021	Not Specified
	<p>Contact Name  </p> <p>Contact Telephone   301-945-7573</p> <p>Contact Email   <a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   28-Dec-2021 , 26-Jan-2022 , 26-Apr-2022 , 26-May-2022 , 26-Aug-2022 , 27-Sep-2022 , 28-Dec-2022 , 26-Jan-2023 , 26-Apr-2023 , 26-May-2023 , 26-Aug-2023 , 26-Sep-2023 , 28-Dec-2023</p> <p>Synopsis   The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies that are NOT conducted with specific applications toward processes or products in mind and which also do not meet the clinical trial definition should submit under the appropriate ‘Clinical Trial Not Allowed’ FOA .</p>			
100648	<a href="#">Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-038	28-Dec-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-945-7573</p> <p>Contact Email <a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 28-Dec-2021 , 26-Jan-2022 , 26-Apr-2022 , 26-May-2022 , 26-Aug-2022 , 27-Sep-2022 , 28-Dec-2022 , 26-Jan-2023 , 26-Apr-2023 , 26-May-2023 , 26-Aug-2023 , 26-Sep-2023 , 28-Dec-2023</p> <p>Synopsis The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trials.</p>				
101245	<a href="#">Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities</a>	National Institutes of Health/DHHS	NOT-MD-21-008	07-Jan-2022	Not Specified
	<p>Contact Name Deborah E. Linares, Ph.D., M.A.</p> <p>Contact Telephone 301-402-2516</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:deborah.linares@nih.gov">deborah.linares@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022</p> <p>Synopsis This Notice of Special Interest (NOSI) highlights the need for research strategies and interventions to address vaccine hesitancy, uptake, and implementation among populations who experience health disparities in the US.* Research is needed to understand and address misinformation, distrust, and hesitancy regarding vaccines (e.g., SARS-CoV-2, pneumococcal, influenza, hepatitis B, human papilloma virus (HPV), and herpes zoster) among adults in the United States and territories, especially in populations at increased risk for morbidity and mortality due to long-standing systemic health and social inequities and chronic medical conditions. The purpose of this NOSI is to solicit community-engaged research to: 1) evaluate intervention strategies (e.g., expand reach, access) to facilitate vaccination uptake in clinical and community contexts; and 2) address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations at high risk and likely to experience vaccine hesitancy.</p>				
100758	<a href="#">Notice of Special Interest (NOSI): Academy of Finland (AKA) – National Institutes of Health (NIH) Partnership Program</a>	National Institutes of Health/DHHS	NOT-OD-21-021	07-Jan-2022	Not Specified
	<p>Contact Name Sarah Scharf, MPA</p> <p>Contact Telephone 301-496-4784</p> <p>Contact Email <a href="mailto:sarah.scharf@nih.gov">sarah.scharf@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to alert the community about this opportunity and disseminate knowledge and information on a program designed to foster the expansion of U.S.-Finland biomedical and behavioral research collaboration.</p>				
101814	<a href="#">Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers</a>	National Institutes of Health/DHHS	NOT-CA-21-028	07-Jan-2022	Not Specified
	Contact Name Natalie Abrams, PhD				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   240-474-7336</p> <p>Contact Email   <a href="mailto:natalie.abrams@nih.gov">natalie.abrams@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the ultimate goal of improving early detection and risk assessment for abdominal cancers. This Notice encourages applications proposing multi-institutional collaborative AI development approaches such as federated learning, which distributes the models to data-owners and aggregates the results without sharing the actual data.</p>				
102638	<a href="#">New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAS-21-150	07-Jan-2022	600,000 USD
	<p>Contact Name   Shilpa Hattangadi, M.D.</p> <p>Contact Telephone   301-594-7726</p> <p>Contact Email   <a href="mailto:shilpam.hattangadi@nih.gov">shilpam.hattangadi@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024</p> <p>Synopsis   This Funding Opportunity Announcement (FOA) seeks innovative grant applications in nonmalignant hematology research that will steer the field in new directions. Applications to this FOA should propose proof of principle research that is tightly focused into one specific aim, which can be accomplished within a 1-3 year project period, and is directed at validating novel concepts and approaches that promise to open new pathways for discovery.</p>				
102694	<a href="#">Notice of Special Interest (NOSI): Using Systems Science Methodologies to Protect and Improve Child and Reproductive Population Health</a>	National Institutes of Health/DHHS	NOT-HD-20-032	07-Jan-2022	Not Specified
	<p>Contact Name   Regina M. Bures, Ph.D.</p> <p>Contact Telephone   301-496-9485</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:regina.bures@nih.gov">regina.bures@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support multi-disciplinary scientific teams proposing research using systems science approaches to address persistent public health challenges. Systems science refers to multi-level methodologies addressing complex behavioral and social phenomena. This initiative encourages applications for both basic and applied research, including methodological and measurement development, with a focus on human behavioral and/or social science. This initiative also seeks to promote interdisciplinary collaboration among health researchers and experts in mathematical modelling.</p>				
102925	<p><a href="#">Notice of Special Interest (NOSI): NIH Research Project Grants on Down Syndrome (R01) for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome) Project</a></p>	National Institutes of Health/DHHS	NOT-OD-20-024	07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to support research project grant (R01) applications that are focused on Down syndrome and that meet programmatic objectives for the INCLUDE Project. Sharing of resources and effective communication of outputs of appropriate interest to broader communities are a high priority of the INCLUDE Project. Applicants responding to this NOSI are strongly encouraged to describe plans for rapid sharing of data and results as well as innovative data analytics approaches (see Goal 3, NIH Strategic Plan For Data Science).</p>				
103050	<p><a href="#">Notice of Special Interest (NOSI): Stimulate Research on the Diagnosis, Treatment, and Mechanistic Understanding of Postural Orthostatic Tachycardia Syndrome (POTS)</a></p>	National Institutes of Health/DHHS	NOT-HL-21-008	07-Jan-2022	Not Specified
	<p>Contact Name Denis Buxton, PhD</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   301-435-0515</p> <p>Contact Email   <a href="mailto:buxtond@nhlbi.nih.gov">buxtond@nhlbi.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024</p> <p>Synopsis   Postural Orthostatic Tachycardia Syndrome (POTS) can be a debilitating condition that affects routine activities such as working or attending school. POTS primarily affects women of child-bearing age, with most studies reporting 80-90% female predominance. The peak incidence is at age 14 years, but half of all individuals with POTS develop it in adulthood. While there are no precise data on the prevalence of POTS, it is estimated to affect 0.2-1% of the U.S. population. There is thus a compelling need to stimulate research to understand the causes of POTS in order to inform the development of treatments. Improving the diagnosis of POTS through the development of biomarkers or improved diagnostic tools represents another major need. Translational studies and mechanistic clinical trials to guide the development of better treatments are also important goals. This NOSI signals interest in this important area with the goal of stimulating research applications to address these critical needs.</p>				
103908	<p><a href="#">Notice of Special Interest (NOSI): NIH Research Project Grant (R01) Applications from Individuals from Diverse Backgrounds, Including Under-Represented Minorities</a></p>	National Institutes of Health/DHHS	NOT-NS-21-049	07-Jan-2022	Not Specified
	<p>Contact Name  </p> <p>Contact Telephone  </p> <p>Contact Email  </p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023</p> <p>Synopsis   The National Institute of Neurological Disorders and Stroke seeks to promote diversity in all of its research programs and to increase the participation of underrepresented groups. As the US population becomes increasingly diverse, reflection of that diversity among the biomedical research workforce is vital to our science enterprise and the NIH research mission (See NOT-OD-20-031). NIH is committed to implementing approaches to address the funding gap for researchers from diverse backgrounds and “committed to instituting new ways to support diversity, equity, and inclusion, and identifying and</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

dismantling any policies and practices that may harm our workforce and our science”. This Notice is being issued to highlight interest in receiving research project applications submitted by investigators from diverse backgrounds.

106813	<a href="#">Genomic Curriculum Development for Medical Students (R25 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-312	25-Jan-2022	450,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Heather A. Colley
Contact Telephone	301-480-2332
Contact Email	<a href="mailto:heather.colley@nih.gov">heather.colley@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	25-Jan-2022 , 25-Jan-2024
Synopsis	<p>The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on Curriculum Development. This NHGRI R25 program offers to support the development of curricula for Master of Science (M.S.) degree programs in genomics, genomic medicine and/or genomic informatics for medical students. Specifically, this FOA will support the development of curriculum designed to be freely available, at no cost to the broader community to enhance training in genomics for medical students.</p>

093210	<a href="#">Independent Scientist Award (Parent K02 - Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-171	07-Jan-2022	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.

093932	<a href="#">NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-188	07-Jan-2022	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	<p><a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p><a href="#">Link to program URL</a></p> <p>07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>
--	--

093935	<a href="#">NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-189	07-Jan-2022	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<a href="#">Basic Experimental Studies with Humans Required</a>					Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis</p> <p>The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
093931	<a href="#">NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-187	07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Pathway to Independence Award (K99/R00) program is to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.</p>				
093953	<a href="#">Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-186	07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and/or junior clinical faculty. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

093214	<a href="#">Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-20-173	07-Jan-2022	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	<p>The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.</p>

093225	<a href="#">Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-174	07-Jan-2022	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA.</p>				
094015	<a href="#">Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-176	07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and "protected time" (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances.. This Funding Opportunity Announcement (FOA) is designed specifically for</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PA-20-190). Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

094038	<a href="#">Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-197	07-Jan-2022	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	<p>The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
094020	<a href="#">Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-190	07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances.. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
094040	<a href="#">Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-20-198	07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p>				



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
094233	<p><a href="#">Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)</a></p>	National Institutes of Health/DHHS	PA-20-201	07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>2023</p> <p>The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
094044	<p><a href="#">Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)</a></p>	National Institutes of Health/DHHS	PA-20-199	07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
093955	<a href="#">Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-193	07-Jan-2022	Not Specified

questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PA-20-197). Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	<p>The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents.. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
094026	<a href="#">Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-20-191	07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis                      The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
093954	<a href="#">Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-20-192	07-Jan-2022	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	<a href="#">Link to program URL</a> 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023 The purpose of the NIH Midcareer Investigator Award in Patient-Oriented Research (K24) is to provide support to mid-career health-professional doctorates for protected time to devote to patient-oriented research (POR) and to act as research mentors for junior clinical investigators pursuing POR research, such as clinical residents and junior clinical faculty. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.
--	--

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
094250	<a href="#">Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-206	07-Jan-2022	Not Specified

Contact Name

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	
Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

094234	<a href="#">Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-202	07-Jan-2022	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	301-496-8580
Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08)

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

094248	<a href="#">Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-205	07-Jan-2022	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

apply to the companion FOA Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.

094235	<a href="#">Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-203	07-Jan-2022	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	301-496-8580
Contact Email	<a href="mailto:grantinfo@nih.gov">grantinfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023
Synopsis	<p>The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
094244	<a href="#">Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-20-204	07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis                      The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Special Note: Not all NIH Institutes and Centers participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest and requirements at the Table of IC-Specific Information, Requirements and Staff Contacts website. ICs that do not participate in this announcement will not consider applications for funding. Consultation with NIH staff before submitting an application is strongly encouraged.</p>				
098640	<a href="#">Mentored Career Development Program (K01) for</a>	National Institutes of	PAR-20-258	07-Jan-2022	Not

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

<a href="#">Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)</a>	Health/DHHS	Specified
---	-------------	-----------

Contact Name	Deborah Philp, Ph.D.
Contact Telephone	301-761-7766
Contact Email	<a href="mailto:deborah.philp@nih.gov">deborah.philp@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023
Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage investigators with support and “protected time” (up to five years) for intensive, research-focused career development program activities under the guidance of an experienced mentorship team with expertise in both the preclinical application of nonhuman primate (NHP) models and in translation of the results from such studies to clinical application. The focus of this program is to increase the number of highly skilled scientists using NHP models to address complex translational biomedical research designed to foster translation of outcomes into the clinic. The expectation is that through this sustained period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant (e.g., R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>

100436	<a href="#">Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)</a>	National Institutes of Health/DHHS	PA-21-049	08-Dec-2021	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:GrantsInfo@nih.gov">GrantsInfo@nih.gov</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 08-Dec-2021 , 07-Jan-2022 , 08-Apr-2022 , 07-May-2022 , 08-Aug-2022 , 07-Sep-2022 , 08-Dec-2022 , 07-Jan-2023 , 08-Apr-2023 , 07-May-2023 , 08-Aug-2023 , 07-Sep-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support students at institutions with NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Candidates must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential to develop into a productive, independent physician/clinician-scientist. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
079360	<a href="#">Bioengineering Research Grants (BRG) (R01 Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAR-19-159	07-Jan-2022	Not Specified
	<p>Contact Name Seila Selimovic, Ph.D. Program Director</p> <p>Contact Telephone 301-451-4577</p> <p>Contact Email <a href="mailto:seila.selimovic@nih.gov">seila.selimovic@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022</p> <p>Synopsis The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed,</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

078543	<a href="#">Processing and Presentation of Non-Conventional MHC Ligands (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-19-067	07-Jan-2022	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name Timothy A. Gondré-Lewis, Ph.D.  
 Contact Telephone 240-627-3566  
 Contact Email [tglewis@niaid.nih.gov](mailto:tglewis@niaid.nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)  
 Deadline Dates (ALL) 07-Jan-2022

Synopsis This Funding Opportunity Announcement (FOA) invites applications to characterize antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands presented by classical and non-classical MHC class I and class II molecules, and to determine the contribution of these unique antigenic ligands to: protective immune responses to infectious pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or in the induction/progression or prevention of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines.

088011	<a href="#">Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-055	07-Jan-2022	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name David M. Panchision, Ph.D.  
 Contact Telephone 301-443-5288  
 Contact Email [panchisiond@mail.nih.gov](mailto:panchisiond@mail.nih.gov)  
 Sponsor Website  
 Program URL [Link to program URL](#)

Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023

Synopsis This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. This FOA is intended to provide support for the further development of projects where preliminary data supports the feasibility of the line of investigation. Applicants without preliminary data may wish to apply to the companion R21 FOA(PAR-20-082).

088091	<a href="#">Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-20-038	07-Jan-2022	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Enrique Michelotti, Ph.D.
Contact Telephone	301-443-5415
Contact Email	<a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023
Synopsis	This Funding Opportunity Announcement (FOA) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research. Projects proposing only preclinical animal studies should consider the companion FOA PAR-20-037 .

088090	<a href="#">Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-037	07-Jan-2022	825,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Enrique Michelotti, Ph.D.
Contact Telephone	301-443-5415

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical feasibility evaluation in pre-clinical studies and appropriate model development. Projects proposing clinical assessments of novel radioligands should respond to FOA PAR-20-038 .</p>				
093908	<a href="#">NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-185	07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 05-Feb-2023</p> <p>Synopsis The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>				
093638	<a href="#">Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-20-180	07-Jan-2022	Not Specified

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	David L. Tilley, MPH, MS, CPH
Contact Telephone	301-827-6014
Contact Email	<a href="mailto:david.tilley@nih.gov">david.tilley@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023
Synopsis	<p>This Funding Opportunity Announcement (FOA) invites applications that seek to support the identification of shared mechanisms and development of innovative interventions to address multimorbidity or multiple chronic conditions (MCCs) and its consequences. Intervention research supported by this initiative should be designed to study: (1) mechanisms or pathways that prevent MCCs, including the identification of early biomarkers, behavioral pathways, and individual and contextual risk factors and interactions that contribute to the development of common MCCs; (2) targeted therapies and management, including self-management, of MCCs to delay progression and prevent onset of new diseases; and (3) innovative health care partnership models for managing or treating MCCs. Studies may include shared mechanisms, and assessments of interactions between risk factors and interventions that address MCCs at different periods of the lifespan in diverse populations. Use of innovative technologies to assess and intervene on risk factors and pathways are encouraged. Studies may also include those that make use of existing data and/or data linkages to explore new research questions that may be helpful in understanding the impact of mechanisms in isolation or in combination. Of particular interest are interventions that target prevention and treatment of multiple chronic health conditions, including study designs that address therapeutic targets for preventing co-occurring MCCs. Prospective applicants whose research interests relate to developing improved measures and methods for understanding multimorbidity, including but not limited to measures/tools to support basic mechanistic discovery of shared MCC pathways and identification and initial evaluation of MCC shared signatures, should see PAR-20-179.</p>

093636	<a href="#">Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-20-179	07-Jan-2022	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	David L. Tilley, MPH, MS, CPH
Contact Telephone	301-827-6014

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	<a href="mailto:david.tilley@nih.gov">david.tilley@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023
Synopsis	<p>This Funding Opportunity Announcement (FOA) invites applications that seek to improve the availability, quality, and utility of data and measures that capture multimorbidity or multiple chronic conditions (MCCs) and the methods for analyzing multimorbidity data. Research supported by this initiative should be designed to discover, develop, and/or evaluate MCC measures/tools that reflect the longitudinality and life course diversity of multimorbidity. This includes but is not limited to measures/tools to support basic mechanistic discovery of shared MCC pathways using animal models of MCCs, and identification and initial biological, analytical, and clinical evaluation of MCC shared signatures. Also sought are patient-focused studies that capture patient reports and related constructs such as functional limitations and quality of life; analytic approaches best suited for use with multimorbidity data and matched to target populations; and approaches that fully harness the wealth of multimorbidity data available in EHR systems. Studies may make use of existing data and data linkages to explore new research questions related to co-occurring MCCs. Prospective applicants whose research interests relate to studies that identify shared mechanisms or development of innovative interventions to address MCCs should see PAR-20-180.</p>

093897	<a href="#">Research Project Grant (Parent R01 Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-183	07-Jan-2022	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023
Synopsis	The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. NOTE: The following Institutes/Centers only accept mechanistic studies that meet NIH's definition of a clinical trial. National Heart, Lung, and Blood Institute (NHLBI) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute of Neurological Disorders and Stroke (NINDS) National Center for Complementary and Integrative Health (NCCIH) National Institute of Mental Health (NIMH)

093907	<a href="#">Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-20-184	07-Jan-2022	Not Specified
--------	---	------------------------------------	-----------	-------------	---------------

Contact Name	
Contact Telephone	301-496-4000
Contact Email	<a href="mailto:grantsinfo@od.nih.gov">grantsinfo@od.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023
Synopsis	<p>The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website.</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

ICs that do not participate in this announcement will not consider applications for funding.

093035	<a href="#">Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01-Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-20-172	07-Jan-2022	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	Larissa Avilés-Santa, MD, MPH
Contact Telephone	301-827-6924
Contact Email	<a href="mailto:avilessantal@nih.gov">avilessantal@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.

104359	<a href="#">Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-21-232	07-Jan-2022	2,500,000 USD
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	Larissa Aviles-Santa, MD, MPH
Contact Telephone	301-827-6924
Contact Email	<a href="mailto:avilessantal@mail.nih.gov">avilessantal@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | This initiative will support innovative research to develop, test and evaluate multi-level/multi-component strategies (including models of health care) to effectively adapt and implement comprehensive clinical care for individuals with Type 2 diabetes mellitus from populations with health disparities concordant with recommended and evidence-based guidelines.

104500	<a href="#">Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to Improve Use of Evidence-Based Practices for HLBS Conditions</a>	National Institutes of Health/DHHS	NOT-HL-21-010	07-Jan-2022	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Rebecca A. Roper, MS, MPH
Contact Telephone	301-496-1051
Contact Email	<a href="mailto:Rebecca.Roper@nih.gov">Rebecca.Roper@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024
Synopsis	This Notice of Special Interest (NOSI) is intended to stimulate the use of behavioral economics strategies for implementation research (BEIR) in order to develop more effective strategies for implementation of evidence-based practices (EBP) to address heart, lung, blood, and sleep (HLBS) conditions. NHLBI encourages applications that recognize the importance of cultural context, patterns of behavior change, and motivators for change across decision-making levels, including individuals (e.g., patients, parents, clinicians, others), groups, healthcare systems and/or communities. Applications that focus on the use of behavioral economics to develop implementation strategies for user-driven, sustainable interventions that may be simplified and minimally disruptive when possible are encouraged. Applications may propose either a clinical trial or non-clinical trial design, as appropriate to the research objectives.

102741	<a href="#">Notice of Special Interest (NOSI): Understanding and Addressing the Impact of Structural Racism and Discrimination on Biomedical Career Progression and the Biomedical Research Enterprise</a>	National Institutes of Health/DHHS	NOT-GM-21-033	18-Jan-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name |

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 18-Jan-2022 , 17-May-2022 , 03-Oct-2022</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to inform applicants of topic areas of interest to the National Institute of General Medical Sciences (NIGMS) to study and/or address the impacts of structural racism and discrimination on biomedical career progression and the biomedical research enterprise.</p>				
100289	<p><a href="#">Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)</a></p>	National Institutes of Health/DHHS	PAR-21-029	07-Jan-2022	Not Specified
	<p>Contact Name Enrique L. Michelotti, Ph.D.</p> <p>Contact Telephone 301-443 5415</p> <p>Contact Email <a href="mailto:michelottiel@mail.nih.gov">michelottiel@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI, and/or NIA and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be the discovery of in vivo chemical probes. Applicants interested in developing cell-based chemical probes may wish to apply using the companion R21 mechanism, (PAR-21-028).</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
099859	<a href="#">Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)</a>	National Institutes of Health/DHHS	NOT-HL-20-814	07-Jan-2022	Not Specified
	<p>Contact Name   Guofei Zhou, PhD</p> <p>Contact Telephone   301-827-7825</p> <p>Contact Email   <a href="mailto:guofei.zhou@nih.gov">guofei.zhou@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of NHLBI in research to understand host resilience as a critical determinant of outcomes in acute respiratory distress syndrome (ARDS) /acute lung injury (ALI).</p>				
104854	<a href="#">Notice of Special Interest (NOSI): Harnessing Big Data to Halt HIV</a>	National Institutes of Health/DHHS	NOT-AI-21-054	07-Jan-2022	Not Specified
	<p>Contact Name   Rosemary McKaig, M.P.H, Ph.D.</p> <p>Contact Telephone   240-627-3214</p> <p>Contact Email   <a href="mailto:rm434n@nih.gov">rm434n@nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024</p> <p>Synopsis   The purpose of this Notice of Special Interest (NOSI) is to promote and support innovative methods in Big Data Science (BDS) to identify unappreciated biomedical, behavioral, social patterns and other social determinants that shed light on HIV acquisition, transmission, the development of comorbidities, and long-term viral control as in the HIV treatment continuum. BDS approaches can bring together data to</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

evaluate the complex interplay between individual, contextual, and structural factors influencing the epidemiology of risk and care. Further, because this field can reveal unexpected associations through analysis of diverse data, BDS approaches may reveal events that are unseen or transient in traditional analysis of datasets. Discovery of these events will considerably advance research on HIV networks of transmission and the care continuum. This NOSI will support the establishment of BDS standards, bioinformatics data tools, machine-learning algorithms, mathematical modeling, advanced epidemiology and statistical analytic methods, and consideration and application of privacy and ethical issues in the use of public and personal data in the context of HIV research.

094931	<a href="#">NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAR-20-217	07-Jan-2022	1,050,000 USD
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Wendy Weber, N.D., Ph.D, M.P.H.
Contact Telephone	301-402-1272
Contact Email	<a href="mailto:weberwj@mail.nih.gov">weberwj@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023
Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to 3 years support for studies to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population.</p> <p>Applications are encouraged to design studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R33 funding mechanism is intended to accelerate the</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

translation of emerging basic science findings about natural products into early stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer.

094932	<a href="#">NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAR-20-218	07-Jan-2022	1,750,000 USD
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Wendy Weber, N.D., Ph.D, M.P.H.
Contact Telephone	301-402-1272
Contact Email	<a href="mailto:weberwj@mail.nih.gov">weberwj@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023
Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to three years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural product’s effect (i.e., measure of mechanism of action) when used by humans on a biological signature(s). If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulation. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R61/R33 funding mechanism is</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. A maximum of 5 years will be supported by the two phases of the R61/R33 award. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

100769	<a href="#">Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-080	07-Jan-2022	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Deborah Linares, Ph.D.
Contact Telephone	301-402-2516
Contact Email	<a href="mailto:deborah.linares@nih.gov">deborah.linares@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant populations.

100780	<a href="#">Addressing Health Disparities among Immigrant Populations through Effective Interventions (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-081	07-Jan-2022	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Deborah Linares, Ph.D.
Contact Telephone	301-402-2516
Contact Email	<a href="mailto:deborah.linares@nih.gov">deborah.linares@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this initiative is to support research to design and implement effective interventions to enhance health advantages and reduce the health disparities among US immigrant populations.			
097522	<a href="#">Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-252	17-Jan-2022	100,000 USD
	Contact Name	Adam J. Kuszak, Ph.D.			
	Contact Telephone	301-496-1795			
	Contact Email	<a href="mailto:kuszakaj@mail.nih.gov">kuszakaj@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	17-Jan-2022 , 15-Apr-2022			
	Synopsis	The rigor and reproducibility of research on dietary supplements are enhanced by rigorous characterization of key experimental resources and biological samples. The dissemination of analytical methods that are validated to accurately and reliably characterize dietary supplements and quantify their constituents and/or metabolites is vital for both basic and clinical research. This FOA builds on existing NIH awards to support the performance and publication of formal single-laboratory validation studies of analytical methods for dietary supplements and other natural products. The method(s) proposed for validation must be used to identify and/or quantify dietary supplement-relevant ingredients or constituents (i.e., active or marker chemical compounds, adulterants, contaminants) or their metabolites in experimental reagents, raw materials, and/or clinical specimens (e.g., urine or plasma samples). The method(s) must already be developed or utilized in fulfillment of the active parent grant's specific aims. Candidate constituents for method validation studies include (but are not limited to): phytochemicals, nutrients, and potentially deleterious substances such as pesticides and mycotoxins. Multi-laboratory validation studies will not be supported through this FOA.			
099865	<a href="#">RFA-NS-21-010 -- HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-NS-21-010	16-Jan-2022 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Michael Oshinsky			
	Contact Telephone	301-496-9964			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	<a href="mailto:michael.oshinsky@nih.gov">michael.oshinsky@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	16-Jan-2022 [Optional][LOI/Pre-App], 15-Feb-2022 , 16-May-2022 [Optional][LOI/Pre-App], 15-Jun-2022 , 14-Sep-2022 [Optional][LOI/Pre-App], 14-Oct-2022 , 14-Jan-2023 [Optional][LOI/Pre-App], 14-Feb-2023
Synopsis	<p>The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads to Phase I clinical trials and readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) <a href="https://heal.nih.gov/research/clinical-research/eppic-net">https://heal.nih.gov/research/clinical-research/eppic-net</a> or other Phase II clinical studies. Applicants must have a promising biologic or small molecule hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, development of a pharmacodynamic/target engagement biomarker, assembly and filing of an Investigational New Drug (IND) application and Phase I clinical testing. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.</p>

081503	<a href="#">Limited Competition: Modular Budget Research Project Grant for NIH Nurse Scientist Scholars (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-19-256	06-Jan-2022	1,250,000 USD
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	David Banks, PhD, MPH, RN
Contact Telephone	301-496-9558
Contact Email	<a href="mailto:david.banks@nih.gov">david.banks@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	06-Jan-2022
Synopsis	<p>The purpose of this funding opportunity announcement (FOA) is to encourage modular budget R01 grant applications from nurse scientists who are currently or were supported within the last 3 years by an NIH Career Development (K) award. This opportunity is limited to those K awardee nurse scientists who have NIH New Investigator status. Through this opportunity, NINR seeks to enhance the transition</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| of nurse scientists to independent investigator status.

097189	<a href="#">Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators (R01)</a>	National Institutes of Health/DHHS	PAR-20-271	05-Jan-2022 [Optional][LOI/Pre-App]	Not Specified
--------	---	------------------------------------	------------	--	---------------

Contact Name	Suzanne Forry, Ph.D.
Contact Telephone	240-276-5922
Contact Email	<a href="mailto:forryscs@mail.nih.gov">forryscs@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Jan-2022 [Optional][LOI/Pre-App], 07-Jan-2022 , 05-Feb-2022 , 05-May-2022 [Optional][LOI/Pre-App], 07-May-2022 , 05-Jun-2022 , 05-Sep-2022 [Optional][LOI/Pre-App], 05-Oct-2022 , 07-Jan-2023
Synopsis	Through this funding opportunity announcement (FOA), NCI wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes (NIDCD, NIMH); and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets. Stages of discovery research covered by this FOA include: 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set; and 4) hit-to-lead optimization.

097158	<a href="#">Notice of Special Interest (NOSI): Stimulating Intervention Research to Reduce Cardiopulmonary Impacts of Particulate Matter in Air Pollution among High-Risk Populations</a>	National Institutes of Health/DHHS	NOT-HL-20-788	07-Jan-2022	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Lawrence J. Fine, MD, DrPH
Contact Telephone	301-435-0305
Contact Email	<a href="mailto:Lawrence.Fine@NIH.gov">Lawrence.Fine@NIH.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023

Synopsis

The purpose of this trans-NIH Notice of Special Interest (NOSI) is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Environmental Health Sciences (NIEHS) have special interest in applications aiming to investigate the impact of personal interventions to reduce exposure to particulate matter (PM) in air pollution on cardiovascular and pulmonary (cardiopulmonary) outcomes. This notice specifically encourages intervention studies or clinical trials that examine the efficacy of personal air pollution interventions to reduce the adverse cardiopulmonary effects of Particulate Matter (PM) <2.5 µm in diameter (PM2.5) in high risk or vulnerable participants.

097215	<a href="#">Notice of Special Interest (NOSI): Fundamental and Translational Research on Decision Making in Aging and/or Alzheimer’s Disease and Alzheimer’s Disease Related Dementias (AD/ADRD)</a>	National Institutes of Health/DHHS	NOT-AG-20-039	07-Jan-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name | Luke Stoeckel, Ph.D.  
 Contact Telephone | 202-570-9388  
 Contact Email | [luke.stoeckel@nih.gov](mailto:luke.stoeckel@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 07-Jan-2022

Synopsis

This Notice of Special Interest (NOSI) underscores NIA’s continued commitment to research that seeks to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer’s disease (AD), and AD-related dementias (ADRD). Research is sought that characterizes the extent to which behavioral, psychological, and neural processes involved in decision making are differentially impacted in normal aging, MCI, and AD/ADRD. Investigations that target the influence of social factors on decision making or other factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse are of particular interest. This NOSI also encourages preclinical and applied research on decision making that may facilitate the design of decision-supportive interventions for midlife and older adults with and without MCI and AD/ADRD. Specific opportunities include the development of decision-support interventions to leverage cognitive, emotional, social, and motivational strengths of these populations;

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

tools to assess decisional capacities; strategies for simplifying choices and offering better defaults; and the promotion of timely adoption of optimal delegation practices (e.g., power of attorney, living wills, etc.). The use of animal models to explore the neural basis of affective, cognitive, social, and motivational parameters as they relate to age-related changes in decision making is also invited.

106715	<a href="#">Role of Astrocytes in Degeneration of the Neurovascular Unit in AD/ADRDs (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-22-037	07-Jan-2022	2,500,000 USD
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	
Contact Telephone	
Contact Email	
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025
Synopsis	This funding opportunity announcement (FOA) invites basic disease-related research to address a gap in the basic research on the mechanisms of reactive astrogliosis in degeneration of the neurovascular unit that contributes to cognitive impairment and dementia. The neurovascular unit involves multiple pathways that contribute to neurodegeneration. Astrocytes, due to their overlapping roles regulating the blood brain barrier, neuronal health and response to degenerating cells, are uniquely positioned to be therapeutic targets for the AD/ADRDs.

105957	<a href="#">Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-305	09-Nov-2021	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Mary Evans, Ph.D.
Contact Telephone	301-594-4578
Contact Email	<a href="mailto:evansmary@mail.nih.gov">evansmary@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	09-Nov-2021 , 09-Dec-2021 , 10-Jan-2022 , 10-Feb-2022 , 10-Mar-2022 , 11-Apr-2022 , 10-May-2022 ,

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>09-Jun-2022 , 11-Jul-2022 , 09-Aug-2022 , 09-Sep-2022 , 07-Oct-2022 , 09-Nov-2022 , 09-Dec-2022 , 10-Jan-2023 , 09-Feb-2023 , 09-Mar-2023 , 11-Apr-2023 , 09-May-2023 , 09-Jun-2023 , 11-Jul-2023 , 09-Aug-2023 , 08-Sep-2023 , 09-Oct-2023 , 10-Oct-2023 , 11-Dec-2023 , 09-Jan-2024 , 09-Feb-2024 , 08-Mar-2024 , 09-Apr-2024 , 08-May-2024 , 10-Jun-2024 , 09-Aug-2024 , 10-Sep-2024</p> <p>This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, sedentary behavior, and/or sleep) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity-related policy or program offers an uncommon and scientifically-compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date; however, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.</p>				
106928	<p><a href="#">RFA-AT-22-001 -- NIH Health Care Systems Research Collaboratory - Pragmatic and Implementation Trials of Embedded Interventions (UG3/UH3, Clinical Trials Optional)</a></p>	National Institutes of Health/DHHS	RFA-AT-22-001	07-Jan-2022	4,500,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Wendy Weber, ND, PhD, MPH</p> <p>301-402-1272</p> <p><a href="mailto:weberwj@mail.nih.gov">weberwj@mail.nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 05-Oct-2024</p> <p>This Funding Opportunity Announcement (FOA) encourages UG3/UH3 phased cooperative research applications to conduct efficient, large-scale pragmatic or implementation trials to improve health and care delivery, with a particular focus on health care systems (HCS) with less historical involvement in</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

research studies focused on improving health outcomes for US patient populations. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a trial conduct phase (UH3). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The overall goal of this initiative is to support the "real world" assessment of health care strategies and clinical practices and procedures in health care systems (HCS) that lead to improved care for populations in a variety of healthcare contexts, with a strong focus on populations with health disparities. Results from the pragmatic studies supported by this FOA should inform policy makers, payers, doctors and patients across diverse patient care settings. This FOA requires that the intervention under study be embedded into health care delivery system, "real world" settings. Studies can propose to integrate multi-modal or multiple interventions that have demonstrated efficacy into HCS; or implement HCS changes to improve adherence to evidence-based guidelines. Trials should be conducted across three or more health care systems (HCS) that provide care to patient populations and will become part of and work with the NIH HCS Research Collaboratory. The NIH HCS Research Collaboratory Program has established a Collaboratory Coordinating Center (CCC) that is providing national leadership and technical expertise in all aspects of research with HCS. Awarded applicants will work with the HCS CCC (<https://rethinkingclinicaltrials.org/>) to facilitate further planning and refinement of the proposed study.

103220	<a href="#">Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children</a>	National Institutes of Health/DHHS	NOT-MH-21-225	07-Jan-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Susan Borja, PhD
Contact Telephone	301-443-1252
Contact Email	<a href="mailto:susan.borja@nih.gov">susan.borja@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022
Synopsis	NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to understand the mental health impact of the Coronavirus Disease 2019 (COVID-19) pandemic on school-aged children, specifically ages 3 - 12. Particularly, we are interested in the potential impact of primary instruction

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

settings disruptions (e.g., pre-school, elementary school) on the mental health, cognitive, social, and emotional development of children. Empirical data would aid in balancing health risks for various public health mitigation strategies affecting children in the current pandemic as well as inform how to both be prepared and respond to future public health emergencies, including pandemics and disaster scenarios.

100892	<a href="#">SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAR-20-130	05-Jan-2022	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name | Dr. Jerome Wujek  
 Contact Telephone | 301-451-2020  
 Contact Email | [wujekjer@nei.nih.gov](mailto:wujekjer@nei.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 05-Jan-2022 , 05-Apr-2022

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R&D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)/Investigational Device Exemption (IDE) enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R&D throughout the award. This Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

100037	<a href="#">Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2021, 2022, 2023 (P50 Clinical Trial Required)</a>	National Institutes of Health/DHHS	PAR-20-305	25-Jan-2022	7,000,000 USD
--------	--	------------------------------------	------------	-------------	---------------

Contact Name | Toby T. Hecht, Ph.D, Associate Director



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   240-276-5683</p> <p>Contact Email   <a href="mailto:hechtt@mail.nih.gov">hechtt@mail.nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023 , 25-May-2023 , 25-Sep-2023</p> <p>Synopsis   Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) and National Institute of Dental and Craniofacial Research (NIDCR) invite applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. For the purpose of this FOA, a group of highly related cancers are those that are derived from the same organ system, such as gastrointestinal, neuroendocrine, head and neck, and other cancers. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers promoted and sustained by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant.</p>				
094050	<a href="#">NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-200	07-Jan-2022	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email   <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R01 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>			
101367	<a href="#">Notice of Special Interest (NOSI): Use of Human Connectome Data for Secondary Analysis</a>	National Institutes of Health/DHHS	NOT-MH-21-175	07-Jan-2022	Not Specified
	Contact Name	Yvonne Bennett, Ph.D.			
	Contact Telephone	301-222-7094			
	Contact Email	<a href="mailto:yvonne.bennett@nih.gov">yvonne.bennett@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024			
	Synopsis	<p>NIMH and participating institutes/centers (ICs) listed above are issuing this Notice of Special Interest (NOSI) to encourage secondary analyses of data from the Human Connectome Project (HCP) including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease. Details about the “Lifespan” and “Disease” Connectomes, including neuroimaging protocols and clinical and behavioral assessments, can be found at the Connectome Coordinating Facility website: <a href="https://www.humanconnectome.org/">https://www.humanconnectome.org/</a> and at the NIMH Data Archive (NDA) <a href="http://www.nda.nih.gov">www.nda.nih.gov</a>.</p>			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

101300	<a href="#">Notice of Special Interest (NOSI): Use of Human Connectome Data for Secondary Analysis</a>	National Institutes of Health/DHHS	NOT-MH-21-075	07-Jan-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Yvonne Bennett, Ph.D.
Contact Telephone	301-222-7094
Contact Email	<a href="mailto:yvonne.bennett@nih.gov">yvonne.bennett@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024
Synopsis	NIMH and participating institutes/centers (ICs) listed above are issuing this Notice of Special Interest (NOSI) to encourage secondary analyses of data from the Human Connectome Project (HCP) including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease. Details about the “Lifespan” and “Disease” Connectomes, including neuroimaging protocols and clinical and behavioral assessments, can be found at the Connectome Coordinating Facility website: <a href="https://www.humanconnectome.org/">https://www.humanconnectome.org/</a> and at the NIMH Data Archive (NDA) <a href="http://www.nda.nih.gov">www.nda.nih.gov</a> .

103732	<a href="#">Notice of Special Interest (NOSI): Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence</a>	National Institutes of Health/DHHS	NOT-DA-21-012	07-Jan-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Keisher Highsmith, DrPH
Contact Telephone	
Contact Email	<a href="mailto:highsmithks@nih.gov">highsmithks@nih.gov</a>
Sponsor Website	

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis The purpose of this Notice is to inform potential applicants of the National Institute on Drug Abuse (NIDA) special interest in grant applications to conduct rigorous basic, translational and/or clinical research to: (1) advance identification of sex and/or gender differences in risk for substance use disorders or the response or medical consequences of alcohol or substance misuse to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research.</p>				
103983	<p><a href="#">Notice of Special Interest (NOSI): Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes</a></p>	National Institutes of Health/DHHS	NOT-AA-21-028	07-Jan-2022	Not Specified
	<p>Contact Name Gregory Bloss, M.A., M.P.P.</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:Gregory.Bloss@nih.gov">Gregory.Bloss@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis This announcement encourages applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, cannabis, tobacco, prescription drugs, and other substances. The purpose of the Notice is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This Notice is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>that may be supported include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes; studies of disparities in policy effects and the role of policy in exacerbating or potentially reducing health disparities; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, cannabis-, tobacco-, and other substance-related behaviors and outcomes.</p>				
105055	<a href="#">Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Population, Clinical and Applied Prevention Mechanisms of Health Effects</a>	National Institutes of Health/DHHS	NOT-OD-21-137	07-Jan-2022	Not Specified
	<p>Contact Name Rachel Grana Mayne, PhD, MPH            Contact Telephone 240-276-5899            Contact Email <a href="mailto:rachel.mayne@nih.gov">rachel.mayne@nih.gov</a>            Sponsor Website            Program URL <a href="#">Link to program URL</a>            Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023            Synopsis The Office of Disease Prevention and participating ICOs are issuing this Notice to communicate our interest in research on electronic nicotine delivery systems (ENDS). Research on alternative nicotine and tobacco delivery systems [e.g., heated tobacco products (also called heat-not-burn)] will also be considered. Research with a focus on other non-combustible nicotine and tobacco products will be considered on a case-by-case basis. Studies should examine population-based, clinical, and applied prevention of disease, including etiology and epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations. Studies exclusively examining smokeless tobacco or combustible tobacco products (e.g., cigarettes, cigars) will be considered non-responsive.</p>				
105292	<a href="#">RFA-AI-21-041 -- Innate Immune Memory Impacting HIV Acquisition and/or Control (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-AI-21-041	07-Jan-2022	275,000 USD

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Que Dang, Ph.D.
Contact Telephone	240-292-6181
Contact Email	<a href="mailto:que.dang@nih.gov">que.dang@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024 , 16-Oct-2024 , 07-Jan-2025
Synopsis	The purpose of this Funding Opportunity Announcement is to investigate innate immune cell effector functions and innate immune memory as a means to prevent HIV infection and/or establishment of disease. Exploratory research from basic molecular mechanisms, translational work, and clinical research examining innate memory are encouraged.

105365	<a href="#">Notice of Special Interest (NOSI): Research to Improve the Interpretation of Patient-Reported Outcomes at the Individual Patient Level for Use in Clinical Practice</a>	National Institutes of Health/DHHS	NOT-OD-20-079	07-Jan-2022	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Ashley Wilder-Smith, Ph.D., MPH
Contact Telephone	240-276-6714
Contact Email	<a href="mailto:smithas@mail.nih.gov">smithas@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023
Synopsis	A patient-reported outcome (PRO) is defined as any report of a person’s health status including symptoms, function and well-being, that is gathered directly from a patient, without interpretation of that report by a clinician, observer, or anyone else. PROs are critical for the support of patient-centered care, as they provide information from the patient’s perspective, and offer important information to improve patient-clinician communication, decision-making, and care delivery. PROs are increasingly being used by clinical stakeholders (e.g., providers, care delivery systems, payers and regulators) to

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

characterize individual patients' symptoms and functional status and the change in outcomes over time. Thus, PROs are becoming an important piece of information for clinical decision-making, including shared decision-making. The purpose of this Notice of Special Interest (NOSI) is to stimulate research that contributes to the evidence base for precise and accurate PRO score interpretation at the individual patient level for use in clinical practice.

105478	<a href="#">Notice of Special Interest (NOSI): Advancing Research in Gastrointestinal Dysfunction in People with Neurodevelopmental Disorders</a>	National Institutes of Health/DHHS	NOT-NS-22-003	07-Jan-2022	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Adam L. Hartman, MD
Contact Telephone	301-496-9135
Contact Email	<a href="mailto:adam.hartman@nih.gov">adam.hartman@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024
Synopsis	The National Institute of Neurological Disorders and Stroke is issuing this Notice to highlight interest in receiving grant applications focused in the following area(s) to support basic, translational, and/or clinical research on the causes, diagnosis, prevention, or treatment of gastrointestinal dysfunction in people with neurodevelopmental disorders.

105363	<a href="#">Notice of Special Interest (NOSI): Integration of Individual Residential Histories in Cancer Research</a>	National Institutes of Health/DHHS	NOT-CA-21-092	07-Jan-2022	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Zaria Tatalovich, Ph.D.
Contact Telephone	240-276-6976
Contact Email	<a href="mailto:tatalovichzp@mail.nih.gov">tatalovichzp@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis

Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024

This Notice of Special Interest (NOSI) seeks to highlight the interest of NCI's Division of Cancer Control and Population Sciences to support investigation of the role of individual Residential Histories - a record of an individual's places of residence over the life course - relative to cancer risk, etiology, prevention, treatment, and outcomes.

078546	<a href="#">Processing and Presentation of Non-Conventional MHC Ligands (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-19-066	07-Jan-2022	275,000 USD
--------	--	------------------------------------	-----------	-------------	-------------

Contact Name | Timothy A. Gondré-Lewis, Ph.D.  
 Contact Telephone | 240-627-3566  
 Contact Email | [tglewis@niaid.nih.gov](mailto:tglewis@niaid.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 07-Jan-2022

Synopsis

This Funding Opportunity Announcement (FOA) invites applications to determine antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands and to determine the contribution of these unique antigenic ligands to protective immune responses against infectious disease pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or limit progression or induction of immune-mediated diseases. These studies may facilitate the development of novel tools and reagents to advance design of immune-based therapeutics and vaccines.

094033	<a href="#">NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PA-20-195	07-Jan-2022	275,000 USD
--------	--	------------------------------------	-----------	-------------	-------------

Contact Name |  
 Contact Telephone |  
 Contact Email | [grantsinfo@nih.gov](mailto:grantsinfo@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis   The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.</p>				
094032	<a href="#">NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)</a>	National Institutes of Health/DHHS	PA-20-194	07-Jan-2022	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:grantsinfo@nih.gov">grantsinfo@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis   The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (seeRelated Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement. The following Institutes/Centers only accept mechanistic studies that meet NIH's definition of a clinical trial. See Related Notices section below. National Institute of Arthritis and</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Musculoskeletal and Skin Diseases (NIAMS) National Institute of Mental Health (NIMH) Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest at the R21 Basic Experimental Studies with Humans Required IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.

094034	<a href="#">NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)</a>	National Institutes of Health/DHHS	PA-20-196	07-Jan-2022	275,000 USD
--------	---	------------------------------------	-----------	-------------	-------------

Contact Name	
Contact Telephone	301-496-4000
Contact Email	<a href="mailto:grantsinfo@od.nih.gov">grantsinfo@od.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023
Synopsis	<p>The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

which ICs participate in this announcement and view their respective areas of research interest at the R21 Basic Experimental Studies with Humans Required IC-Specific Scientific Interests and Contact website. ICs that do not participate in this announcement will not consider applications for funding.

104865	<a href="#">Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition</a>	National Institutes of Health/DHHS	NOT-HD-21-027	08-Nov-2021	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Sonia Lee, PhD
Contact Telephone	301-594-4783
Contact Email	<a href="mailto:leesonia@mail.nih.gov">leesonia@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	08-Nov-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-Mar-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 08-Nov-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-Mar-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Nov-2023 , 07-Jan-2024
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to encourage applications in high-priority research areas related to pediatric health care transition for youth with chronic physical/medical conditions or intellectual/developmental disabilities. Research applications that will advance our understanding of promising practices designed to facilitate successful health care transitions (HCT) from pediatric to adult care settings as well as barriers and facilitators to such transition are encouraged. The ultimate goal is to improve care quality and patient and family outcomes during and after HCT.

105050	<a href="#">Notice of Special Interest (NOSI): Use of Digital Technology and Mobile Health (mHealth) to Improve Diagnosis, Assessments, Interventions, Management and Outcomes for Individuals with Down Syndrome Across the Lifespan (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	NOT-OD-21-092	07-Jan-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Sujata Bardhan, Ph.D.
Contact Telephone	301-435-0471
Contact Email	<a href="mailto:sujata.bardhan@nih.gov">sujata.bardhan@nih.gov</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023
Synopsis	This Notice invites applications specifically aimed at developing or building upon existing technological tools to improve diagnosis, assessments, interventions, management, and outcomes for infants, children, adolescents and adults with Down Syndrome.

105052	<a href="#">Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Basic Mechanisms of Health Effects</a>	National Institutes of Health/DHHS	NOT-OD-21-127	07-Jan-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Ron Johnson, Ph.D.
Contact Telephone	240-276-6250
Contact Email	<a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023
Synopsis	The Office of Disease Prevention and participating ICOs are issuing this Notice to communicate our interest in research examining how electronic nicotine delivery systems (ENDS) affect normal and disease states relevant to human cells, tissues, organs, and behaviors. Research on alternative nicotine and tobacco delivery systems [e.g., heated tobacco products (also called heat-not-burn)] will also be considered. Studies exclusively examining smokeless tobacco or combustible tobacco products (e.g., cigarettes, cigars) will be considered non-responsive.

104784	<a href="#">Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies</a>	National Institutes of Health/DHHS	NOT-AI-21-056	05-Jan-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Usha Sharma, PhD
Contact Telephone	240-292-4809

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	<a href="mailto:usharma@niaid.nih.gov">usharma@niaid.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	05-Jan-2022 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 17-Feb-2022 , 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 01-Jul-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 17-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 06-Jul-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 05-Apr-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024
Synopsis	This Notice of Special Interest (NOSI) is to inform potential applicants of NIAID’s interest in the development and optimization of next generation methodologies for HIV-1 drug resistance (DR) mutation detection and reporting. This is needed to improve the guidance available to treatment and prevention programs for both individuals and populations. Research responsive to this NOSI could include the development of: (i) highly sensitive mutation detection technologies that can be integrated into multiplex assay systems capable of simultaneous assessment of large numbers of potential mutations (ii) point of care (POC) DR assays, or (iii) strategies for rapid acquisition, curation and analysis of these HIV DR data and timely dissemination to healthcare providers and public health decision makers. Strategies applicable to low and middle income countries as defined by the World Bank are especially encouraged.

105002	<a href="#">The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional)</a>	National Institutes of Health/DHHS	PAR-21-275	07-Jan-2022	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Rada K. Dagher, PhD, MPH
Contact Telephone	301-451-2187
Contact Email	<a href="mailto:rada.dagher@nih.gov">rada.dagher@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 07-Sep-2024
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative population-

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

based research that can contribute to identifying and characterizing pathways and mechanisms through which work or occupation influences health outcomes and health status among populations with health and/or health care disparities, and how work functions as a social determinant of health.

099505	<a href="#">Notice of Special Interest (NOSI): Advancing the Science of Geriatric Palliative Care</a>	National Institutes of Health/DHHS	NOT-AG-20-041	07-Jan-2022	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Basil Eldadah, M.D., Ph.D.
Contact Telephone	301-496-6761
Contact Email	<a href="mailto:eldadahb@nia.nih.gov">eldadahb@nia.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023
Synopsis	This Notice of Special Interest (NOSI) encourages research grant applications focused on palliative care in geriatric populations. This NOSI covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, long-term care facilities, hospices, and other healthcare or community settings. This NOSI encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure is encouraged. Study designs may include observational approaches, quasi-experimental designs, and interventional studies.

099801	<a href="#">Notice of Special Interest (NOSI): Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design Notice Number:</a>	National Institutes of Health/DHHS	NOT-AI-20-071	07-Jan-2022	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Que Dang, PhD
Contact Telephone	240-292-6181

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	<a href="mailto:que.dang@nih.gov">que.dang@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023
Synopsis	<p>The purpose of this Notice of Special Interest (NOSI) is to stimulate innovative studies to identify and understand the immune responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Studies may focus on any stage of mycobacterial infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational TB vaccines and may include HIV-infected or uninfected individuals. Research supported under this NOSI should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection, or by HIV/AIDS. Applications that include characterization of the timing, anatomical location, and contribution to disease outcome, of mucosal and/or systemic immune responses to mycobacterial infection and/or vaccination are sought. This research is expected to advance understanding of immune mechanisms in Mtb infection/vaccination and contribute to the advancement of new TB vaccines, including in populations also infected with HIV.</p>

099392	<a href="#">Notice of Special Interest (NOSI): Optimizing Precision Treatment of Gynecologic, Reproductive and Obstetrical Outcomes in Adolescents and Adults with PCOS and Associated Comorbid Conditions (Clinical Trial Optional)</a>	National Institutes of Health/DHHS	NOT-HD-20-026	07-Jan-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Esther Eisenberg, MD MPH
Contact Telephone	301-496-6516
Contact Email	<a href="mailto:esther.eisenberg@nih.gov">esther.eisenberg@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | The National Institute of Child Health and Human Development (NICHD) is issuing this Notice of Special Interest (NOSI) to announce the opportunity for investigators to apply for funding to optimize treatments of comorbid conditions in adolescents and reproductive age women with a diagnosis of Polycystic Ovary Syndrome (PCOS). The goals of this initiative are to stimulate interdisciplinary scientific collaboration between gynecologists/reproductive endocrinologists/obstetricians and subspecialists in diverse medical fields, including cardiologists, endocrinologists, gastroenterologists, psychiatrists, mental health professionals, pulmonologists, among others, to: 1) advance individualized treatments consistent with gynecologic, reproductive and obstetrical needs and desires; 2) promote translational and clinical research to increase knowledge and understanding of interaction of various therapies on gynecologic, reproductive and obstetric outcomes; and 3) discover and develop novel safe and more effective therapies for adolescents and women with PCOS with underlying comorbid conditions. Ultimately, this research would advance precision therapeutics for adolescents and adults with PCOS who have concomitant medical conditions.

100050	<a href="#">Notice of Special Interest (NOSI): Research on Rehabilitation Needs Associated with the COVID-19</a>	National Institutes of Health/DHHS	NOT-HD-20-031	07-Jan-2022	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Theresa Cruz, PhD.
Contact Telephone	301-496-9233
Contact Email	<a href="mailto:cruzth@mail.nih.gov">cruzth@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023
Synopsis	The purpose of this Notice of Special Interest is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation: Encourage research to address the rehabilitation needs of survivors of COVID-19 Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities Research applications addressing these topics are considered responsive; not all topics are expected within the same application. Applications will be directed to the National Center for Medical Rehabilitation Research (NCMRR) at NICHD.



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101780	<a href="#">Notice of Special Interest (NOSI): Promoting Research on Interoception and Its Impact on Health and Disease</a>	National Institutes of Health/DHHS	NOT-AT-21-002	07-Jan-2022	Not Specified
	<p>Contact Name   Wen G. Chen, M.MSc, Ph.D.</p> <p>Contact Telephone   301-451-3989</p> <p>Contact Email   <a href="mailto:chenw@mail.nih.gov">chenw@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis   The purpose of this NOSI is to promote innovative and rigorous research on interoception and its impact on health and disease. This initiative is broadly supported by many participating NIH institutes, centers, and offices (ICOs). For this NOSI, interoception includes the processes by which an organism senses, interprets, integrates, and regulates signals originating from within itself and represents its internal states. This NOSI encourages basic and clinical research projects that 1) combine diverse expertise; 2) develop and use innovative technologies and approaches to delineate interoceptive mechanisms at the molecular, cellular, circuit, functional, and/or behavioral levels; 3) assess pathophysiological processes of interoception in the context of diseases and disorders; 4) determine the impact of interventions and therapies to manipulate interoceptive processes on health and/or disease; and 5) develop and validate predictive biomarkers, computational models, or artificial intelligence models relevant to interoception and its impact on health and disease.</p>				
104076	<a href="#">Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PA-21-180	07-Jan-2022	450,000 USD
	<p>Contact Name   Keisher Highsmith, DrPH</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:duffys@nida.nih.gov">duffys@nida.nih.gov</a></p> <p>Sponsor Website  </p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities.</p>				
104057	<p><a href="#">Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)</a></p>	National Institutes of Health/DHHS	PA-21-219	07-Jan-2022	275,000 USD
	<p>Contact Name Karrah Benson</p> <p>Contact Telephone 301-496-0838</p> <p>Contact Email <a href="mailto:Karrah.benson@nih.gov">Karrah.benson@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. While this funding opportunity also accepts clinical trials, only applications proposing “mechanistic clinical trials or studies” (studying pathophysiology or mechanism of action of an intervention, but not safety or</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

efficacy) or basic experimental studies with humans (BESH) will be supported. For information on NIH clinical trial definitions and the types of clinical trials that are within scope of this funding opportunity announcement refer to the NIH Definition of a Clinical Trial page and the Funding Opportunity Description, below, respectively.

104053	<a href="#">Notice of Special Interest (NOSI): Biology of Lung and Head and Neck Preneoplasia</a>	National Institutes of Health/DHHS	NOT-CA-21-057	07-Jan-2022	Not Specified
	Contact Name	Ron Johnson, Ph.D.			
	Contact Telephone	240-276-6250			
	Contact Email	<a href="mailto:rjohnso2@mail.nih.gov">rjohnso2@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023			
	Synopsis	<p>This Notice of Special Interest (NOSI) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to invasive lung and head and neck (HN) cancers. Despite having better molecular understanding of lung and HN cancers and improved therapies for affected patients, these tumors remain a major health problem in the United States (US) and globally. While molecular markers of early injury of the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. In addition, growing evidence highlights the importance of the interaction between the immune system and cancer development. In recent years, immune-based therapies (especially, checkpoint inhibitors) have come to the forefront of standard therapies for many malignancies including lung and HN cancers. However, little is known about the immune regulation of premalignancy, including lung and HN preneoplasias. A functional understanding of the key molecular and cellular changes involved in the formation and advancement of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective, rationally designed, preventive and therapeutic strategies.</p>			
103986	<a href="#">Notice of Special Interest (NOSI): Early-life Factors and Cancer Development Later in Life</a>	National Institutes of Health/DHHS	NOT-CA-21-074	20-Oct-2021	Not Specified
	Contact Name				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 20-Oct-2021 , 08-Nov-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 24-Feb-2022 , 07-Mar-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 24-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 20-Oct-2022 , 08-Nov-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-Mar-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Nov-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to stimulate research focused on the roles of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life.</p>				
105890	<a href="#">Notice of Special Interest (NOSI): Precision Imaging of Oral Lesions</a>	National Institutes of Health/DHHS	NOT-DE-21-010	07-Jan-2022	Not Specified
	<p>Contact Name Zhong Chen, MD, PhD</p> <p>Contact Telephone 301-529-7083</p> <p>Contact Email <a href="mailto:zhong.chen@nih.gov">zhong.chen@nih.gov</a></p> <p>Sponsor Website</p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis Diagnosing and treating lesions of the oral cavity and oropharynx are challenging due to reliance on subjective analyses of clinical features and histopathological diagnostic criteria. High resolution and quantitative tools are needed to enhance the precision of diagnostic approaches for oral pathologies to guide options for treatment. This Notice of Special Interest (NOSI) is to encourage research projects that develop, adapt, optimize, and validate imaging-based applications and data analysis tools to enhance oral disease detection, diagnosis, and treatment. The long-term goal is to facilitate translation of research findings into clinical practice, paving the way for personalized health care through objective</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	measures that promote accurate and timely diagnosis, targeted therapies, and improved patient survival and quality of life.				
105889	<a href="#">Notice of Special Interest (NOSI): Somatic Cell Gene Editing Therapies To Improve Transplantation Outcomes</a>	National Institutes of Health/DHHS	NOT-AI-21-067	07-Jan-2022	Not Specified
	<p>Contact Name: Nasrin Nabavi, Ph.D.</p> <p>Contact Telephone: 240-627-3538</p> <p>Contact Email: <a href="mailto:nnabavi@mail.nih.gov">nnabavi@mail.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024</p> <p>Synopsis: The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting research that applies somatic cell gene editing (SCGE) approaches to improve graft survival and outcomes for recipients of allogenic solid organ, pancreatic islet, or vascularized composite allograft (VCA) transplants in animal models or human tissues or organs excluded from clinical use.</p>				
105732	<a href="#">Notice of Special Interest (NOSI): Immune Responses to Arthropod Feeding on Vertebrate Hosts</a>	National Institutes of Health/DHHS	NOT-AI-21-059	07-Jan-2022	Not Specified
	<p>Contact Name: Qian "Joy" Liu, M.D., MSc.</p> <p>Contact Telephone: 301-761-6621</p> <p>Contact Email: <a href="mailto:liujoy@niaid.nih.gov">liujoy@niaid.nih.gov</a></p> <p>Sponsor Website:</p> <p>Program URL: <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL): 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024

Synopsis This Notice of Special Interest (NOSI) solicits transdisciplinary research projects to understand the immunologic events in the vertebrate host that occur at the bite site (skin) and systemically during and after feeding by hematophagous and ectoparasitic arthropods. Exploratory research on arthropod blood feeding was formerly supported by NIAID through the expired FOA, PAR-18-860, "Immune Response to Arthropod Blood Feeding (R21 Clinical Trial Not Allowed). The intent of this NOSI is to indicate continued NIAID support for research in this area as described below through applications to the parent R01 and R21 FOAs.

088012	<a href="#">Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)</a>	National Institutes of Health/DHHS	PAR-20-082	07-Jan-2022	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	David M. Panchision, Ph.D.
Contact Telephone	301-443-5288
Contact Email	<a href="mailto:panchisiond@mail.nih.gov">panchisiond@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023
Synopsis	This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high reward projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may wish to apply to the companion R01 mechanism (PAR-20-NNN).

100292	<a href="#">Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-028	07-Jan-2022	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Enrique L. Michelotti, Ph.D.
--------------	------------------------------

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone | 301-443 5415  
 Contact Email | [michelottiel@mail.nih.gov](mailto:michelottiel@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024  
 Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in: 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI and/or NIA; and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be the discovery of cell-based chemical probes. Applicants interested in developing in vivo chemical probes may wish to apply using the companion R01 mechanism, (PAR-21-029).

103419	<a href="#">Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health</a>	National Institutes of Health/DHHS	NOT-OD-21-100	14-Dec-2021	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name | Wendy Nelson, PhD, MPH  
 Contact Telephone | 240-276-6971  
 Contact Email | [nelsonw@mail.nih.gov](mailto:nelsonw@mail.nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 14-Dec-2021 , 07-Jan-2022 , 05-Feb-2022 , 15-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 10-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 14-Dec-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 10-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024

Synopsis

This Notice of Special Interest (NOSI) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR) with participation from multiple NIH Institutes, Centers, and Offices. This NOSI calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. The specific research interests of participating NIH Institutes and Centers are detailed within.

103312	<a href="#">Notice of Special Interest (NOSI): Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being</a>	National Institutes of Health/DHHS	NOT-OD-21-087	07-Jan-2022	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Bramaramba Kowtha MS, RDN, LDN
Contact Telephone	301-435-8052
Contact Email	<a href="mailto:bramaramba.kowtha@nih.gov">bramaramba.kowtha@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024
Synopsis	<p>The Office of Disease Prevention and participating ICOs are issuing this Notice to highlight our interest in encouraging highly innovative and promising translational research to improve our understanding of how to increase and maintain health-enhancing physical activity using multi-level interventions in a wide range of population groups across the lifespan (e.g., including racial and ethnic minorities, children, older adults, persons with medical/behavioral health conditions, and persons with disabilities). This includes efficacy, effectiveness and dissemination and implementation studies. It also includes support for pilot, exploratory, or developmental work in preparation for full-scale, fully powered efficacy studies, preliminary feasibility studies, as well as expanded feasibility work for a discrete, specified, circumscribed project that is based on well-established theory, existing data and evidence-based interventions.</p>



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

103541	<a href="#">Notice of Special Interest (NOSI): Research on Strategies to Enhance Mental Health Interventions and Services within Employment and Job Training Settings</a>	National Institutes of Health/DHHS	NOT-MH-21-230	07-Jan-2022	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Stephen O'Connor, Ph.D.
Contact Telephone	301-480-8366
Contact Email	<a href="mailto:stephen.o'connor2@nih.gov">stephen.o'connor2@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 15-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 07-Sep-2023
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to encourage research focused on detection and intervention to prevent or treat mental health concerns, symptoms or disorders including drug-related conditions among unemployed and underemployed people participating in employment programs and job training settings (referred to here as “employment service customers” or “customers”). Considering the COVID-19 pandemic, the sharp rise and potentially long duration of unemployment raises concerns about the development and worsening of mental health symptoms and disorders, drug use behaviors, and suicide risk and necessitates further research to confirm the efficacy or demonstrate effectiveness of strategies in this area.

103244	<a href="#">Notice of Special Interest (NOSI): Research to Advance the Understanding and Management of the Multiple Organ Dysfunction Syndrome in Children (R01, R21)</a>	National Institutes of Health/DHHS	NOT-HD-21-024	07-Jan-2022	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Robert Tamburro, MD, MSc
Contact Telephone	301-451-4295
Contact Email	<a href="mailto:robert.tamburro@nih.gov">robert.tamburro@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 06-Feb-2023 , 07-May-2023</p> <p>Synopsis   The purpose of this Notice of Scientific Interest (NOSI) is to continue a program of research to advance the understanding, prevention and treatment of pediatric multiple organ dysfunction syndrome (MODS). MODS is a clinical condition commonly encountered in the pediatric intensive care unit that is associated with significant morbidity and mortality. It is characterized by the failure or dysfunction of a consistent group of body organs or organ systems. It is triggered by a wide range of disease processes and clinical insults, most notably sepsis and trauma, and is frequently associated with uncontrolled inflammation. Despite its high prevalence and unfavorable outcomes, this clinical entity remains poorly understood. First described over 40 years ago, it still can only be described as a “syndrome,” a constellation of symptoms, rather than as a specific pathologic entity with a distinguishable cause. The current lack of understanding underscores the need for more basic, exploratory and longitudinal research. Applications may include any appropriate study design ranging from basic science and animal models through prospective randomized controlled trials. It is hoped that as a result of research solicited through this NOSI, outcomes will improve both in terms of the prevention and treatment of MODS in children. Applicants planning to submit an application in response to this NOSI are strongly encouraged to contact the NICHD scientific/programmatic contact(s) listed on this NOSI in advance of the application due date.</p>				
106126	<a href="#">Notice of Special Interest (NOSI): Social, Behavioral, and Economic Impact of COVID-19 in Underserved and Vulnerable Populations</a>	National Institutes of Health/DHHS	NOT-MH-21-330	07-Jan-2022	Not Specified
	<p>Contact Name   Adam Haim, Ph.D.</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:haima@mail.nih.gov">haima@mail.nih.gov</a></p> <p>Sponsor Website  </p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022 , 05-Feb-2022 , 08-Feb-2022 , 15-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 04-Oct-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 06-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 03-Oct-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 06-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 ,</p>				

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis

05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024

NIH Institutes, Centers, and Offices participating in the Social, Behavioral, and Economic Impacts of COVID-19 in Vulnerable and Health Disparity Populations initiative are issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the understanding and response to the Coronavirus Disease 2019 (COVID-19) pandemic and help us prepare more effectively for future public health emergencies. While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, there are additional urgent public health needs, particularly in populations who experience health disparities and in vulnerable populations. The purpose of this Notice is to 1) emphasize the roles and impacts of interventions, particularly those under the umbrella of digital health, as well as community-engaged and multi-level interventions in healthcare settings to address access, reach, delivery, engagement, effectiveness, scalability, and sustainability of services that are utilized during and following the pandemic, and 2) encourage the leveraging of existing large-scale data sources with broad population coverage to improve prediction of various mitigation efforts (including vaccinations, masking, and physical distancing to inform the public health response) on transmission reduction and on social and economic impacts, and assess the downstream health and healthcare access effects, with an emphasis on underserved and vulnerable populations. Additionally, the use of large-scale data sources to study the indirect health impacts of the pandemic and subsequent social and economic changes is needed to understand the costs and benefits of various COVID-19 mitigation strategies.

106131	<a href="#">Notice of Special Interest (NOSI): Maximizing the Scientific Value of Secondary Analyses of Existing Cohorts and Datasets in Order to Address Research Gaps and Foster Additional Opportunities in Aging Research</a>	National Institutes of Health/DHHS	NOT-AG-21-020	07-Jan-2022	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Rosalyn Correa-de-Araujo, MD, MSc, Ph.D.
Contact Telephone	301-496-6762
Contact Email	<a href="mailto:rosaly.correa-de-Araujo@nih.gov">rosaly.correa-de-Araujo@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024

Synopsis

The goal of this Notice of Special Interest (NOSI) is to encourage the use of existing cohorts and datasets for well-focused secondary analyses to investigate novel scientific ideas and/or address clinically related issues on: (1) aging changes influencing health across the lifespan (e.g., Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD)), (2) diseases and disabilities in older persons, and/or (3) the changes in basic biology of aging that underlie these impacts on health (the hallmarks of aging). Activities of high priority include those addressing specific hypotheses in basic biological research, clinical aging research, behavioral or social research, and/or translational geroscience to inform: the design and implementation of future epidemiologic or human intervention studies; interventions in animal models of aging; research on behavioral and social factors over the life course that influence health (e.g., early life adversity); current geriatric practice in maintenance of health, disease management, and prevention of disability; or research testing of possible causal relationships between rates of aging and findings extracted by secondary analysis of the existing data. Existing datasets may also be used to develop and test new mathematical modeling and statistical analytical approaches. Analyses of sex and/or gender differences across health disparity groups (e.g., racial and ethnic groups, socioeconomic status, and sexual and gender minorities) are of high relevance. Use of cohorts that are linked to electronic health record systems and/or Centers for Medicare and Medicaid Services (CMS) administrative data are especially welcome. Applicants responding to this NOSI are strongly encouraged to describe plans for rapid sharing of data and results as well as innovative data analytics approaches (see Goal 3, NIH Strategic Plan For Data Science). Please note that applications proposing exploratory or developmental projects should consider using PA-20-195, whereas projects that already have sufficient preliminary data or a very strong and well-developed scientific premise should use PA-20-185.

106119	<a href="#">Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-21-313	07-Jan-2022	375,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Katrina J. Serrano, Ph.D.
Contact Telephone	301-480-7855
Contact Email	<a href="mailto:katrina.serrano@nih.gov">katrina.serrano@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or the National Human Genome Research Institute (NHGRI). New investigators at the time of award under this FOA will have had less than \$125,000 direct costs of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate transition to research independence. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.			
076848	<a href="#">NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)</a>	National Library of Medicine/NIH/DHHS	PAR-18-896	07-Jan-2022	1,000,000 USD
	Contact Name	Dr. Hua-Chuan Sim			
	Contact Telephone	301-594-4882			
	Contact Email	<a href="mailto:simh@mail.nih.gov">simh@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022			
	Synopsis	National Library of Medicine (NLM) offers support for innovative research and development in biomedical informatics and data science. The scope of NLM's interest in these research domains is broad, with emphasis on new methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, reusable approaches to discovery, curation, analysis, organization and management of health-related digital objects. Biomedical informatics and data science draw upon many fields, including mathematics, statistics, information science, computer science and engineering, and social/behavioral sciences. Application domains include health care delivery, basic biomedical research, clinical and translational research, precision medicine, public health, biosurveillance, health information management in disasters, and similar areas. NLM defines biomedical			

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

informatics as the science of optimal representation, organization, management, integration and presentation of information relevant to human health and biology. NIH defines data science as the interdisciplinary field of inquiry in which quantitative and analytical approaches, processes, and systems are developed and used to extract knowledge and insights from increasingly large and/or complex sets of data. This FOA will use the NIH Research Project (R01) award mechanism.

099844	<a href="#">Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)</a>	National Library of Medicine/NIH/DHHS	PAR-20-304	07-Jan-2022	1,000,000 USD
--------	---	---------------------------------------	------------	-------------	---------------

Contact Name	Alan VanBiervliet, PhD
Contact Telephone	301-594-4882
Contact Email	<a href="mailto:vanbiervlietaq@mail.nih.gov">vanbiervlietaq@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023
Synopsis	National Library of Medicine (NLM) wishes to accelerate the availability of and access to secure, complete data sets and computational models that can serve as the basis of transformative biomedical discoveries by improving the speed and scope of the curation processes.

095761	<a href="#">Administrative Supplements for Research on Dietary Supplements (Admin Supp Clinical Trial Not Allowed)</a>	Office of Dietary Supplements/NIH/DHHS	PA-20-227	15-Jan-2022	Not Specified
--------	--	--	-----------	-------------	---------------

Contact Name	Cindy Davis
Contact Telephone	301-496-0168
Contact Email	<a href="mailto:davisci@mail.nih.gov">davisci@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	15-Jan-2022 , 15-Apr-2022 , 15-Oct-2022 , 15-Jan-2023 , 15-Apr-2023
Synopsis	This Funding Opportunity Announcement (FOA) announces the availability of administrative

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

supplements to support research in which the supplemental funding would investigate the role of dietary supplements and/or their ingredients in health maintenance and disease prevention. Parent awards need not be focused on dietary supplements; this FOA may provide support to include dietary supplements within the scope of relevant research projects. Research interests of ODS are not limited to specific health conditions, organ systems or population groups. ODS supports all types of research, including pre-clinical, clinical, behavioral, and epidemiological. Additionally, ODS supports research and training programs that build future research capacity for studying the role of dietary supplements in health and disease prevention. Primary consideration for support will be given to applications that stimulate dietary supplement research where it is lacking or lagging, clarify gaps, opportunities and balance between benefits and risks where data are in conflict, target special population groups where additional science on dietary supplements is needed, and focus on the use of dietary supplements in improving or maintaining health and reducing the risk of chronic disease. This FOA will not support new clinical trials.

103971	<a href="#">Limited Competition: Development and Renovation of Research Space for HIV/AIDS Research at Institutions Serving Underrepresented Populations or Located in Institutional Development Award (IDeA)-eligible States (C06 Clinical Trial Not Allowed)</a>	Office of Research Infrastructure Programs/NIH/DHHS	PAR-21-238	06-Jan-2022	2,000,000 USD
--------	--	---	------------	-------------	---------------

Contact Name | Guanghu Wang, Ph.D., M.B.A  
 Contact Telephone | 301-435-0772  
 Contact Email | [guanghu.wang@nih.gov](mailto:guanghu.wang@nih.gov)  
 Sponsor Website |  
 Program URL | [Link to program URL](#)  
 Deadline Dates (ALL) | 06-Jan-2022

Synopsis | This Funding Opportunity Announcement (FOA) invites applications from qualified research institutions to seek funds to develop or renovate research facilities that support HIV/AIDS research in areas of basic, translational, clinical, and social and behavioral science research. Targeted are institutions that serve underrepresented and underserved populations or that are in Institutional Development Award (IDeA)-eligible states. Research-intensive institutions are not eligible. The facilities must support research aligned with the NIH-established priorities for HIV/AIDS research. Any request must be justified by current and anticipated future research needs.

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
103868	<a href="#">Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R41/R42 Clinical Trial Not Allowed)</a>	Office of Research Infrastructure Programs/NIH/DHHS	PAR-21-226	05-Jan-2022	Not Specified
	Contact Name	Miguel Contreras, Ph.D.			
	Contact Telephone	301-594-9410			
	Contact Email	<a href="mailto:contre1@mail.nih.gov">contre1@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jan-2022 , 05-Apr-2022 , 05-Sep-2022 , 05-Jan-2023 , 05-Apr-2023 , 05-Sep-2023 , 05-Jan-2024 , 05-Apr-2024 , 05-Sep-2024			
	Synopsis	This funding opportunity announcement (FOA) encourages applications from small business concerns (SBCs) for Small Business Technology Transfer (STTR) projects to facilitate the design, creation, and implementation of novel tools and devices for the health and management of research animals, and to advance equipment that improves the operation and environmental conditions of animal facilities that support biomedical and bio-behavioral research.			
103867	<a href="#">Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed)</a>	Office of Research Infrastructure Programs/NIH/DHHS	PAR-21-225	05-Jan-2022	Not Specified
	Contact Name	Miguel Contreras, Ph.D.			
	Contact Telephone	301-594-9410			
	Contact Email	<a href="mailto:contre1@mail.nih.gov">contre1@mail.nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	05-Jan-2022 , 05-Apr-2022 , 05-Sep-2022 , 05-Jan-2023 , 05-Apr-2023 , 05-Sep-2023 , 05-Jan-2024 , 05-Apr-2024 , 05-Sep-2024			
	Synopsis	This funding opportunity announcement (FOA) encourages applications from small business concerns (SBCs) for Small Business Innovation Research (SBIR) projects to facilitate the design, creation, and implementation of novel tools and devices for the health and management of research animals, and to advance equipment that improves the operation and environmental conditions of animal facilities that			



## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| support biomedical and bio-behavioral research.

101526	<a href="#">Limited Competition: Specific Pathogen Free Macaque Colonies (U42 Clinical Trial Not Allowed)</a>	Office of Research Infrastructure Programs/NIH/DHHS	PAR-21-089	07-Jan-2022	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Sheri Hild, Ph.D.
Contact Telephone	301-594-8937
Contact Email	<a href="mailto:sheri.hild@nih.gov">sheri.hild@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 07-May-2022 , 07-Sep-2022 , 07-Jan-2023 , 07-May-2023 , 07-Sep-2023 , 07-Jan-2024
Synopsis	The purpose of this Funding Opportunity Announcement is to provide continuing support for specific pathogen-free (SPF) macaque colonies previously funded under the auspices of PAR-18-669 and PAR-14-066. Breeding colonies are essential to sustain appropriate macaques for research related to Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS). Pedigree SPF macaques are free of certain viruses, which may confound the results of HIV/AIDS-related investigations or present a risk to the personnel who care for the animals. The SPF macaques are genetically characterized for major histocompatibility complex (MHC) class I types, because MHC class I genotypes have large effects on macaque immune responses to Simian Immunodeficiency Virus (SIV, which can induce AIDS in nonhuman primates (NHP)) and on human immune responses to HIV.

095227	<a href="#">Limited Competition: National Primate Research Centers (P51) (Clinical Trials Not Allowed)</a>	Office of Research Infrastructure Programs/NIH/DHHS	PAR-20-181	25-Jan-2022	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Sheri Ann Hild, PhD
Contact Telephone	301-594-8937
Contact Email	<a href="mailto:hildsa@mail.nih.gov">hildsa@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	25-Jan-2022 , 25-May-2022 , 25-Sep-2022 , 25-Jan-2023 , 25-May-2023

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p>	<p>This FOA encourages grant applications that support the activities of the National Primate Research Centers (NPRCs). Nonhuman primates (NHPs) are most closely related to humans, both physiologically and genetically. Therefore, NHPs are critical animal models for basic and translational research aimed at understanding human biology, both in normal and diseased states. Proper husbandry and management of NHPs require specialized physical and intellectual resources, which are most effectively and economically provided in centralized primate centers, the resources of which are made available to investigators on a national basis. The NPRCs provide these resources to investigators/grantees who utilize NHPs in biomedical research and thereby complement and help enable the missions of the NIH Institutes and Centers.</p>			
085529	<p><a href="#">RFA-OD-19-027--Resource-Related Research Projects for Development of Animal Models and Related Materials (R24 Clinical Trials Not-Allowed)</a></p>	<p>Office of Research Infrastructure Programs/NIH/DHHS</p>	<p>RFA-OD-19-027</p>	<p>10-Jan-2022</p>	<p>Not Specified</p>
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Stephanie Murphy, VMD, PhD</p> <p>301-451-7818</p> <p><a href="mailto:stephanie.murphy@nih.gov">stephanie.murphy@nih.gov</a></p> <p></p> <p><a href="#">Link to program URL</a></p> <p>10-Jan-2022 , 26-Jan-2022 , 10-May-2022 , 26-May-2022 , 08-Sep-2022</p> <p>The Office of Research Infrastructure Programs (ORIP) encourages grant applications aimed at developing, characterizing or improving animal models of human diseases; improving access to information about or generated from the use of animal models of human disease; or improving diagnosis and control of diseases of laboratory animals. The animal models and related materials developed must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIP's trans-NIH mission. Applications must describe the need and potential impact of the proposed resources on broad research areas supported by multiple NIH ICs. Applications to develop models that relate strictly to a specific disease or a select area of research will not be considered acceptable. Projects that predominantly address the research interests of one NIH IC but are only peripherally related to the research interests of other Institutes and Centers will also not be acceptable for this FOA.</p>			
088104	<p><a href="#">Animal and Biological Material Resource Centers (P40) (Clinical Trials Not-Allowed)</a></p>	<p>Office of Research Infrastructure</p>	<p>RFA-OD-20-002</p>	<p>07-Jan-2022</p>	<p>Not Specified</p>

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

### Programs/NIH/DHHS

Contact Name	Oleg Mirochnitchenko, Ph.D.
Contact Telephone	301-435-0748
Contact Email	<a href="mailto:oleg.mirochnitchenko@mail.nih.gov">oleg.mirochnitchenko@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 26-Jan-2022 , 07-May-2022 , 26-May-2022 , 07-Sep-2022 , 27-Sep-2022 , 07-Jan-2023
Synopsis	<p>This FOA encourages grant applications for national Animal and Biological Material Resource Centers. These Centers provide support for special colonies of laboratory animals, as well as other resources such as informatics tools, reagents, cultures (cells, tissues, and organs) and genetic stocks that serve the biomedical research community in a variety of research areas on a local, regional, and national basis. The important mission of the projects described by this FOA is to provide research resources, which are facilitating the optimization and enhancement of scientific rigor, transparency and experimental reproducibility of biomedical research. Proposed Animal and Biological Material Resource Centers must have broad application to multiple NIH Institutes or Centers (ICs) to align with the ORIP's trans-NIH mission (<a href="https://orip.nih.gov/about-orip">https://orip.nih.gov/about-orip</a>). This funding opportunity is designed to support both continuation of existing resources and to develop new ones when appropriate. Prior to preparing an application, all applicants are strongly encouraged to consult with Scientific/Research staff to be advised on appropriateness of the intended resource plans for this program, competitiveness of a potential application, and ORIP's program priorities.</p>

102835	<a href="#">Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)</a>	Office of Research Infrastructure Programs/NIH/DHHS	PAR-21-167	07-Jan-2022	275,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Sige Zou, Ph.D.
Contact Telephone	301-435-0749
Contact Email	<a href="mailto:zous@mail.nih.gov">zous@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-

## NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024 , 16-Feb-2024 , 07-May-2024</p> <p>This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs' (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC, will be considered not acceptable to this FOA and will be withdrawn.</p>				
079634	<a href="#">Methods Development for Cryogenic or Other Long-term Preservation and Revival of Drosophila and Zebrafish Genetic Stocks (R21 Clinical Trial Not Allowed)</a>	Office of Research Infrastructure Programs/NIH/DHHS	PAR-19-176	07-Jan-2022	275,000 USD
	<p>Contact Name: Sigé Zou, Ph.D.            Contact Telephone: 301-435-0749            Contact Email: <a href="mailto:zous@mail.nih.gov">zous@mail.nih.gov</a>            Sponsor Website:            Program URL: <a href="#">Link to program URL</a>            Deadline Dates (ALL): 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis: This funding opportunity announcement (FOA) supports exploratory research projects aimed at developing cryogenic or other long-term preservation and revival approaches for Drosophila or zebrafish genetic stocks, which are essential laboratory animal models for biomedical research. The proposed project should address critical knowledge and technology gaps and describe approaches towards the development of reliable, easy-to-use and cost effective cryogenic or other long-term preservation and revival methods for wild-type and mutant strains of Drosophila or zebrafish.</p>				

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
106192	<a href="#">Ecology and Evolution of Infectious Diseases (EEID)</a>	National Science Foundation	21-609	24-Nov-2021	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Katharina Dittmar</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>703-292-7799</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:kdittmar@nsf.gov">kdittmar@nsf.gov</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td><a href="#">Link to sponsor website</a></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>24-Nov-2021 , 16-Nov-2022</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td> <p>The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, organismal, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease (re)emergence and transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of (re)emergence and transmission among any host species, including but not limited to humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of vectors and reservoir species or hosts; how the physiology or behavior of the pathogen, vector, or host species biology affects transmission dynamics; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission and disease. Research may be on zoonotic, environmentally-borne, vector-borne, enteric, or respiratory pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to Low- or Middle-Income Countries (LMICs) are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, behaviorists, epidemiologists, evolutionary biologists, entomologists, immunologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases.</p> </td> </tr> </table>					Contact Name	Katharina Dittmar	Contact Telephone	703-292-7799	Contact Email	<a href="mailto:kdittmar@nsf.gov">kdittmar@nsf.gov</a>	Sponsor Website	<a href="#">Link to sponsor website</a>	Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	24-Nov-2021 , 16-Nov-2022	Synopsis	<p>The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, organismal, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease (re)emergence and transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of (re)emergence and transmission among any host species, including but not limited to humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of vectors and reservoir species or hosts; how the physiology or behavior of the pathogen, vector, or host species biology affects transmission dynamics; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission and disease. Research may be on zoonotic, environmentally-borne, vector-borne, enteric, or respiratory pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to Low- or Middle-Income Countries (LMICs) are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, behaviorists, epidemiologists, evolutionary biologists, entomologists, immunologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases.</p>
Contact Name	Katharina Dittmar																		
Contact Telephone	703-292-7799																		
Contact Email	<a href="mailto:kdittmar@nsf.gov">kdittmar@nsf.gov</a>																		
Sponsor Website	<a href="#">Link to sponsor website</a>																		
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	24-Nov-2021 , 16-Nov-2022																		
Synopsis	<p>The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, organismal, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease (re)emergence and transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of (re)emergence and transmission among any host species, including but not limited to humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of vectors and reservoir species or hosts; how the physiology or behavior of the pathogen, vector, or host species biology affects transmission dynamics; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission and disease. Research may be on zoonotic, environmentally-borne, vector-borne, enteric, or respiratory pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to Low- or Middle-Income Countries (LMICs) are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, behaviorists, epidemiologists, evolutionary biologists, entomologists, immunologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases.</p>																		
106509	<a href="#">NSF-DFG Lead Agency Activity in Chemistry and Transport in Confined Spaces (NSF-DFG Confine)</a>	National Science Foundation	21-626	29-Nov-2021 [LOI/Pre-App]	5,000,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Colby A. Foss</td> </tr> </table>					Contact Name	Colby A. Foss												
Contact Name	Colby A. Foss																		

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Contact Telephone	703-292-5327			
	Contact Email	<a href="mailto:NSFDFG@nsf.gov">NSFDFG@nsf.gov</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	29-Nov-2021 [LOI/Pre-App], 07-Mar-2022			
	Synopsis	<p>Recognizing the importance of international collaborations in promoting scientific discoveries, the National Science Foundation (NSF) and the Deutsche Forschungsgemeinschaft (German Research Foundation, DFG) have signed a Memorandum of Understanding (MoU) on research cooperation. The MoU provides an overarching framework to enhance opportunities for collaborative activities between US and German research communities and sets out the principles by which jointly-supported activities might be developed. To facilitate the support of collaborative work between US researchers and their German counterparts under this MoU, the Division of Chemistry (CHE) and the Division of Chemical, Bioengineering, Environmental and Transport Systems (CBET) at the NSF and the Divisions of Physics and Chemistry (PC) and Engineering Sciences (ING 1) at the DFG are pleased to announce a Lead Agency Opportunity in the areas of Chemistry and Transport in Confined Spaces. Chemical and physical processes that operate under spatial confinement often exhibit complex, interesting, and poorly understood variations in chemical properties and physical dynamics. Many such systems are intrinsically nonlinear and dynamic, often involving simultaneous reaction, diffusion and convection and/or chemical processes far from equilibrium. Improved experimental and computational tools are needed to predict how variations over the confinement length scale affect the overall dynamics and efficiency of large-scale processes. Much of the needed research requires synergistic efforts among those versed in the applications and experts in measurement techniques, modeling methods, and data analysis. The goal of this Lead Agency Opportunity is to reduce current barriers to working internationally by allowing US and German researchers to submit a single collaborative proposal that will undergo a single review process while funding organizations maintain budgetary control over their awards. Proposals eligible for funding consideration through this Lead Agency Opportunity in FY 2022 will need to have a research focus relevant to the topic areas identified above, within the scope of research supported through these divisions.</p>			

106593	<a href="#">Emerging Frontiers in Research and Innovation 2021 (EFRI-2021)</a>	National Science Foundation	21-615	10-Nov-2021 [LOI/Pre-App]	2,000,000 USD
--------	--	-----------------------------	--------	---------------------------	---------------

	Contact Name	Sohi Rastegar			
	Contact Telephone	703-292-8305			
	Contact Email	<a href="mailto:srastega@nsf.gov">srastega@nsf.gov</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 10-Nov-2021 [LOI/Pre-App], 16-Dec-2021 [LOI/Pre-App], 10-Mar-2022 , 12-Sep-2022 [LOI/Pre-App], 13-Oct-2022 [LOI/Pre-App], 07-Feb-2023</p> <p>Synopsis The Emerging Frontiers in Research and Innovation (EFRI) program of the NSF Directorate for Engineering (ENG) serves a critical role in helping ENG focus on important emerging areas in a timely manner. This solicitation is a funding opportunity for interdisciplinary teams of researchers to embark on rapidly advancing frontiers of fundamental engineering research. For this solicitation, we will consider proposals that aim to investigate emerging frontiers in one of the following two research areas: Engineered Living Systems (ELiS); and Brain-Inspired Dynamics for Engineering Energy-Efficient Circuits and Artificial Intelligence (BRAID).</p>				
106410	<a href="#">ECosystem for Leading Innovation in Plasma Science and Engineering (ECLIPSE)</a>	National Science Foundation	PD-21-110Z	15-Nov-2021	Not Specified
	<p>Contact Name Raymond A. Adomaitis</p> <p>Contact Telephone 703-292-7519</p> <p>Contact Email <a href="mailto:radomait@nsf.gov">radomait@nsf.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Nov-2021</p> <p>Synopsis The ECLIPSE program has been created to foster an inclusive community of scientists and engineers, an ecosystem spanning multiple NSF Directorates, in the pursuit of translational research at the interface of fundamental plasma science and technological innovation. The ECLIPSE program builds on the long history of NSF leadership in supporting multi-disciplinary research in plasma science and engineering, and is intended to enhance organizational unity within NSF, and potentially with other funding agencies, in considering proposals and supporting projects that may otherwise struggle to find a natural home within the existing hierarchy of Directorates, Divisions, and programs within the Foundation.</p>				
099749	<a href="#">Collaborative Research in Computational Neuroscience (CRCNS)</a>	National Science Foundation	20-609	23-Nov-2021	1,250,000 USD
	<p>Contact Name Kenneth Whang</p> <p>Contact Telephone 703-292-5149</p> <p>Contact Email <a href="mailto:kwhang@nsf.gov">kwhang@nsf.gov</a></p>				

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 23-Nov-2021 , 22-Nov-2022</p> <p>Synopsis Computational neuroscience provides a theoretical foundation and a rich set of technical approaches for understanding complex neurobiological systems, building on the theory, methods, and findings of computer science, neuroscience, and numerous other disciplines. Through the CRCNS program, the U.S. National Science Foundation (NSF), National Institutes of Health (NIH), and Department of Energy (DOE); the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF); the French National Research Agency (Agence Nationale de la Recherche, ANR); the United States-Israel Binational Science Foundation (BSF); Japan’s National Institute of Information and Communications Technology (NICT); and Spain’s State Research Agency (Agencia Estatal de Investigación, AEI) and National Institute of Health Carlos III (Instituto de Salud Carlos III, ISCIII) support collaborative activities that will advance the understanding of nervous system structure and function, mechanisms underlying nervous system disorders, and computational strategies used by the nervous system.</p>				
105972	<p><a href="#">Harnessing the Data Revolution (HDR): Transdisciplinary Research in Principles of Data Science Phase II (TRIPODS) - HDR TRIPODS Phase II</a></p>	National Science Foundation	21-604	16-Nov-2021 [LOI/Pre-App]	Not Specified
	<p>Contact Name Funda Ergun</p> <p>Contact Telephone 703-292-8910</p> <p>Contact Email <a href="mailto:fergun@nsf.gov">fergun@nsf.gov</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 16-Nov-2021 [LOI/Pre-App], 18-Jan-2022</p> <p>Synopsis Harnessing the Data Revolution: Transdisciplinary Research In Principles Of Data Science Phase II (HDR TRIPODS Phase II) aims to bring together the electrical engineering, mathematics, statistics, and theoretical computer science communities to develop the theoretical foundations of data science through integrated research and training activities. Phase I, described in solicitation NSF 19-550, supported the development of small collaborative Institutes. Phase II, described in this solicitation, will support a smaller number of larger Institutes, selected from the Phase I Institutes via a second competitive proposal process. All HDR TRIPODS Institutes must involve significant and integral participation by researchers representing the four aforementioned communities. When responding to this solicitation, even though proposals must be submitted through the Directorate for Engineering, Division of Electrical, Communications, and Cyber Systems, once received, the proposals will be</p>				



## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| managed by a cross-disciplinary team of NSF Program Directors.

090168	<a href="#">ADVANCE: Organizational Change for Gender Equity in STEM Academic Professions (ADVANCE)</a>	National Science Foundation	20-554	03-Nov-2021	Not Specified
--------	---	-----------------------------	--------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis:</p>	<p>Jessie DeAro</p> <p>703-292-5350</p> <p><a href="mailto:ADVANCE@nsf.gov">ADVANCE@nsf.gov</a></p> <p><a href="#">Link to sponsor website</a></p> <p><a href="#">Link to program URL</a></p> <p>03-Nov-2021</p> <p>The NSF ADVANCE program contributes to the National Science Foundation's goal of a more diverse and capable science and engineering workforce. In this solicitation, the NSF ADVANCE program seeks to build on prior NSF ADVANCE work and other research and literature concerning gender, racial, and ethnic equity. The NSF ADVANCE program goal is to broaden the implementation of evidence-based systemic change strategies that promote equity for STEM faculty in academic workplaces and the academic profession. The NSF ADVANCE program provides grants to enhance the systemic factors that support equity and inclusion and to mitigate the systemic factors that create inequities in the academic profession and workplaces. Systemic (or organizational) inequities may exist in areas such as policy and practice as well as in organizational culture and climate. For example, practices in academic departments that result in the inequitable allocation of service or teaching assignments may impede research productivity, delay advancement, and create a culture of differential treatment and rewards. Similarly, policies and procedures that do not mitigate implicit bias in hiring, tenure, and promotion decisions could lead to women and racial and ethnic minorities being evaluated less favorably, perpetuating historical under-participation in STEM academic careers and contributing to an academic climate that is not inclusive.</p>
--	--

## Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

106950	<a href="#">Rural Communities Opioid Response Program-Implementation</a>	Office of Rural Health Policy/HRSA/DHHS	HRSA-22-057	13-Jan-2022	1,000,000 USD
--------	--	---	-------------	-------------	---------------

Contact Name	Sabrina Frost
Contact Telephone	301-945-5131
Contact Email	<a href="mailto:sfrost@hrsa.gov">sfrost@hrsa.gov</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	
Deadline Dates (ALL)	13-Jan-2022
Synopsis	The Health Resources and Services Administration (HRSA) is accepting applications for fiscal year (FY) 2022 Rural Communities Opioid Response Program-Implementation (RCORP-Implementation). RCORP is a multi-year initiative by HRSA aimed at reducing the morbidity and mortality of substance use disorder (SUD), including opioid use disorder (OUD), in high-risk rural communities. This funding opportunity, RCORPImplementation, will advance RCORP’s overall goal by strengthening and expanding SUD/OUD prevention, treatment, and recovery services to enhance rural residents’ ability to access treatment and move towards recovery.

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
060608	<a href="#">Research Innovation Collaborations Program</a>	23andme		14-Jan-2022	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%;">Contact Name</td> <td></td> </tr> <tr> <td>Contact Telephone</td> <td></td> </tr> <tr> <td>Contact Email</td> <td><a href="mailto:apply.research@23andme.com">apply.research@23andme.com</a></td> </tr> <tr> <td>Sponsor Website</td> <td><a href="#">Link to sponsor website</a></td> </tr> <tr> <td>Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td>14-Jan-2022</td> </tr> <tr> <td>Synopsis</td> <td>The 23andMe Research Innovation Collaborations Program pairs up academic researchers with 23andMe scientists to perform analyses. Through this program, academic researchers can access de-identified, aggregated data from the 23andMe Research Cohort.</td> </tr> </table>					Contact Name		Contact Telephone		Contact Email	<a href="mailto:apply.research@23andme.com">apply.research@23andme.com</a>	Sponsor Website	<a href="#">Link to sponsor website</a>	Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	14-Jan-2022	Synopsis	The 23andMe Research Innovation Collaborations Program pairs up academic researchers with 23andMe scientists to perform analyses. Through this program, academic researchers can access de-identified, aggregated data from the 23andMe Research Cohort.
Contact Name																			
Contact Telephone																			
Contact Email	<a href="mailto:apply.research@23andme.com">apply.research@23andme.com</a>																		
Sponsor Website	<a href="#">Link to sponsor website</a>																		
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	14-Jan-2022																		
Synopsis	The 23andMe Research Innovation Collaborations Program pairs up academic researchers with 23andMe scientists to perform analyses. Through this program, academic researchers can access de-identified, aggregated data from the 23andMe Research Cohort.																		
055772	<a href="#">Delivery System Science Fellowship</a>	AcademyHealth		03-Jan-2022	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%;">Contact Name</td> <td></td> </tr> <tr> <td>Contact Telephone</td> <td>202-292-6700</td> </tr> <tr> <td>Contact Email</td> <td><a href="mailto:dssf@academyhealth.org">dssf@academyhealth.org</a></td> </tr> <tr> <td>Sponsor Website</td> <td><a href="#">Link to sponsor website</a></td> </tr> <tr> <td>Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td>03-Jan-2022</td> </tr> <tr> <td>Synopsis</td> <td>The AcademyHealth Delivery System Science Fellowship (DSSF) provides a paid post-doctoral learning experience to help researchers gain more applied experience conducting research in delivery system settings. Students and researchers with an interest in conducting research in delivery system settings are encouraged to apply.</td> </tr> </table>					Contact Name		Contact Telephone	202-292-6700	Contact Email	<a href="mailto:dssf@academyhealth.org">dssf@academyhealth.org</a>	Sponsor Website	<a href="#">Link to sponsor website</a>	Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	03-Jan-2022	Synopsis	The AcademyHealth Delivery System Science Fellowship (DSSF) provides a paid post-doctoral learning experience to help researchers gain more applied experience conducting research in delivery system settings. Students and researchers with an interest in conducting research in delivery system settings are encouraged to apply.
Contact Name																			
Contact Telephone	202-292-6700																		
Contact Email	<a href="mailto:dssf@academyhealth.org">dssf@academyhealth.org</a>																		
Sponsor Website	<a href="#">Link to sponsor website</a>																		
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	03-Jan-2022																		
Synopsis	The AcademyHealth Delivery System Science Fellowship (DSSF) provides a paid post-doctoral learning experience to help researchers gain more applied experience conducting research in delivery system settings. Students and researchers with an interest in conducting research in delivery system settings are encouraged to apply.																		
043223	<a href="#">Anna D. Barker Fellowship in Basic Cancer Research</a>	American Association for Cancer		25-Jan-2022	110,000 USD														

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Research					
	<p>Contact Name</p> <p>Contact Telephone 215-446-7280</p> <p>Contact Email <a href="mailto:grants@aacr.org">grants@aacr.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 25-Jan-2022</p> <p>Synopsis The AACR Anna D. Barker Basic Cancer Research Fellowship encourages and supports postdoctoral or clinical research fellows to establish a successful career path in cancer research. The research proposed for funding may be in any area of basic cancer research. This fellowship provides \$110,000 over a two-year period.</p>				
071402	<a href="#">AADR Student Research Fellowships</a>	American Association for Dental Research		31-Jan-2022	2,100 USD
	<p>Contact Name Anthony Jones, Awards, Fellowships and Grants Coordinator</p> <p>Contact Telephone 703-548-0066</p> <p>Contact Email <a href="mailto:ajones@iadr.org">ajones@iadr.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 31-Jan-2022</p> <p>Synopsis AADR Student Research Fellowships have been created to encourage dental students living in the United States to consider careers in oral health research. Proposals are sought in basic and clinical research related to oral health.</p>				
076846	<a href="#">Jack D. Pressman-Burroughs Wellcome Fund Career Development Award</a>	American Association for the History of Medicine		31-Jan-2022	1,000 USD
	Contact Name Jessica Martucci				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email <a href="mailto:martuccj@gmail.com">martuccj@gmail.com</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 31-Jan-2022</p> <p>Synopsis This award and a stipend of \$1,000 is given yearly for outstanding work in twentieth-century history of medicine or medical biomedical sciences, as demonstrated by the completion of the Ph.D. and a proposal to turn the dissertation into a publishable monograph.</p>				
068422	<a href="#">Bridge Award</a>	American Association for the Study of Liver Diseases		22-Oct-2021	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone 703-299-9766</p> <p>Contact Email <a href="mailto:awards@asld.org">awards@asld.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 22-Oct-2021 , 18-Jan-2022</p> <p>Synopsis The AASLD Foundation Bridge Award supports investigators who have recently submitted an NIH R or other federally-funded equivalent award and have received competitive scores on their proposal, but were not funded, as they strengthen their proposal for resubmission to the NIH or other federal agency. Applicant must not have other federal funding or significant institutional bridge funding (greater than \$25,000, excluding PI salary support).</p>				
059175	<a href="#">Advanced/Transplant Hepatology Fellowship</a>	American Association for the Study of Liver Diseases		18-Jan-2022	4,000 USD
	Contact Name				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   703-299-9766</p> <p>Contact Email   <a href="mailto:awards@asld.org">awards@asld.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   18-Jan-2022</p> <p>Synopsis   The purpose of this award is to encourage the academic career of exceptional hepatology trainees. The Advanced/Transplant Hepatology Award provides \$5,000 in travel funds to fourth year Transplant Hepatology fellows or third year GI/Hepatology dual certification program fellows in accredited US, Canadian, or Mexican programs to attend The Liver Meeting® and one additional educational meeting (approved by the Research Awards Committee).</p>				

099951	<a href="#">Postdoctoral Research Fellowships</a>	American Epilepsy Society		14-Jan-2022	50,000 USD
--------	---	---------------------------	--	-------------	------------

	<p>Contact Name  </p> <p>Contact Telephone   312-883-3800</p> <p>Contact Email   <a href="mailto:grants@aesnet.org">grants@aesnet.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   14-Jan-2022</p> <p>Synopsis   Postdoctoral Research Fellowships support postdoctoral trainees conducting basic, translational, or clinical research into the causes, treatment, and consequences of epilepsy, seizures, and related disorders and their treatment under the guidance of a mentor with expertise in epilepsy research. The fellowship award offers up to \$49,000 for stipend and/or benefits, \$1,000 for travel support to the AES annual meeting, as well as one year of complimentary AES membership and registration for the AES annual meeting.</p>				
--	--	--	--	--	--

099952	<a href="#">Predoctoral Research Fellowships</a>	American Epilepsy Society		14-Jan-2022	30,000 USD
--------	--	---------------------------	--	-------------	------------

	Contact Name				
--	--------------	--	--	--	--

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 312-883-3800</p> <p>Contact Email <a href="mailto:grants@aesnet.org">grants@aesnet.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Jan-2022</p> <p>Synopsis AES Predoctoral Research Fellowships support predoctoral students pursuing dissertation research with an epilepsyrelevant theme under the guidance of a mentor with expertise in epilepsy research. The research can encompass basic, translational, or clinical research into the causes, treatment, and consequences of epilepsy, seizures, and related disorders and their treatment. The fellowship award offers up to \$30,000 with \$29,000 for stipend and and/or benefits, \$1,000 to support attendance at the AES annual meeting, as well as one year of complimentary AES membership and registration for the AES annual meeting.</p>				
099948	<a href="#">Research and Training Fellowships for Clinicians</a>	American Epilepsy Society		14-Jan-2022	50,000 USD
	<p>Contact Name Jennifer Brummet, PhD</p> <p>Contact Telephone 312-883-3800</p> <p>Contact Email <a href="mailto:grants@aesnet.org">grants@aesnet.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Jan-2022</p> <p>Synopsis AES Research and Training Fellowships for Clinicians (RTFC) provide mentored support for clinical fellows or clinical faculty who intend to pursue a career in epilepsy research. The fellowship award provides up to \$50,000 for one year, with \$49,000 for stipend and \$1,000 for travel support to attend the AES Annual Meeting, as well as complimentary registration to the AES Annual Meeting and one-year of complimentary AES membership.</p>				
099949	<a href="#">Epilepsy Study Consortium Mini Grant</a>	American Epilepsy Society		14-Jan-2022	22,000 USD

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 312-883-3800</p> <p>Contact Email <a href="mailto:grants@aesnet.org">grants@aesnet.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Jan-2022</p> <p>Synopsis The Epilepsy Study Consortium is sponsoring a mini-grant of up to \$22,000 for epilepsy fellows to undertake a mentored research project on anti-epileptic drug therapy during their fellowship training, and funds to support attendance at the AES Annual Meeting. The award does not require past experience with research or a specific percent protected time for research but instead focuses on the mentorship and training experience for the fellow. Applicants may request funding periods of six months to one year.</p>				
099950	<a href="#">Junior Investigator Research Awards</a>	American Epilepsy Society		14-Jan-2022	50,000 USD
	<p>Contact Name</p> <p>Contact Telephone 312-883-3800</p> <p>Contact Email <a href="mailto:grants@aesnet.org">grants@aesnet.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 14-Jan-2022</p> <p>Synopsis Junior Investigator Research Awards support epilepsy research by recently independent investigators and are intended to facilitate successful competition for subsequent longer-term support from the NIH or other sources. Proposals are welcome across the spectrum of basic, translational, or clinical research into the causes, treatment, and consequences of epilepsy, seizures, and related disorders and their treatment. This award provides up to \$50,000 for one year to support the direct costs of research.</p>				
000596	<a href="#">Junior Physician-Investigator Awards</a>	American Federation for Medical		15-Jan-2022	1,250 USD



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Research Foundation					
	Contact Name Contact Telephone 978-927-8330 Contact Email <a href="mailto:awards@afmr.org">awards@afmr.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 15-Jan-2022 Synopsis Junior Physician-Investigator Awards were created to honor young AFMR investigators whose research projects complement an overall program of research, teaching and clinical medicine.				
061500	<a href="#">ALA/ALVRE Research Grant</a>	American Laryngological Association		01-Dec-2021 [LOI/Pre-App]	11,000 USD
	Contact Name Maxine Cunningham Contact Telephone 615-812-6170 Contact Email <a href="mailto:maxine.c@comcast.net">maxine.c@comcast.net</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Dec-2021 [LOI/Pre-App], 14-Jan-2022 Synopsis The purpose of this award is to support basic, translational, or clinical research projects in laryngology (voice, airway, swallowing), outcomes, and related subjects, and should lead to furthering the fields of laryngology or neurolaryngology.				
035671	<a href="#">Seymour R. Cohen Research Grant</a>	American Laryngological Association		01-Dec-2021 [LOI/Pre-App]	15,000 USD
	Contact Name Maxine Cunningham				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 615-812-6170 Contact Email <a href="mailto:maxine.c@comcast.net">maxine.c@comcast.net</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Dec-2021 [LOI/Pre-App], 14-Jan-2022 Synopsis The purpose of this award is to support basic science research projects in the area of laryngology or neurolaryngology with relevance to the pediatric population, and should lead to furthering the fields of pediatric laryngology or pediatric neurolaryngology.				
058266	<a href="#">Overseas Assistance Grants</a>	American Medical Women's Association		05-Jan-2022	1,000 USD
	Contact Name Contact Telephone 847-517-2801 Contact Email <a href="mailto:associatedirector@amwa-doc.org">associatedirector@amwa-doc.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 05-Jan-2022 , 05-May-2022 , 05-Sep-2022 Synopsis The AWHS Overseas Assistance Grant provides assistance with transportation costs up to \$1,000 connected with pursuing medical studies in an off-campus setting where the medically neglected will benefit.				
071243	<a href="#">Development Grants</a>	American Neuromuscular Foundation		10-Jan-2022 [LOI/Pre-App]	50,000 USD
	Contact Name Contact Telephone 507-538-1037 Contact Email <a href="mailto:foundation@neuromuscularfoundation.org">foundation@neuromuscularfoundation.org</a>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 10-Jan-2022 [LOI/Pre-App], 14-Feb-2022 Synopsis The AANEM Foundation is offering development grants intended as seed money to help launch research into muscle and nerve disorders by promising new researchers.				
061501	<a href="#">Clinical Investigations Grant</a>	American Otological Society		01-Nov-2021 [LOI/Pre-App]	66,000 USD
	Contact Name Andrea Vambutas Contact Telephone 217-638-0801 Contact Email <a href="mailto:avambuta@northwell.edu">avambuta@northwell.edu</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Nov-2021 [LOI/Pre-App], 31-Jan-2022 Synopsis The purpose of the American Otological Society (AOS) Research Fund is to encourage and support academic research in sciences related to the ear.				
061551	<a href="#">Fellowship Grant</a>	American Otological Society		01-Nov-2021 [LOI/Pre-App]	44,000 USD
	Contact Name Andrea Vambutas, MD, Executive Secretary Contact Telephone 217-638-0801 Contact Email <a href="mailto:avambuta@northwell.edu">avambuta@northwell.edu</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 01-Nov-2021 [LOI/Pre-App], 31-Jan-2022 Synopsis The American Otological Society is committed to the non-promotional advancement of knowledge and science and to				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

a free exchange of medical education in otology and neurotology. All of the AOS grant awards may involve research on any topic related to ear disorders. The research need not be directly on an otological disease but may explore normal functions of the cochlea, labyrinth or central auditory or vestibular systems. However, the applicant must describe how the proposed research will benefit our understanding, diagnosis or treatment of otological disorders. Research supported by all of the grant mechanisms can relate to any aspects of the ear, hearing and balance disorders. Fellowships are \$44,000 for one year.

025077	<a href="#">Research Grants</a>	American Otological Society		01-Nov-2021 [LOI/Pre-App]	55,000 USD
--------	---------------------------------	-----------------------------	--	---------------------------	------------

Contact Name	Andrea Vambutas, MD, Executive Secretary
Contact Telephone	217-638-0801
Contact Email	<a href="mailto:avambuta@northwell.edu">avambuta@northwell.edu</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	01-Nov-2021 [LOI/Pre-App], 31-Jan-2022

Synopsis The American Otological Society is committed to the non-promotional advancement of knowledge and science and to a free exchange of medical education in otology and neurotology. The American Otological Society, through its Research Foundation, is offering Research Grant Awards. All of the AOS grant awards may involve research on any topic related to ear disorders. The research need not be directly on an otological disease but may explore normal functions of the cochlea, labyrinth or central auditory or vestibular systems. However, the applicant must describe how the proposed research will benefit our understanding, diagnosis or treatment of otological disorders. Research supported by all of the grant mechanisms can relate to any aspects of the ear, hearing and balance disorders.

063861	<a href="#">Catherine Acuff Congressional Fellowships</a>	American Psychological Association		03-Jan-2022	90,000 USD
--------	---	------------------------------------	--	-------------	------------

Contact Name	Ben Vonachen
Contact Telephone	202-336-5500

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:bvonachen@apa.org">bvonachen@apa.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 03-Jan-2022</p> <p>Synopsis The purpose of the APA Congressional Fellowship is to provide psychologists with an invaluable public policy learning experience, to contribute to the more effective use of psychological knowledge in government and to broaden awareness about the value of psychology-government interaction among psychologists and within the federal government. Applications for the APA Congressional Fellowship are reviewed as a single group. When selections are made, specialty designations may be given to incoming Fellows who fit the criteria. Applicants for the Catherine Acuff Fellow must have five or more years of professional experience post-doctorate.</p>				
089368	<a href="#">Educational Scholarship</a>	American Society for Laser Medicine and Surgery, Inc.		09-Jan-2022	1,000 USD
	<p>Contact Name Amy Rauman, Education Program Manager</p> <p>Contact Telephone 715-845-9283</p> <p>Contact Email <a href="mailto:abstracts@aslms.org">abstracts@aslms.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 09-Jan-2022</p> <p>Synopsis Educational Scholarships are available for select students and medical/research trainees who submit an abstract and are accepted as the presenting author for oral presentation at the Annual Conference.</p>				
079445	<a href="#">ASM Infectious Disease (ID) Travel Award (Temporarily Suspended)</a>	American Society for Microbiology		26-Jan-2022	1,000 USD
	<p>Contact Name</p> <p>Contact Telephone 202-942-9317</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email <a href="mailto:asmcuc@asmusa.org">asmcuc@asmusa.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 26-Jan-2022 Synopsis The Travel Award Committee will award a limited number of travel awards to support recipients' travel to ASM Microbe 2020.				
086633	<a href="#">American Society of Animal Science Award for Industry Innovation</a>	American Society of Animal Science		14-Jan-2022	Not Specified
	Contact Name Contact Telephone 217-356-9050 Contact Email <a href="mailto:asas@asas.org">asas@asas.org</a> Sponsor Website <a href="#">Link to sponsor website</a> Program URL <a href="#">Link to program URL</a> Deadline Dates (ALL) 14-Jan-2022 Synopsis The American Society of Animal Science presents the American Society of Animal Science Award for Industry Innovation to recognize excellence in development of applied technologies that enhances animal production, wellness or wellbeing.				
021033	<a href="#">Minority Medical Student Award Program</a>	American Society of Hematology		15-Nov-2021	Not Specified
	Contact Name Contact Telephone 202-776-0544 Contact Email <a href="mailto:awards@hematology.org">awards@hematology.org</a> Sponsor Website <a href="#">Link to sponsor website</a>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Nov-2021 , 31-Jan-2022</p> <p>Synopsis The ASH Minority Medical Student Award Program (MMSAP) provides underrepresented minority medical students with an opportunity to conduct a research project under the supervision of an ASH member, receive guidance from a career-development mentor, gain valuable knowledge of hematology, and ultimately, advance their careers. As part of the ASH Minority Recruitment Initiative, the MMSAP aims to expand the program's reach to the next generation of hematologists.</p>				
030069	<a href="#">Research Training Award for Fellows (RTAF)</a>	American Society of Hematology		18-Jan-2022	71,000 USD
	<p>Contact Name</p> <p>Contact Telephone 202-776-0544</p> <p>Contact Email <a href="mailto:awards@hematology.org">awards@hematology.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 18-Jan-2022</p> <p>Synopsis The ASH Research Training Award for Fellows (RTAF) is designed to encourage junior researchers in hematology, hematology/oncology, and other hematology-related training programs to pursue careers in academic hematology. The award provides each recipient with \$70,000 for a one-year period.</p>				
032661	<a href="#">ASH Medical Student Physician-Scientist Award</a>	American Society of Hematology		18-Jan-2022	42,000 USD
	<p>Contact Name</p> <p>Contact Telephone 202-776-0544</p> <p>Contact Email <a href="mailto:awards@hematology.org">awards@hematology.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 18-Jan-2022</p> <p>Synopsis The ASH Medical Student Physician-Scientist Award provides an opportunity for first-, second-, and third-year medical students to gain experience in hematology research under the mentorship of an ASH member and to learn more about the specialty. Awardees must agree to spend more than 80 percent of their time during the immersive, year-long project conducting laboratory, translational, or clinical hematology research. The award provides \$42,000 of funding for a one-year period, which includes \$32,000 to support the trainee, \$4,000 for research supplies, \$4,000 for insurance and educational expenses (including one course), and \$2,000 for meeting attendance (including the ASH annual meeting).</p>				
076833	<a href="#">ASPO Research Grant</a>	American Society of Pediatric Otolaryngology		17-Dec-2021 [LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 703-836-4444</p> <p>Contact Email <a href="mailto:COREGrants@entnet.org">COREGrants@entnet.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 17-Dec-2021 [LOI/Pre-App], 18-Jan-2022</p> <p>Synopsis The American Society of Pediatric Otolaryngology (ASPO) awards funds annually to support innovative research in pediatric otolaryngology.</p>				
019031	<a href="#">ATS Foundation Unrestricted Research Grants</a>	American Thoracic Society		11-Jan-2022	40,000 USD
	<p>Contact Name</p> <p>Contact Telephone 212-315-8600</p> <p>Contact Email <a href="mailto:researchprogram@thoracic.org">researchprogram@thoracic.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p>				



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-Jan-2022</p> <p>Synopsis The ATS Foundation will award research grants to support junior investigators interested in research that advances the knowledge and understanding of the three pillars of the ATS: pulmonary, critical care, and sleep medicine. A primary goal of the ATS Research Program is to enable junior investigators the chance to make the transition to careers as established investigators.</p>				
013387	<a href="#">Award for Distinguished Research in the Biomedical Sciences</a>	Association of American Medical Colleges		28-Jan-2022	10,000 USD
	<p>Contact Name Sandra Gordon</p> <p>Contact Telephone 202-828-0472</p> <p>Contact Email <a href="mailto:sgordon@aamc.org">sgordon@aamc.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 28-Jan-2022 , 08-Apr-2022</p> <p>Synopsis The Award for Distinguished Research in the Biomedical Sciences honors an individual or a team of two individuals for outstanding research in the basic or translational sciences. The awardee receives the Research Award and a prize of \$10,000.</p>				
054263	<a href="#">Dr. Jay Brown Best Abstract Award</a>	Association of Black Cardiologists, Inc.		14-Jan-2022	1,000 USD
	<p>Contact Name Katrese Phelps-McCullum, Program Director</p> <p>Contact Telephone 646-599-1925</p> <p>Contact Email <a href="mailto:kphelps@abcardio.org">kphelps@abcardio.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	14-Jan-2022			
	Synopsis	The Dr. Jay Brown Best Abstract Award is for an abstract summarizing any problem that relates to cardiovascular disease whether it is: Clinical, Basic or Population Science.			
043710	<a href="#">AMD Resident Research Grant</a>	Association of Migraine Disorders		17-Dec-2021 [LOI/Pre-App]	10,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:info@migrainedisorders.org">info@migrainedisorders.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	17-Dec-2021 [LOI/Pre-App], 18-Jan-2022			
	Synopsis	The purpose of this grant is to stimulate original resident research in migraine-related head and neck disorder projects that are well-conceived and scientifically valid, with the potential to advance the understanding of migraine disease.			
057954	<a href="#">Audio Visual Prize</a>	Association of Surgeons of Great Britain & Ireland		23-Jan-2022	411 USD
	Contact Name				
	Contact Telephone	020 7304 4770			
	Contact Email	<a href="mailto:dvds@asgbi.org.uk">dvds@asgbi.org.uk</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	23-Jan-2022			
	Synopsis	ASGBI offers an competition for the best video submitted for their annual meeting. Entries must be of general surgical interest, suitable for an audience of consultants and higher surgical trainees and may include topic presentations as			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		well as operative surgery.			
099665	<a href="#">Early Career Research Awards</a>	Biochemical Society		31-Jan-2022	1,370 USD
	Contact Name				
	Contact Telephone				
	Contact Email	<a href="mailto:awards@biochemistry.org">awards@biochemistry.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	31-Jan-2022			
	Synopsis	The Biochemical Society Early Career Research Awards recognize the impact of research carried out by early career scientists i.e. those who have no more than six years postdoctoral research experience. It is expected that successful candidates will have produced international quality research outputs, and be able to demonstrate ambitions and aspirations consistent with the potential to achieve world-leading status.			
005671	<a href="#">Scholarship Scheme</a>	British Society for Oral and Maxillofacial Pathology		31-Jan-2022	1,370 USD
	Contact Name	Dr Ali Khurram			
	Contact Telephone				
	Contact Email	<a href="mailto:thebsomp@gmail.com">thebsomp@gmail.com</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	31-Jan-2022			
	Synopsis	The British Society for Oral & Maxillofacial Pathology Scholarship provides funding for scholarship projects which contribute to the advancement of oral pathology.			
053378	<a href="#">Interfaces in Science: Career Awards at the Scientific Interface</a>	Burroughs Wellcome Fund		07-Jan-2022	500,000 USD

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name   Kelly Rose, Program Officer</p> <p>Contact Telephone   919-991-5120</p> <p>Contact Email   <a href="mailto:krose@bwfund.org">krose@bwfund.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   07-Jan-2022</p> <p>Synopsis   BWF's Career Awards at the Scientific Interface (CASI) provide \$500,000 over five years to bridge advanced postdoctoral training and the first three years of faculty service.</p>				
026399	<a href="#">Baer Reintegration Scholarship</a>	Center for Reintegration		31-Jan-2022	Not Specified
	<p>Contact Name  </p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:baerscholarships@reintegration.com">baerscholarships@reintegration.com</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   31-Jan-2022</p> <p>Synopsis   The goal of the Baer Reintegration Scholarship is to help people with schizophrenia, schizoaffective disorder or bipolar disorder acquire the educational and vocational skills necessary to reintegrate into society, secure jobs, and regain their lives.</p>				
083322	<a href="#">Crohn's &amp; Colitis Foundation/NASPGHAN IBD Young Investigator Award</a>	Crohn's & Colitis Foundation of America		05-Nov-2021 [LOI/Pre-App]	Not Specified
	<p>Contact Name  </p> <p>Contact Telephone   646-943-7505</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email <a href="mailto:grant@crohnscolitisfoundation.org">grant@crohnscolitisfoundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Nov-2021 [LOI/Pre-App], 28-Jan-2022</p> <p>Synopsis This three-year grant, in partnership with the NASPGHAN Foundation and the Crohn's &amp; Colitis Foundation, is available to research fellows or junior faculty. Applications must propose original clinical, translational, epidemiological, or basic scientific research related to pediatric inflammatory bowel disease. Applicants must indicate in their submission for either a Crohn's &amp; Colitis Foundation Career Development or Research Fellowship Award, if they want their award to be considered for the joint Crohn's &amp; Colitis Foundation/NASPGHAN IBD Young Investigator Award.</p>				
033065	<a href="#">Clinical Pilot and Feasibility Awards</a>	Cystic Fibrosis Foundation		25-Jan-2022	160,000 USD
	<p>Contact Name</p> <p>Contact Telephone 301-841-2614</p> <p>Contact Email <a href="mailto:grants@cff.org">grants@cff.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 25-Jan-2022</p> <p>Synopsis The intent of the Clinical Pilot and Feasibility Award is to enable investigators to collect sufficient preliminary data to determine the best strategies and methods for approaching a major question that ultimately will require assessment through a larger-scale research and/or multi-center, collaborative clinical trial. Support may be requested for \$80,000 annually (plus 12 percent for indirect costs) for up to two years.</p>				
044913	<a href="#">AB-SSD Distinguished Research Award in Dysphagia</a>	Dysphagia Research Society		31-Jan-2022	500 USD
	<p>Contact Name</p> <p>Contact Telephone 920-560-5624</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Email	<a href="mailto:DRS@badgerbay.co">DRS@badgerbay.co</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	31-Jan-2022
Synopsis	The AB-SSD Distinguished Research Award in Dysphagia is given to a speech-language pathologist who presents a scientific paper at the Dysphagia Research Society Annual Meeting for topics related to swallowing function and disorders.

044915	<a href="#">Michael Donovan NFOSD Innovation Award</a>	Dysphagia Research Society	31-Jan-2022	500 USD
--------	--	----------------------------	-------------	---------

Contact Name	
Contact Telephone	920-560-5624
Contact Email	<a href="mailto:DRS@badgerbay.co">DRS@badgerbay.co</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	31-Jan-2022
Synopsis	The Michael Donovan NFOSD Innovation Award is open to all disciplines and is specifically targeted to translational research with the greatest likelihood of directly benefiting the patient / caregiver. The award winner will receive \$500.

044914	<a href="#">Head and Neck Cancer Alliance Awards</a>	Dysphagia Research Society	31-Jan-2022	500 USD
--------	--	----------------------------	-------------	---------

Contact Name	
Contact Telephone	920-560-5624
Contact Email	<a href="mailto:DRS@badgerbay.co">DRS@badgerbay.co</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p style="margin-left: 40px;">Deadline Dates (ALL) 31-Jan-2022</p> <p style="margin-left: 80px;">Synopsis The Head and Neck Cancer Alliance Awards are open to all disciplines and is specifically targeted for swallowing research in patients with head and neck cancer. An award will be presented to both an oral presenter and a poster presenter. Each award winner will receive \$500.</p>					
044912	<a href="#">New Investigator Award</a>	Dysphagia Research Society		31-Jan-2022	1,000 USD
<p style="margin-left: 40px;">Contact Name</p> <p style="margin-left: 40px;">Contact Telephone 920-560-5624</p> <p style="margin-left: 40px;">Contact Email <a href="mailto:DRS@badgerbay.co">DRS@badgerbay.co</a></p> <p style="margin-left: 40px;">Sponsor Website <a href="#">Link to sponsor website</a></p> <p style="margin-left: 40px;">Program URL <a href="#">Link to program URL</a></p> <p style="margin-left: 40px;">Deadline Dates (ALL) 31-Jan-2022</p> <p style="margin-left: 80px;">Synopsis The Dysphagia Research Society (DRS) New Investigator Awards will be given to two eligible participants who submit the best abstracts for the annual meeting.</p>					
073232	<a href="#">Research Experiences for Graduate and Medical Students (REGMS)</a>	Endocrine Society		31-Jan-2022	Not Specified
<p style="margin-left: 40px;">Contact Name</p> <p style="margin-left: 40px;">Contact Telephone 202-971-3636</p> <p style="margin-left: 40px;">Contact Email <a href="mailto:awards@endocrine.org">awards@endocrine.org</a></p> <p style="margin-left: 40px;">Sponsor Website <a href="#">Link to sponsor website</a></p> <p style="margin-left: 40px;">Program URL <a href="#">Link to program URL</a></p> <p style="margin-left: 40px;">Deadline Dates (ALL) 31-Jan-2022</p> <p style="margin-left: 80px;">Synopsis The Endocrine Society offers Summer Research Fellowships to encourage promising undergraduate students, medical students and first year graduate school students to pursue careers in endocrinology.</p>					

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
001855	<a href="#">Postdoctoral Research Fellowship</a>	Epilepsy Foundation of America		14-Jan-2022	50,000 USD
	Contact Name				
	Contact Telephone	312-883-3800			
	Contact Email	<a href="mailto:grants@aesnet.org">grants@aesnet.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	14-Jan-2022			
	Synopsis	AES Postdoctoral Research Fellowships support postdoctoral trainees conducting research into the causes, treatment, and consequences of epilepsy under the guidance of a mentor with expertise in epilepsy research. Proposals are welcomed across the spectrum of basic, translational, and clinical epilepsy research. The fellowship award offers up to \$49,000 for stipend and/or benefits, \$1,000 for travel support to the AES annual meeting, as well as one year of complimentary AES membership and registration for the AES annual meeting. The number of awards granted each year is contingent upon available funds.			
001887	<a href="#">One-year Scholarship</a>	European Association of Urology		01-Jan-2022	34,800 USD
	Contact Name	Angela Terberg			
	Contact Telephone	+31(0)26 389 06 80			
	Contact Email	<a href="mailto:eusp@uroweb.org">eusp@uroweb.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jan-2022 , 01-May-2022 , 01-Sep-2022			
	Synopsis	The European Association of Urology offers support through their European Urology Scholarship Programme (EUSP). Members may apply for a one-year scholarship of up to €30,000 to be completed at a leading European research institution.			



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
030560	<a href="#">Therapeutic Pipeline Program</a>	Fox (Michael J.) Foundation for Parkinson's Research		13-Jan-2022	500,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>800-708-7644</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:grants@michaelifox.org">grants@michaelifox.org</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td><a href="#">Link to sponsor website</a></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>13-Jan-2022</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The Therapeutic Pipeline Program seeks to build the development of Parkinson's disease therapeutics with potential for fundamentally altering disease course or significantly improving treatment or management of non-motor or motor symptoms beyond current standards of care. For this round, only pre-clinical projects will be funded. The award amount is up to \$500,000.</td> </tr> </table>					Contact Name		Contact Telephone	800-708-7644	Contact Email	<a href="mailto:grants@michaelifox.org">grants@michaelifox.org</a>	Sponsor Website	<a href="#">Link to sponsor website</a>	Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	13-Jan-2022	Synopsis	The Therapeutic Pipeline Program seeks to build the development of Parkinson's disease therapeutics with potential for fundamentally altering disease course or significantly improving treatment or management of non-motor or motor symptoms beyond current standards of care. For this round, only pre-clinical projects will be funded. The award amount is up to \$500,000.
Contact Name																			
Contact Telephone	800-708-7644																		
Contact Email	<a href="mailto:grants@michaelifox.org">grants@michaelifox.org</a>																		
Sponsor Website	<a href="#">Link to sponsor website</a>																		
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	13-Jan-2022																		
Synopsis	The Therapeutic Pipeline Program seeks to build the development of Parkinson's disease therapeutics with potential for fundamentally altering disease course or significantly improving treatment or management of non-motor or motor symptoms beyond current standards of care. For this round, only pre-clinical projects will be funded. The award amount is up to \$500,000.																		
036254	<a href="#">Keith Michael Andrus Cardiac Award</a>	Friedreich's Ataxia Research Alliance		15-Jan-2022 [LOI/Pre-App]	300,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>484-879-6160</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td><a href="mailto:grants@curefa.org">grants@curefa.org</a></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td><a href="#">Link to sponsor website</a></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td><a href="#">Link to program URL</a></td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>15-Jan-2022 [LOI/Pre-App], 01-Mar-2022</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The Keith Michael Andrus Cardiac Research Award was made in honor of its namesake to remember Keith's legacy and to help advanced our understanding and treatment of the cardiomyopathy associated with FA. Proposals for this award should focus on advancing understanding and/or treatment of the cardiac involvement in FA.</td> </tr> </table>					Contact Name		Contact Telephone	484-879-6160	Contact Email	<a href="mailto:grants@curefa.org">grants@curefa.org</a>	Sponsor Website	<a href="#">Link to sponsor website</a>	Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	15-Jan-2022 [LOI/Pre-App], 01-Mar-2022	Synopsis	The Keith Michael Andrus Cardiac Research Award was made in honor of its namesake to remember Keith's legacy and to help advanced our understanding and treatment of the cardiomyopathy associated with FA. Proposals for this award should focus on advancing understanding and/or treatment of the cardiac involvement in FA.
Contact Name																			
Contact Telephone	484-879-6160																		
Contact Email	<a href="mailto:grants@curefa.org">grants@curefa.org</a>																		
Sponsor Website	<a href="#">Link to sponsor website</a>																		
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	15-Jan-2022 [LOI/Pre-App], 01-Mar-2022																		
Synopsis	The Keith Michael Andrus Cardiac Research Award was made in honor of its namesake to remember Keith's legacy and to help advanced our understanding and treatment of the cardiomyopathy associated with FA. Proposals for this award should focus on advancing understanding and/or treatment of the cardiac involvement in FA.																		

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
011491	<a href="#">Gates Cambridge Scholarship</a>	Gates Cambridge Trust		02-Dec-2021	Not Specified		
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; vertical-align: top;">                     Contact Name                      Contact Telephone                      Contact Email                      Sponsor Website                      Program URL                      Deadline Dates (ALL)                      Synopsis                 </td> <td style="border-left: 1px solid black; padding-left: 10px;">                     +44 (0)1223 338467  <a href="mailto:info@gatescambridge.org">info@gatescambridge.org</a>  <a href="#">Link to sponsor website</a>  <a href="#">Link to program URL</a>                      02-Dec-2021 , 06-Jan-2022                      Each year Gates Cambridge offers c.80 full-cost scholarships to outstanding applicants from countries outside the UK to pursue a full-time postgraduate degree in any subject available at the University of Cambridge. Approximately two-thirds of these awards will be offered to PhD students, with approximately 25 awards available in the US round and 55 available in the International round.                 </td> </tr> </table>					Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	+44 (0)1223 338467 <a href="mailto:info@gatescambridge.org">info@gatescambridge.org</a> <a href="#">Link to sponsor website</a> <a href="#">Link to program URL</a> 02-Dec-2021 , 06-Jan-2022 Each year Gates Cambridge offers c.80 full-cost scholarships to outstanding applicants from countries outside the UK to pursue a full-time postgraduate degree in any subject available at the University of Cambridge. Approximately two-thirds of these awards will be offered to PhD students, with approximately 25 awards available in the US round and 55 available in the International round.
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	+44 (0)1223 338467 <a href="mailto:info@gatescambridge.org">info@gatescambridge.org</a> <a href="#">Link to sponsor website</a> <a href="#">Link to program URL</a> 02-Dec-2021 , 06-Jan-2022 Each year Gates Cambridge offers c.80 full-cost scholarships to outstanding applicants from countries outside the UK to pursue a full-time postgraduate degree in any subject available at the University of Cambridge. Approximately two-thirds of these awards will be offered to PhD students, with approximately 25 awards available in the US round and 55 available in the International round.						
077274	<a href="#">Faculty Scholars Program</a>	Greenwall Foundation		10-Jan-2022	Not Specified		
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; vertical-align: top;">                     Contact Name                      Contact Telephone                      Contact Email                      Sponsor Website                      Program URL                      Deadline Dates (ALL)                      Synopsis                 </td> <td style="border-left: 1px solid black; padding-left: 10px;">                     Kyle Ruempler                      212-679-7266  <a href="mailto:kruempler@greenwall.org">kruempler@greenwall.org</a>  <a href="#">Link to sponsor website</a>  <a href="#">Link to program URL</a>                      10-Jan-2022                      The Greenwall Faculty Scholars Program in Bioethics is a career development award to enable junior faculty members to carry out innovative bioethics research. It supports research that goes beyond current work in bioethics to help resolve pressing ethical issues in clinical care, biomedical research, and public policy, and creates a community that enhances future bioethics research by Scholars and Alumni/ae.                 </td> </tr> </table>					Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Kyle Ruempler 212-679-7266 <a href="mailto:kruempler@greenwall.org">kruempler@greenwall.org</a> <a href="#">Link to sponsor website</a> <a href="#">Link to program URL</a> 10-Jan-2022 The Greenwall Faculty Scholars Program in Bioethics is a career development award to enable junior faculty members to carry out innovative bioethics research. It supports research that goes beyond current work in bioethics to help resolve pressing ethical issues in clinical care, biomedical research, and public policy, and creates a community that enhances future bioethics research by Scholars and Alumni/ae.
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Kyle Ruempler 212-679-7266 <a href="mailto:kruempler@greenwall.org">kruempler@greenwall.org</a> <a href="#">Link to sponsor website</a> <a href="#">Link to program URL</a> 10-Jan-2022 The Greenwall Faculty Scholars Program in Bioethics is a career development award to enable junior faculty members to carry out innovative bioethics research. It supports research that goes beyond current work in bioethics to help resolve pressing ethical issues in clinical care, biomedical research, and public policy, and creates a community that enhances future bioethics research by Scholars and Alumni/ae.						

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
008357	<a href="#">Grants Program</a>	Gyllenberg (Signe and Ane) Foundation		31-Jan-2022	Not Specified														
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Antonia Laszlo</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">09-647390</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;"><a href="mailto:antonia.laszlo@gyllenbergs.fi">antonia.laszlo@gyllenbergs.fi</a></td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"><a href="#">Link to sponsor website</a></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;"><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">31-Jan-2022</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">In order to support medical activity, The Signe and Ane Gyllenberg Foundation offers grants every second year, gives support to universities, and organizes symposiums.</td> </tr> </table>						Contact Name	Antonia Laszlo	Contact Telephone	09-647390	Contact Email	<a href="mailto:antonia.laszlo@gyllenbergs.fi">antonia.laszlo@gyllenbergs.fi</a>	Sponsor Website	<a href="#">Link to sponsor website</a>	Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	31-Jan-2022	Synopsis	In order to support medical activity, The Signe and Ane Gyllenberg Foundation offers grants every second year, gives support to universities, and organizes symposiums.
Contact Name	Antonia Laszlo																		
Contact Telephone	09-647390																		
Contact Email	<a href="mailto:antonia.laszlo@gyllenbergs.fi">antonia.laszlo@gyllenbergs.fi</a>																		
Sponsor Website	<a href="#">Link to sponsor website</a>																		
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	31-Jan-2022																		
Synopsis	In order to support medical activity, The Signe and Ane Gyllenberg Foundation offers grants every second year, gives support to universities, and organizes symposiums.																		
089513	<a href="#">Complex Joint Reconstruction Center Clinical Fellowship</a>	Hospital for Special Surgery		02-Jan-2022	Not Specified														
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; padding: 5px;">Contact Name</td> <td style="padding: 5px;">Dr. Peter Sculco</td> </tr> <tr> <td style="padding: 5px;">Contact Telephone</td> <td style="padding: 5px;">1-212-774-2572</td> </tr> <tr> <td style="padding: 5px;">Contact Email</td> <td style="padding: 5px;"><a href="mailto:complexjoint@hss.edu">complexjoint@hss.edu</a></td> </tr> <tr> <td style="padding: 5px;">Sponsor Website</td> <td style="padding: 5px;"><a href="#">Link to sponsor website</a></td> </tr> <tr> <td style="padding: 5px;">Program URL</td> <td style="padding: 5px;"><a href="#">Link to program URL</a></td> </tr> <tr> <td style="padding: 5px;">Deadline Dates (ALL)</td> <td style="padding: 5px;">02-Jan-2022</td> </tr> <tr> <td style="padding: 5px;">Synopsis</td> <td style="padding: 5px;">The Complex Joint Reconstruction Center (CJRC) Fellowship in the Department of Orthopaedic Surgery of the Hospital for Special Surgery (HSS) is a program to train clinicians in the evaluation and management of patients in the musculoskeletal specialty of hip and knee arthroplasty. The one-year clinical fellowship is designed to provide the fellow with an ongoing, in-depth experience in the management of patients undergoing complex primary joint replacement and revision surgery. Emphasis is placed on the preoperative evaluation and operative management of these problems. The fellowship will accomplish these objectives through didactic clinical lectures, academic</td> </tr> </table>						Contact Name	Dr. Peter Sculco	Contact Telephone	1-212-774-2572	Contact Email	<a href="mailto:complexjoint@hss.edu">complexjoint@hss.edu</a>	Sponsor Website	<a href="#">Link to sponsor website</a>	Program URL	<a href="#">Link to program URL</a>	Deadline Dates (ALL)	02-Jan-2022	Synopsis	The Complex Joint Reconstruction Center (CJRC) Fellowship in the Department of Orthopaedic Surgery of the Hospital for Special Surgery (HSS) is a program to train clinicians in the evaluation and management of patients in the musculoskeletal specialty of hip and knee arthroplasty. The one-year clinical fellowship is designed to provide the fellow with an ongoing, in-depth experience in the management of patients undergoing complex primary joint replacement and revision surgery. Emphasis is placed on the preoperative evaluation and operative management of these problems. The fellowship will accomplish these objectives through didactic clinical lectures, academic
Contact Name	Dr. Peter Sculco																		
Contact Telephone	1-212-774-2572																		
Contact Email	<a href="mailto:complexjoint@hss.edu">complexjoint@hss.edu</a>																		
Sponsor Website	<a href="#">Link to sponsor website</a>																		
Program URL	<a href="#">Link to program URL</a>																		
Deadline Dates (ALL)	02-Jan-2022																		
Synopsis	The Complex Joint Reconstruction Center (CJRC) Fellowship in the Department of Orthopaedic Surgery of the Hospital for Special Surgery (HSS) is a program to train clinicians in the evaluation and management of patients in the musculoskeletal specialty of hip and knee arthroplasty. The one-year clinical fellowship is designed to provide the fellow with an ongoing, in-depth experience in the management of patients undergoing complex primary joint replacement and revision surgery. Emphasis is placed on the preoperative evaluation and operative management of these problems. The fellowship will accomplish these objectives through didactic clinical lectures, academic																		

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

conferences, supervised patient care, in-depth surgical exposure, and research projects that support the concepts and skills learned in the clinical arena.

089514	<a href="#">Complex Joint Reconstruction Center Research Fellowship</a>	Hospital for Special Surgery		02-Jan-2022	Not Specified
--------	---	------------------------------	--	-------------	---------------

Contact Name	Dr. Peter Sculco, MD
Contact Telephone	1-212-774-2572
Contact Email	<a href="mailto:complexjoint@hss.edu">complexjoint@hss.edu</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	02-Jan-2022
Synopsis	The Complex Joint Reconstruction Center (CJRC) Research Fellowship in the Department of Orthopaedic Surgery of the Hospital for Special Surgery (HSS) is a program to train clinicians in the evaluation and management of patients in the musculoskeletal specialty of hip and knee arthroplasty. The one-year clinical fellowship is designed to provide physicians with clinical knowledge and research skills necessary for a successful academic clinical career in this field.

070987	<a href="#">Public Health Award in honor of Babcock-Hart &amp; Gilbert A. Leveille</a>	Institute of Food Technologists		14-Jan-2022	3,000 USD
--------	--	---------------------------------	--	-------------	-----------

Contact Name	
Contact Telephone	312-782-8424
Contact Email	<a href="mailto:info@ift.org">info@ift.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	14-Jan-2022
Synopsis	The Institute of Food Technologists provides an award to honor a member of the its organization who has attained distinction by contributions to food technology which result in improved public health through nutrition or more

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

nutritious food.

043741	<a href="#">Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Programme</a>	International AIDS Society		29-Oct-2021 [LOI/Pre-App]	300,000 USD
--------	---	----------------------------	--	---------------------------	-------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>+41-(0)22-7 100 800</p> <p><a href="mailto:cipher@iasociety.org">cipher@iasociety.org</a></p> <p><a href="#">Link to sponsor website</a></p> <p><a href="#">Link to program URL</a></p> <p>29-Oct-2021 [LOI/Pre-App], 27-Jan-2022</p> <p>The CIPHER Grant Programme directly supports the development of early-stage investigators, awarding up to US\$150,000 for up to two years to address research gaps in paediatric and adolescent HIV in resource-limited settings. The purpose of the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant Programme is to fund research projects with the potential to address critical research questions that remain unanswered in the global response in order to inform policy change and ensure better outcomes in infants, children and adolescents living with and affected by HIV in resource-limited settings. Designed for early-stage investigators, a key aim of the programme is to build research capacity within resource-limited settings by fostering the next generation of investigators in paediatric and adolescent HIV. It is intended to attract young investigators from inside and outside the field of HIV. This will help encourage innovative ideas and lead to the design of evidence-based approaches and interventions to overcome major obstacles in the field.</p>
---	--

080906	<a href="#">Innovation in Oral Care Awards</a>	International Association for Dental Research		31-Jan-2022	50,000 USD
--------	--	---	--	-------------	------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p>	<p>Anthony Jones</p> <p>703-548-0066</p> <p><a href="mailto:ajones@iadr.org">ajones@iadr.org</a></p>
---	--

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	31-Jan-2022			
	Synopsis	The Innovation in Oral Care Awards (“Award(s)”) are intended to help investigators pursue innovative and novel research in oral care, above and beyond the bounds of traditional dental research.			
049954	<a href="#">Kulzer Travel Award</a>	International Association for Dental Research		17-Jan-2022	2,500 USD
	Contact Name	Anthony Jones; Awards, Fellowships and Grants Coordinator			
	Contact Telephone				
	Contact Email	<a href="mailto:ajones@iadr.org">ajones@iadr.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	17-Jan-2022			
	Synopsis	The IADR is inviting applications from young investigators who have submitted an abstract which has a dental materials component for a travel award to support their attendance at the IADR General Session. The winner of each award will receive US \$2,500 for expenses to attend the IADR General Session & Exhibition.			
050004	<a href="#">Student Research Fellowship</a>	International Association for Dental Research		31-Jan-2022	2,700 USD
	Contact Name	Anthony Jones, Awards, Fellowships and Grants Coordinator			
	Contact Telephone	1-703-548-0066			
	Contact Email	<a href="mailto:ajones@iadr.org">ajones@iadr.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	31-Jan-2022			
	Synopsis	The AADR Student Research Fellowships, supported by several major industrial companies, as well as by AADR and IADR Group Chapters, Sections, and members, are sponsored and administered by the AADR and have been created to encourage dental students living in the United States to consider careers in oral health research. Proposals are sought in basic and clinical research related to oral health.			
049993	<a href="#">Periodontal Research Group Past Presidents' Travel Award</a>	International Association for Dental Research		17-Jan-2022	3,000 USD
	Contact Name	Panos N. Papapanou, DDS, PhD; Chair, Section of Oral and Diagnostic Sciences			
	Contact Telephone	+1.703.548.0066			
	Contact Email	<a href="mailto:pp192@cumc.columbia.edu">pp192@cumc.columbia.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	17-Jan-2022			
	Synopsis	In honor of the PRG's Past Presidents, the Group is offering the PRG Presidents' Travel Award in line with its focus on enhancing research and attracting junior researchers into academia.			
106697	<a href="#">Request for Applications - Clinical Trials to Advance Therapies for Nephropathy and Cardiovascular Disease in Type 1 Diabetes</a>	Juvenile Diabetes Research Foundation International		08-Nov-2021 [LOI/Pre-App]	900,000 USD
	Contact Name	Jonathan Rosen, Ph.D			
	Contact Telephone	+1-212-785-9595			
	Contact Email	<a href="mailto:jrosen@jdrf.org">jrosen@jdrf.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-Nov-2021 [LOI/Pre-App], 05-Jan-2022			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Juvenile Diabetes Research Foundation (JDRF) has issued a request for applications (RFA) to solicit proposals to advance drugs -- novel or repositioned, in clinical development or already approved for an indication -- for diabetic nephropathy (DN) and/or cardiovascular disease (CVD) in T1D by executing clinical trials to assess efficacy and safety of these agents in this understudied population.			
029379	<a href="#">Lupus Insight Prize</a>	Lupus Research Alliance		20-Jan-2022	100,000 USD
	Contact Name	Diomaris Gonzalez			
	Contact Telephone	646-884-6086			
	Contact Email	<a href="mailto:dgonzalez@lupusresearch.org">dgonzalez@lupusresearch.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	20-Jan-2022			
	Synopsis	The Lupus Research Alliance requests nominations for the 2022 Lupus Insight Prize recognizing and honoring significant scientific insights relevant to understanding the causes, pathogenesis, or treatment of lupus. The Prize also aims to stimulate further advances leading to improved outcomes for patients with lupus and ultimately to a cure.			
076661	<a href="#">MRS/OSA Congressional Science and Engineering Fellowship</a>	Materials Research Society		07-Jan-2022	78,750 USD
	Contact Name	Damon Dozier			
	Contact Telephone	724-779-3003			
	Contact Email				
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	07-Jan-2022			
	Synopsis	The MRS/OSA Congressional Science and Engineering Fellow spends one year working as a special legislative assistant on the staff of a member of Congress or congressional committee. Activities may involve conducting legislative or			



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		oversight work, assisting in congressional hearings and debates and preparing briefs and writing speeches. The fellow also attends an orientation program administered by the American Association for the Advancement of Science (AAAS) on congressional and executive branch operations, which includes guidance in the congressional placement process, and a year-long seminar series on science and public policy issues. The AAAS also administers many other aspects of the program for the OSA/MRS fellow, as well as other fellows sponsored by nearly two dozen other scientific societies.			
012868	<a href="#">Neurologic Surgery - Endovascular Surgical Neuroradiology Fellowship (Florida)</a>	Mayo Clinic College of Medicine and Science		01-Jan-2022 [Optional]	Not Specified
	Contact Name	Carolyn D. Rizzo			
	Contact Telephone	904-953-8410			
	Contact Email	<a href="mailto:Rizzo.carolyn@mayo.edu">Rizzo.carolyn@mayo.edu</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	01-Jan-2022 [Optional]			
	Synopsis	Mayo Clinic's campus in Jacksonville, Florida, offers a premier fellowship program for neuroendovascular training. The unique Endovascular Surgical Neuroradiology Fellowship offers broad exposure to cerebrovascular disorders along with a state-of-the-art management approach in a multidisciplinary environment. The full two-year Endovascular Surgical Neuroradiology Fellowship is divided into junior (12 months) and senior (12 months) training.			
068239	<a href="#">Grants Program - Health &amp; Medical Research</a>	McGowan (William G.) Charitable Fund, Inc.		15-Nov-2021 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	312-761-9503			
	Contact Email	<a href="mailto:info@williamgmcgowanfund.org">info@williamgmcgowanfund.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL)   15-Nov-2021 [LOI/Pre-App], 03-Jan-2022</p> <p>Synopsis   The McGowan Charitable Fund partners with institutions that advance cardiac-disease research and organizations that build healthy communities through innovative heart disease prevention programs.</p>				
027743	<a href="#">Clinician Scientist Fellowship (CSF)</a>	Medical Research Council (MRC)		12-Jan-2022	Not Specified
	<p>Contact Name   Research Career Awards (Fellowships)</p> <p>Contact Telephone  </p> <p>Contact Email   <a href="mailto:fellows@headoffice.mrc.ac.uk">fellows@headoffice.mrc.ac.uk</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL  </p> <p>Deadline Dates (ALL)   12-Jan-2022</p> <p>Synopsis   The CSF develops talented medically and other clinically qualified professionals who have gained a higher research degree to lead their own research plans and establish their own research team to make the transition to independent investigator.</p>				
106597	<a href="#">Special Opportunity: RTFCCR-MRA Team Science Awards on Patient-Centric Melanoma Clinical Trials</a>	Melanoma Research Alliance		19-Jan-2022	7,500,000 USD
	<p>Contact Name   Rachel Fischer</p> <p>Contact Telephone   202-336-8935</p> <p>Contact Email   <a href="mailto:rfischer@curemelanoma.org">rfischer@curemelanoma.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   19-Jan-2022</p> <p>Synopsis   The Melanoma Research Alliance (MRA) and the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) will</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>jointly support two team awards for clinical trials with the potential to provide significant impact to melanoma patients. These awards seek to support novel, interventional clinical trials with the goal of making a significant difference to melanoma patients in the short term. Patient engagement must be actively demonstrated throughout the full life cycle of the clinical trial, including planning and dissemination. Awards are up to to \$1,500,000.</p>					
034734	<a href="#">Team Science Award</a>	Melanoma Research Alliance		19-Jan-2022	900,000 USD
	<p>Contact Name Rachel Fischer</p> <p>Contact Telephone 202-336-8935</p> <p>Contact Email <a href="mailto:rfischer@curemelanoma.org">rfischer@curemelanoma.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 19-Jan-2022</p> <p>Synopsis Team Science Awards are designed to foster a collaborative research process and promote transformational melanoma research advances with the potential for rapid clinical translation. Evidence of prior collaboration among team members is encouraged, but not required. Up to \$300,000 per year for three years (up to \$900,000 total) are available.</p>				
106580	<a href="#">Team Science Academic-Industry Partnership Award</a>	Melanoma Research Alliance		19-Jan-2022	900,000 USD
	<p>Contact Name Rachel Fischer</p> <p>Contact Telephone 202-336-8935</p> <p>Contact Email <a href="mailto:rfischer@curemelanoma.org">rfischer@curemelanoma.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 19-Jan-2022</p> <p>Synopsis The Academic-Industry Partnership Award (for Teams) is designed to enhance translational research by extending</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>academic capabilities to clinical investigations and to facilitate interactions between the academic and industrial research sectors. These awards will be co-funded by MRA and an industry partner whose involvement is essential to the project. The award is up to \$300,000 per year for three years (up to \$900,000 total).</p>			
040683	<a href="#">Junior Faculty Career Development Award (Kornfeld Scholars Program)</a>	National Palliative Care Research Center		05-Nov-2021 [LOI/Pre-App]	180,000 USD
	<p>Contact Name</p> <p>Contact Telephone 212-241-7447</p> <p>Contact Email <a href="mailto:npcrc@mssm.edu">npcrc@mssm.edu</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 05-Nov-2021 [LOI/Pre-App], 21-Jan-2022</p> <p>Synopsis</p>	<p>The National Palliative Care Research Center (NPCRC) provides Junior Faculty Career Development Awards to allow junior faculty to have the protected time required to develop and conduct the pilot research necessary to be competitive for larger, extramurally funded awards. Recipients of the career development award will work with a mentor/co-mentor who has extensive palliative care research experience. The goal of the advisor is to ensure that funded junior investigators receive appropriate mentoring, that projects move forward in an efficient and timely manner, that projects continue to address the core mission of the Center, and to connect junior faculty with other investigators in the field of palliative care.</p>			
030480	<a href="#">Addressing Disparities Program</a>	Patient-Centered Outcomes Research Institute (PCORI)		11-Jan-2022	5,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone 202-627-1884</p> <p>Contact Email <a href="mailto:sciencequestions@pcori.org">sciencequestions@pcori.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-Jan-2022</p> <p>Synopsis The Patient-Centered Outcomes Research Institute (PCORI) funds patient-centered outcomes research (PCOR), a type of comparative clinical effectiveness research (CER) that focuses on outcomes that matter to patients, their caregivers, and their families. PCORI-funded studies must include the perspectives of patients and other healthcare stakeholders. One area this PFA will provide support for has a focus on Addressing Disparities.</p>				
030477	<a href="#">Broad PCORI Funding</a>	Patient-Centered Outcomes Research Institute (PCORI)		11-Jan-2022	3,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone 202-827-7700</p> <p>Contact Email <a href="mailto:info@pcori.org">info@pcori.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 11-Jan-2022</p> <p>Synopsis The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with priority areas for research. This PFA covers the following four priority areas: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; Communication and Dissemination Research, and Improving Health Systems. Applications should address needs of patients, caregivers, clinicians, and other healthcare stakeholders in making personalized clinical decisions across a wide range of conditions, populations, and treatments. These broad areas encompass the patient-centered comparative clinical effectiveness research PCORI supports. As its work progresses and PCORI engages with a broad range of patients, caregivers, clinicians, and other healthcare stakeholders, PCORI may develop additional national priorities for research. In addition to these four priority areas, PCORI’s 2019 reauthorizing legislation provided additional direction about national research priorities to include research with respect to intellectual and developmental disabilities and to maternal mortality.</p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
088268	<a href="#">Assessment of Prevention, Diagnosis, and Treatment Options Program</a>	Patient-Centered Outcomes Research Institute (PCORI)		11-Jan-2022	5,000,000 USD
	Contact Name				
	Contact Telephone	202-627-1885			
	Contact Email	<a href="mailto:pfa@pcori.org">pfa@pcori.org</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	11-Jan-2022			
	Synopsis	The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with our priority areas for research. This PFA covers the following four priority areas: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; Communication and Dissemination Research, and Improving Health Systems. Applications should address needs of patients, caregivers, clinicians, and other healthcare stakeholders in making personalized clinical decisions across a wide range of conditions, populations, and treatments.			
053400	<a href="#">Pershing Square Sohn Prize for Young Investigators in Cancer Research</a>	Pershing Square Foundation		08-Nov-2021 [LOI/Pre-App]	600,000 USD
	Contact Name	Olivia Tournay Flatto, PhD, Executive Director			
	Contact Telephone				
	Contact Email	<a href="mailto:otflatto@persq.org">otflatto@persq.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	08-Nov-2021 [LOI/Pre-App], 28-Jan-2022			
	Synopsis	The Pershing Square Sohn Prize for Young Investigators in Cancer Research provides New York area-based early career scientists the freedom to take risks and pursue their boldest research at a stage when traditional funding is			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
lacking. Prize winners each receive \$200,000 a year for up to three years. At least six grants are awarded annually.					
066668	<a href="#">Research Grant</a>	PKD Foundation for Research in Polycystic Kidney Disease		17-Jan-2022	160,000 USD
	Contact Name				
	Contact Telephone	816-931-2600			
	Contact Email	<a href="mailto:research@pkdcure.org">research@pkdcure.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	17-Jan-2022			
	Synopsis	The PKD Foundation will provide support for research on clinical interventions for the treatment of Polycystic Kidney Disease. Award amounts will equal \$80,000 direct costs per year for two years, for a total grant award of \$160,000.			
063066	<a href="#">Derek Harwood-Nash International Education Scholar Grant</a>	Radiological Society of North America		10-Jan-2022	75,000 USD
	Contact Name	Keshia Osley, Assistant Director, Grant Administration			
	Contact Telephone	630-571-7816			
	Contact Email	<a href="mailto:rmurray@rsna.org">rmurray@rsna.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	10-Jan-2022			
	Synopsis	This grant funds investigators looking to affect radiology education around the world. All projects are eligible for funding as long as they are on an international scale.			
104960	<a href="#">Rapid Research Pilot Program</a>	RADx-UP Coordination and Data Collection Center (CDCC)		31-Dec-2021 [Optional][LOI/Pre-App]	200,000 USD

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email <a href="mailto:RADx-UPMiniGrant-PilotProgramAdmin@dm.duke.edu">RADx-UPMiniGrant-PilotProgramAdmin@dm.duke.edu</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 31-Dec-2021 [Optional][LOI/Pre-App], 21-Jan-2022 , 25-Mar-2022 [Optional][LOI/Pre-App], 15-Apr-2022</p> <p>Synopsis            Evaluation of established as well as new diagnostic tests and their ultimate implementation by communities adversely affected by COVID-19 is critical to reducing the disease burden in the US. Clinicians, the public health community, advocates, policymakers, and the public require reliable, accurate information regarding the accessibility and effective utilization of COVID-19 diagnostic tests in underserved populations. This evaluation includes assessment of facilitators and barriers to utilization of current available tests such as nucleic acid detection, antigen detection, and antibody tests. Important implementation issues will include personal and community factors involved with obtaining and transporting the test, the optimal site and timing of tests, as well as returning information to individuals regarding the meaning of positive and negative test results. Information pertaining to post-test management, including the transmittal of action steps on receipt of a test result, possible isolation, participation in work or school, as well as conformance with local, state, and/or federal reporting requirements is also important. Given the number and variety of vulnerable populations, we anticipate that a range of testing methods will be necessary to understand how to best engage and test individuals in various underserved communities. As the number and types of commercially available tests increase, including point-of-care tests, the sponsor anticipates that both accessibility and challenges to their equitable utilization will need to be addressed.</p>				
044536	<a href="#">Fellowship Grants</a>	Rally Foundation		14-Jan-2022	100,000 USD
	<p>Contact Name Leigh Anna Lang</p> <p>Contact Telephone 404-847-1270</p> <p>Contact Email <a href="mailto:Leighanna@RallyFoundation.org">Leighanna@RallyFoundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p>				



## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	14-Jan-2022			
	Synopsis	The Rally Foundation is administrating collaborative pediatric research awards, including a Fellowship. Fellowship Grants are available for one or two years of support. Each funded grant will be awarded up to \$50,000 per year.			
044280	<a href="#">Young Investigator and Independent Investigator Research Grants</a>	Rally Foundation		14-Jan-2022	100,000 USD
	Contact Name	Leigh Anna Lang			
	Contact Telephone	404-847-1270			
	Contact Email	<a href="mailto:Leighanna@RallyFoundation.org">Leighanna@RallyFoundation.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	14-Jan-2022			
	Synopsis	Young Investigator and Independent Investigator Grants are for one or two years of support. Each funded grant will be awarded up to \$50,000 per year.			
057069	<a href="#">Consortium Grants</a>	Rally Foundation		14-Jan-2022	200,000 USD
	Contact Name	Leigh Anna Lang			
	Contact Telephone	404-847-1270			
	Contact Email	<a href="mailto:Leighanna@RallyFoundation.org">Leighanna@RallyFoundation.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	14-Jan-2022			
	Synopsis	Consortium Grants are intended to provide support to three or more institutions collaborating on a grant-supported research project. Grants are for one or two years of support. At the end of the award, recipients may apply for additional funding the next grant cycle. Each funded grant will be awarded up to \$100,000 per year.			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
017844	<a href="#">Early Career Investigator Award</a>	Research Society on Alcoholism		31-Jan-2022	Not Specified
	Contact Name	Rebecca Thomas, Operations Analyst			
	Contact Telephone	512-454-0022			
	Contact Email	<a href="mailto:Beckyrsoa@gmail.com">Beckyrsoa@gmail.com</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	31-Jan-2022			
	Synopsis	The RSA Early Career Investigator Award recognizes an early career investigator who has demonstrated research excellence, potential to be a future leader, and a commitment to the alcohol field.			
017807	<a href="#">Distinguished Researcher Award</a>	Research Society on Alcoholism		31-Jan-2022	Not Specified
	Contact Name	Rebecca Thomas, Operations Analyst			
	Contact Telephone	512-454-0022			
	Contact Email	<a href="mailto:Beckyrsoa@gmail.com">Beckyrsoa@gmail.com</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	31-Jan-2022			
	Synopsis	The RSA Distinguished Researcher Award recognizes a senior researcher who has made outstanding scientific contributions to the alcohol field.			
017850	<a href="#">Henri Begleiter Excellence in Research Award</a>	Research Society on Alcoholism		31-Jan-2022	Not Specified
	Contact Name	Rebecca Thomas, Operations Analyst			

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone   512-454-0022</p> <p>Contact Email   <a href="mailto:Beckyrsoa@gmail.com">Beckyrsoa@gmail.com</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   31-Jan-2022</p> <p>Synopsis   The Henri Begleiter Excellence in Research Award is given to an individual demonstrating innovation or creativity and excellence in their research and/or to someone whose work has a major impact on the field.</p>				
060678	<a href="#">Dr. Ernest J. Ring Academic Development Grant</a>	SIR Foundation		15-Jan-2022	100,000 USD
	<p>Contact Name  </p> <p>Contact Telephone   703-691-1805</p> <p>Contact Email   <a href="mailto:grants@sirfoundation.org">grants@sirfoundation.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p> <p>Program URL   <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL)   15-Jan-2022</p> <p>Synopsis   The Dr. Ernest J. Ring Academic Development Grant program is designed to provide support to junior interventional radiology faculty members early in their academic careers to allow time for the conduct of research. The goal of this program is to have grant recipients subsequently obtain additional funding from other sources, such as National Institutes of Health (NIH) grants.</p>				
017331	<a href="#">Allied Scientist Training Grant</a>	SIR Foundation		15-Jan-2022	40,000 USD
	<p>Contact Name   Sara Myers</p> <p>Contact Telephone   703-691-1805</p> <p>Contact Email   <a href="mailto:smyers@sirweb.org">smyers@sirweb.org</a></p> <p>Sponsor Website   <a href="#">Link to sponsor website</a></p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jan-2022</p> <p>Synopsis The SIR Foundation Allied Scientist Training Grant is designed to provide support to trainees enrolled in graduate-level training programs that are outside the clinical realm of interventional radiology but are still considered crucial to the future of IR. The goal is to create collaborative research training environments that benefit from the unique perspectives of established scientists and interventional radiologists.</p>				
060679	<a href="#">Academic Transition Grant</a>	SIR Foundation		15-Jan-2022	25,000 USD
	<p>Contact Name</p> <p>Contact Telephone 703-691-1805</p> <p>Contact Email <a href="mailto:grants@sirfoundation.org">grants@sirfoundation.org</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p> <p>Program URL <a href="#">Link to program URL</a></p> <p>Deadline Dates (ALL) 15-Jan-2022</p> <p>Synopsis The Academic Transition Grant is designed for interventional radiologists over the age of 40 who have recently begun academic careers after spending several years in non-academic practice. The grant is intended to facilitate the establishment of a record of independent research by the investigator in order to promote a successful academic career.</p>				
002575	<a href="#">NOAA Postdoctoral Program in Climate and Global Change</a>	University Corporation for Atmospheric Research		07-Jan-2022	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 303-497-1605</p> <p>Contact Email <a href="mailto:cpaess-apply@ucar.edu">cpaess-apply@ucar.edu</a></p> <p>Sponsor Website <a href="#">Link to sponsor website</a></p>				

## Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	07-Jan-2022
Synopsis	<p>The UCAR Cooperative Programs for the Advancement of Earth System Science (CPAESS) is pleased to announce that the NOAA Climate and Global Change Postdoctoral Fellowship Program is seeking applications for the 2022 appointments. The fellowship program has an outstanding reputation for attracting the best and the brightest PhDs in the sciences relevant to the NOAA Climate and Global Change Program. This prestigious NOAA-sponsored program appoints fellows that are hosted by a mentoring scientist at a U.S. university or research institution to work in an area of mutual interest.</p>